Curriculum Vitae
Arthur J. Matas, M.D.

Education
Postdoctoral Training
Research Training
Board Certification
Academic Appointments
Hospital Appointments
Committees
Societies and Memberships
Editorial Boards
Bibliography
Abstracts
Invited Presentations/Session Chairs - National and International

EDUCATION:

University of Manitoba,
College of Liberal Arts, 1966-1968

University of Manitoba,
College of Medicine, 1968-1972,
M.D., B. Sc.(Med)

Top of page

POSTDOCTORAL TRAINING:

Surgery Internship, University of Minnesota
Hospitals, Minneapolis, MN., 1972-1973

Resident in Surgery, University of Minnesota
Hospitals, 1973-1979

Fellowship in Transplantation,
University of Minnesota Hospitals, 1979-1980

Top of page

RESEARCH TRAINING:

Neonatology, University of Manitoba Medical
College, 1969-1970
Thesis: "The Effect of Inhibition of Fetal
Adrenal Corticosteroid Formation by
Metapyrone (SU 4885) on the Formation of
Surfactant in the Fetal Lung."

Transplantation and Immunology, University of
Minnesota Medical School, 1974-1977. Areas:
Islet and hepatocellular transplantation.
Clinical transplantation.

Top of page

BOARD CERTIFICATION:

American Board of Surgery, 1980
Recertified, 1989

Top of page

ACADEMIC APPOINTMENTS:

Assistant Professor of Surgery,
State University of New York,
Downstate Medical Center,
Brooklyn, New York, 1980-1981

Assistant Professor of Surgery,
Albert Einstein College of Medicine,
Bronx, New York, 1981 to June 1986

Associate Professor of Surgery
Jack D. Weiler Hospital of the Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, 1986 - 1988

Associate Professor of Surgery
Director, Renal Transplant Service
University of Minnesota
Minneapolis, Minnesota 1988 - 1991

Professor of Surgery
Director, Renal Transplant Service
University of Minnesota
Minneapolis, Minnesota 1991

Top of page

HOSPITAL APPOINTMENTS:

Attending in Surgery, Kings County Hospital,
Brooklyn, New York, 1980-1981.

Attending in Surgery, Montefiore Medical Center, Bronx, New York, 1981 - 1988

Attending in Surgery, University of Minnesota
Hospital and Clinic, 1988 - to date

Consultant, Minnesota Veterans Administration
Hospital, 1988 - to date

Compliance Officer, Surgery Clinical Services Unit, University of Minnesota Physicians, Inc., 1998 - to date

Top of page

COMMITTEES:

Senate of Albert Einstein College of Medicine, 1982
Ambulatory Medical Audit Committee 1982 - 1985
Joint Med/Nursing Review Committee (HAECOM), 1983 - 1985
Resident Evaluation Committee (Surgery) (HAECOM) 1983 - 1988
Montefiore Medical Center Bioethics Committee 1984 - 1986
Director, Student Clerkships. Montefiore Medical Center 1984 - 1988
Quality Assurance Committee, University of Minnesota, 1988 - 1989
Pharmacy and Therapeutics Committee, University of Minnesota, 1988 -
Committee on Surgical Education, Society of University Surgeons, 1989 - 1992
Ethics Committee, American Society of Transplant Surgeons, 1990 - 1993
Publications Committee, American Society of Transplant Surgeons, 1991 - 94
Board of Directors, Upper Midwest Organ Procurement Organization 1988 -
Treasurer, Upper Midwest Organ Procurement Organization 1990 - 1992
President, Upper Midwest Organ Procurement Organization, 1996 -
Promotions & Tenure Committee, University of Minnesota, 1995 -
Scientific Study Committee, North American Pediatric Renal Transplant Cooperative Study (NAPRTCS), 1996-1998
Committee on Organ Donation, American Society of Transplant Physicians, 1996-1999
Co-chair, ASTS/ASTP Scientific Studies Joint Subcommittee on Steroid Withdrawal in Clinical Transplantation
Standards in Organ Procurement Committee, ASTS 1996-1998
Membership Committee, ASTS, 1997-1999
Compliance Committee, University of Minnesota Physicians, 1998-
American Society of Transplant Physicians Awards Committee 1998-2001
Councilor, The International Society for Organ Sharing, 1999-
Nominations Committee, ASTS, 2000-2002
Informatics and Data Management Committee, ASTS, 2000-2001

Top of page

SOCIETIES AND MEMBERSHIPS:

American College of Surgeons
American Society for Histocompatibility and Immunogenetics
American Society of Transplant Physicians
American Society of Transplant Surgeons
Association for Academic Surgery
International Society of Transplantation
Society of University Surgeons
The American Society of Nephrology
American Surgical Association

Top of page

EDITORIAL BOARDS:

Clinical Transplantation
Transplantation Science
Transplantation
Frontiers in Bioscience
Pediatric Transplantation
Nephrology News and Issues
Graft
Transplantation and Immunology Letter

Top of page

BIBLIOGRAPHY:

1. *Matas AJ and Kremen AJ: Idiopathic systemic fibrosis - The simultaneous occurrence of retroperitoneal fibrosis and desmoid tumor. Minn Med 57: 279-280, 1974.

2. *Matas AJ, Simmons RL, Buselmeier TJ, Najarian JS, and Kjellstrand CM: Lethal complications of bilateral nephrectomy and splenectomy in hemodialyzed patients. Am J Surg 129: 616-620, 1975.

3. *Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, and Najarian JS: Increased incidence of malignancy during chronic renal failure. Lancet 1: 883-886, 1975.

4. *Matas AJ, Simmons RL, and Najarian JS: Hypothesis - Chronic antigenic stimulation, viral-activation and malignancy in the transplant recipient. Lancet 1: 1277-1279, 1975.

5. *Matas AJ, Simmons RJ, Kersey JH, Kjellstrand CM, and Najarian JS: Cytomegalovirus and lymphoma in a pediatric transplant recipient. J Pediatr 87: 494-495, 1975.

6. Matas AJ, Sutherland DER, Steffes MW, Simmons RL, and Najarian JS: Hepatocellular transplantation in UDP-glucuronyl transferase deficient rats. Surg Forum 26: 428-430, 1975.

7. *Matas AJ, Simmons RL, Kjellstrand CM, and Najarian JS.: Increased serum creatinine resulting from hyperglycemia mimicking rejection. Ann Intern Med 83: 519, 1975.

8. *Matas AJ, Simmons RL, Buselmeier TJ, Kjellstrand CM, and Najarian JS: Successful transplantation in patients with prior history of malignancy. Am J Med 59: 791-795, 1975.

9. *Buselmeier TJ, Simmons RL, Duncan DA, Toledo LH, Mauer SM, Matas AJ, Hong C, Najarian JS, and Kjellstrand CM: Local steroid treatment of intractable ascites in dialysis patients. Proc Clin Dialysis Transpl Forum 5: 9-11, 1975.

10. *Matas AJ, Simmons RL, Goetz FC, Kjellstrand CM, Buselmeier TJ, and Najarian JS: Hyperglycemic pseudorejection in the diabetic transplant recipient. Surgery 79: 132-137, 1976.

11. Burk M, Matas AJ, and Simmons RL: Paraneoplastic syndromes. In: Najarian JS, and Delaney JP (eds): Advances in Cancer Surgery, Miami: Symposia Specialists, 1976, pp. 145-151.

12. Najarian JS and Matas AJ: Cancer in the immunosuppressed patient. In: Najarian JS and Delaney JP (eds): Advances in Cancer Surgery, Miami: Symposia Specialists, 1976, pp. 129-133.

13. *Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, and Najarian JS: Transplantation of the aging kidney. Transplantation 21: 160-161, 1976.

14. *Matas AJ, Mauer SM, Sutherland DER, Spanos P, Simmons RL, and Najarian JS: Polar infarct of a kidney transplant simulating appendicitis. Am J Surg 131: 363-365, 1976.

15. *Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Islet transplantation using neonatal pancreata: Quantitative studies. J Surg Res 20: 143-147, 1976.

16. *Buselmeier TJ, Simmons RL, Najarian JS, Mauer SM, Matas AJ, and Kjellstrand CM.: Uremic pericardial effusion: Treatment by catheter drainage and local nonabsorbable steroid administration. Nephron 16: 371-380, 1976.

17. *Matas AJ, Sutherland DER, Steffes MW, Mauer SM, Simmons R, and Najarian JS: Hepatocellular transplantation for metabolic diseases: Decreased serum bilirubin in uridine diphosphate glucuronyl transferase (UDPGT) deficient rats. Science 192: 892-894, 1976.

18. *Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Minimal collagenase digestion: Amelioration of diabetes with transplantation of one dispersed neonatal pancreas. Transplantation 22: 71-73, 1976.

19. *Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Short term culture of adult pancreatic fragments for purification and transplantation of islets of Langerhans. Surgery 80: 183-191, 1976.

20. *Matas AJ, Sutherland DER, and Najarian JS: The current status of islet and pancreas transplantation. Diabetes 25: 785-795, 1976.

21. *Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, and Najarian JS: Fate of renal transplant recipient surviving three years posttransplantation. Surgery 80: 390-395, 1976.

22. *Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Islet transplantation following prolonged warm ischemia of rat neonatal donors. Surg Forum 27: 343-345, 1976.

23. *Najarian JS, Simmons RL, Condie RM, Thompson EJ, Fryd DS, Howard RJ, Matas AJ, Sutherland DER, Ferguson RM, and Schmidtke JR: Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg 184: 352-368, 1976.

24. *Matas AJ, Hertel B, Rosai J, Simmons RL, and Najarian JS: Post-transplant malignant lymphoma - distinctive morphologic features related to its pathogenesis. Am J Med 61: 716-721, 1976.

25. *Matas AJ, Sheinman J, Rattazzi L, Mozes M, Simmons RL, and Najarian JS: Immunopathologic studies of the ruptured human renal allograft. Transplantation 5: 420-426, 1976.

26. *Sutherland DER, Kjellstrand CM, Simmons RL, Mauer SM, Buselmeier TJ, Goetz FC, Matas AJ, Haymond M, Howard RJ, Buls J, and Najarian JS: Renal transplantation in the diabetic. Minn Med 59: 766-771, 1976.

27. *Sutherland DER, Matas AJ, Steffes MW, and Najarian JS: Infant human pancreas: A potential source of islet tissue for transplantation. Diabetes 25: 1123-1128, 1976.

28. Kjellstrand CM, Davin TJ, Matas AJ, and Buselmeier TJ: Postoperative acute renal failure: Diagnosis, etiologic and symptomatic treatment and prognosis. In: Najarian JS and Delaney JP (eds): Critical Surgical Care, New York: Stratton International Medical Book Corp, 1977, pp. 309-334.

29. *Matas AJ, Payne WD, Simmons RL, Buselmeier TJ, and Kjellstrand CM.: Acute renal failure following blunt civilian trauma. Ann Surg 185: 301-306, 1977.

30. Matas AJ, Najarian JS, and Simmons RL: The complex pathogenesis of cancer in the transplant recipient. Compr Ther 3: 49-53, 1977.

31. *Matas AJ, Simmons RL, Kjellstrand CM, and Najarian JS: Pseudorejection: Factors mimicking rejection in renal allograft recipients. Ann Surg 186: 51-59, 1977.

32. *Sutherland DER, Matas AJ, and Najarian JS: Pancreas and islet transplantation for diabetes mellitus. World J Surg 1: 185-195, 1977.

33. Matas AJ, Sutherland DER, Kretschmer G, Steffes MW, and Najarian JS: Pancreatic tissue culture: Depletion of exocrine enzymes and purification of islets for transplantation. Transplant Proc 9: 337-339, 1977.

34. Najarian JS, Sutherland DER, Matas AJ, Steffes MW, and Goetz FC: Human islet transplantation: A preliminary experience. Transplant Proc 9: 233-236, 1977.

35. Sutherland DER, Matas AJ, Steffes MW, Simmons RL, and Najarian JS: Transplantation of liver cells in an animal model of congenital enzyme deficiency disease: The Gunn rat. Transplant Proc 9: 317-320, 1977.

36. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, and Najarian JS: Increased incidence of malignancy in uremic patients. Transplant Proc 9: 1977.

37. *Matas AJ, Sutherland DER, Payne WD, Kretschmer GJ, Steffes MW, and Najarian JS: Islet transplantation: The critical period of donor ischemia in neonatal rats. Transplantation 23: 295-298, 1977.

38. *Matas AJ, Simmons RL, Kjellstrand CM, Fryd DS, and Najarian JS: When should the third renal transplant rejection episode be treated? Ann Surg 186: 114-120, 1977.

39. *Simmons RL, Matas AJ, Rattazzi LC, Balfour HH, Howard RJ, and Najarian JS: Clinical characteristics of the lethal cytomegalovirus syndrome. Surgery 82: 537-546, 1977.

40. *Sutherland DER, Numata M, Matas AJ, Simmons RL, and Najarian JS: Hepatocellular transplantation in acute liver failure. Surgery 82: 124-132, 1977.

41. *Kretschmer GJ, Sutherland DER, Matas AJ, Cain TL and Najarian JS: Autotransplantation of pancreatic islets without separation of exo and endocrine tissue in totally pancreatectomized dogs. Surgery 82: 74-81, 1977.

42. *Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Islet transplantation. Surg Gynecol Obstet 145: 757-772, 1977.

43. Payne WD, Sutherland DER, Matas AJ, and Najarian JS: Amelioration of diabetes in rats by transplantation of islet tissue from a single donor to multiple recipients. Surg Forum 28: 301-304, 1977.

44. Numata M, Sutherland DER, Matas AJ, Simmons RL, and Najarian JS: Allogenic liver cell transplantation for acute hepatic failure. Surg Forum 28: 307-309, 1977.

45. Kretschmer GJ, Sutherland DER, Matas AJ, Olson L, and Najarian JS: Islet autotransplantation in pancreatectomized dog: Liver vs. spleen as a site of pancreatic tissue implantation. Surg Forum 28: 292-294, 1977.

46. *Kretschmer GJ, Sutherland DER, Matas AJ, Steffes MW, and Najarian JS: The dispersed pancreas: Transplantation without islet purification in totally pancreatectomized dogs. Diabetologia 13: 495-502, 1977.

47. Matas AJ, Sutherland DER, Payne WD, Steffes MW, Kretschmer GJ, and Najarian JS: Successful transplantation of neonatal rat islet tissue preserved up to 63 hours. Trans Amer Soc Artif Int Organs 23: 347-350, 1977.

48. Sutherland DER, Kretschmer GJ, Matas AJ, and Najarian JS: Experience with transplantation of pancreatic fragments to the spleen of totally pancreatectomized dogs. Trans Amer Soc Artif Int Organs 23: 723-725, 1977.

49. *Matas AJ, Payne WD, Grotting JC, Sutherland DER, Steffes MW, Hertel B, and Najarian JS: Portal vs. systemic islet transplantation using neonatal donors. Transplantation 24: 333-337, 1977.

50. Matas AJ, Simmons RL, and Desnick RJ: Organ and tissue transplantation for the treatment of metabolic disease. In: Buchwald H and Varco RL (eds): Surgery in Metabolic Disease, New York: Grune and Stratton, 1978, pp. 177-227.

51. *Matas AJ, Sutherland DER, Payne WD, Ekhardt J, and Najarian JS: A mouse model of islet transplantation using neonatal donors. Transplantation 24: 389-393, 1978.

52. *Kretschmer GJ, Sutherland DER, Matas AJ, Payne WD, and Najarian JS: Autotransplantation of pancreatic fragments to the portal vein and spleen of totally pancreatectomized dogs: A comparative evaluation. Ann Surg 187: 79-86, 1978.

53. Matas AJ and Simmons RL: The role of viruses in the pathogenesis of cancer in renal transplant recipients. In: Transplantation and Clinical Immunology, Amsterdam-Oxford: Vol. IX (prox. 9th International Course, Lyon, June 6-8, 1977). Excerpta Medica, 1978, pp. 71-80.

54. Sutherland DER, Matas AJ, and Najarian JS: Pancreatic islet cell transplantation. In Symposium on Organ Transplantation. Surg Clin North Am 58: 365-382, 1978.

55. *Matas AJ, Payne WD, Sutherland DER, and Najarian JS: On the interpretation of islet allograft and xenograft data. Transplantation 25: 281-283, 1978.

56. *Sheinman JI, Fish AJ, Matas AJ, and Michael AF: The immunohistopathology of glomerular antigens. II. The glomerular basement membrane, actomyosin and fibroblast surface antigens in normal, diseased and transplanted human kidneys. Am J Pathol 90: 71-88, 1978.

57. *Matas AJ, Simmons RL, Desnick RJ, and Najarian JS: Clinical and experimental transplantation in enzymatic deficiency diseases. Surg Gynecol Obstet 146: 975-982, 1978.

58. *Vialettes B, Sutherland DER, Payne WD, Matas AJ, and Najarian JS: Synergistic effect of donor specific soluble membrane antigen injection and antilymphocyte globulin administration on the survival of islet allografts in rats. Transplantation 25: 336-338, 1978.

59. *Mauer SM, Brown DM, Matas AJ, and Steffes MW: Effects of pancreatic islet transplantation upon the increased urinary albumin excretion rates in intact and uni-nephrectomized rats with diabetes mellitus. Diabetes [YEAR?];27: 959-964.

60. *Grotting JC, Rosai J, Matas AJ, Payne WD, Sutherland DER, and Najarian JS: Morphological and immunohistochemical studies on intraportally transplanted islets in diabetic rats. Am J Pathol 92: 653-670, 1978.

61. Howard RJ, Sutherland DER, Matas AJ, and Najarian JS: Successful treatment of viral induced diabetes mellitus by islet transplantation. Surg Forum 29: 343-345, 1978.

62. Payne WD, Sutherland DER, Matas AJ, and Najarian JS: Cryopreservation of neonatal rat islet tissue. Surg Forum 29: 347-349, 1978.

63. Vialettes B, Matas AJ, Sutherland DER, Payne WD, and Najarian JS: Effect of islet transplantation on plasma lipid levels in diabetic rats. Surg Forum 29: 345-347, 1978.

64. Hong C, Sutherland DER, Matas AJ, Simmons RL, and Najarian JS: Enzyme replacement in acatalasemic mice by bone marrow transplantation. Surg Forum 29: 333-335, 1978.

65. Matas AJ, Sutherland DER, and Najarian JS: Transplantation of hepatocytes and pancreatic islets. In: Gregoriadis, G. (eds): Drug Carriers in Biology and Medicine, London: Academic Press, 1979, pp. 191-209.

66. *Payne WD, Sutherland DER, Matas AJ, Gorecki P, and Najarian JS: DL-enthionine treatment of adult pancreatic donors: Amelioration of diabetes in multiple recipients with tissue from a single donor. Ann Surg 189: 248-256, 1979.

67. *Vialettes B, Sutherland DER, Matas AJ, Payne WD, and Najarian JS: Amelioration of streptozotocin induced diabetes in rats: Effect of islet isografts on plasma lipids and other metabolic abnormalities according to donor source and site of transplantation. Metabolism 28: 489-494, 1979.

68. *Howard RJ, Balfour HH, Jr, Matas AJ, Najarian JS, and Sutherland, D.E.R.: Encephalomyocarditis virus-induced diabetes mellitus treated by islet transplantation. Transplantation 27: 200-202, 1979.

69. *Steffes MW, Brown DM, Basgen J, Matas AJ, and Mauer SM: Glomerular basement membrane thickness following islet transplantation in the rat. Lab Invest 41: 116-118, 1979.

70. *Lum CT, Sutherland DER, Eckhardt J, Matas AJ, and Najarian JS: Effect of an adenosine deaminase (ADA) inhibitor on survival of mouse pancreatic islet allografts. Transplantation 27: 355-357, 1979.

71. Kretschmer GJ, Sutherland DER, Matas AJ, and Najarian JS: Preliminary experience with allotransplantation of pancreatic fragments to the spleen of totally pancreatectomized dogs. Transplant Proc 11: 537-542, 1979.

72. Sommer BG, Sutherland DER, Matas AJ, and Najarian JS: Hepatocellular transplantation for treatment of D-galactosamine induced acute liver failure in rats. Transplant Proc 11: 578-584, 1979.

73. Najarian JS, Sutherland DER, Matas AJ, and Goetz FC: Human islet autotransplantation following pancreatectomy. Transplant Proc 11: 336-340, 1979.

74. Hong C, Sutherland DER, Matas AJ, and Najarian JS: Bone marrow transplantation for correction of enzyme deficiency disease. Transplant Proc 11: 498-503, 1979.

75. Howard RJ, Matas AJ, Balfour HH, Cohn R, Najarian JS, and Sutherland DER: Reversal of encephalomyocarditis virus-induced diabetes mellitus by islet transplantation. Transplant Proc 11: 557-559, 1979.

76. Foker JE, Schwartz R, Smith DC, and Matas AJ: Surgical problems arising in immunodeficient and immunosuppressed children. Surg Clin North Am 59: 213-221, 1979.

77. Sutherland DER, Matas AJ, Kretschmer GJ, and Najarian JS: Clinical applications and future of islet transplantation. In: Touraine JL et al. (eds): Transplantation and Clinical Immunology, Amsterdam-Oxford, Vol. 10. Excerpta Medica, 1979, pp. 227-231.

78. Sutherland DER, Frenzel E, Payne DW, Matas AJ, and Najarian JS: Transplantation of adult islet tissue in rats: Spleen vs. portal vein site. Surg Forum 30: 305-307, 1979.

79. *Lum CT, Sutherland DER, Matas AJ, Eckhardt J, and Najarian JS: Prolongation of mouse pancreatic islet cell allografts by inhibition of adenosine deaminase (ADA). J Surg Res 28: 44-48, 1980.

80. Matas AJ, Simmons RL, and Najarian JS: Sepsis following renal transplantation. In: Hardy JD (ed): Critical Surgical Illness, Philadelphia: W.B. Saunders Co, 1980, pp. 552-590.

81. *Sutherland DER, Matas AJ, Goetz FC, and Najarian JS: Transplantation of dispersed pancreatic islet tissue in humans: Autografts and allografts. Diabetes 29 (Suppl. 1): 31-44, 1980.

82. Sutherland DER, Goetz FC, Rynasiewicz J, Kawahara K, Matas AJ, Payne WD, Baumgartner D, and Najarian JS: Pancreas and islet transplantation for clinical and experimental diabetes. In: Bibergeil H, Zuhlke H, and Poser U (eds): Proc. of X. Karlsberg Symposium: Early Diabetes - Pathogenesis, Diagnosis, Prevention. Karlsberg: Cent. Inst. Diabetes Gerhardt Katsch, 1980, pp. 225-278.

83. Najarian JS, Sutherland DER, Matas AJ, and Goetz FC: Near total pancreatectomy with islet cell autotransplantation for chronic pancreatitis. In: Najarian JS and Delaney JP (eds): Hepatic, Biliary and Pancreatic Surgery. Year Book Medical Publishers, Chicago, 1980, pp. 357-371.

84. *Grotting JC, Rosai J, Matas AJ, Frenzel EM, Huchnert L, Sutherland DER, and Najarian JS: Morphologic characterization of long term pancreatic islet transplants in diabetic rats. Minn Med 63: 321-326, 1980.

85. *Sutherland DER, Matas AJ, and Najarian JS: The mutual impact of transplantation on advances in the understanding and treatment of metabolic diseases. Transplant Proc 12: 634-642, 1980.

86. Najarian JS, Sutherland DER, Baumgartner D, Burke B, Rynesiewicz J, Matas AJ, and Goetz FC: Total or near total pancreatectomy and islet autotransplantation for treatment of pancreatitis. Ann Surg 192: 526-542, 1980.

87. Kjellstrand C, Matas A, Cosio F, and Davin T: Are malignancies increased in uremia and dialysis? Proc 8th Int Cong Neph, Athens, pp. 1217-1222, 1981.

88. Matas AJ, Simmons RL, Fryd D, and Najarian JS: Persistent, recurrent and late cytomegalovirus infection. Transplant Proc 13: 114-116, 1981.

89. Matas AJ and Najarian JS: Defining who is at high risk for breast cancer. In: Najarian JS and Delaney JP (eds): Breast Surgery, New York: Appleton-Century-Crofts, 1981, pp. 1-14.

90. *Hong JH, Shirani K, Arshad A, Parsa I, Matas A, Adamsons R and Butt K: Influence of cadaver donor age on the success of kidney transplantation. Transplantation 32: 532-534, 1981.

91. *Matas AJ, Sutherland DER, Payne WD, Van Hook EJ, Simmons RL, and Najarian JS: Retrieval of kidneys for transplantation from cadaveric donors in Minnesota: One center's experience. Minn Med 65: 165-166, 1982.

92. *Matas AJ, Sibley R, Mauer SM, Kim T, Sutherland DER, Simmons RL, and Najarian JS: Pre-discharge, post-transplant kidney biopsy does not predict rejection. J Surg Res 32: 269-274, 1982.

93. *Norin AJ, Emeson EE, Kamholz SL, Pinsker KL, Montefusco CM, Matas AJ, and Veith FJ: Cyclosporine A as the initial immunosuppressive agent for canine lung transplantation: Short and long term assessment of rejection phenomena. Transplantation 34: 372-375, 1982.

94. *Matas AJ, Tellis VA and Veith FJ: Renal transplantation in the patient with juvenile onset diabetes mellitus - An overview. NY State J Med 82: 1015-1019, 1982.

95. Mollenkopf F, Matas A, Veith FJ, Sprayregen S, Soberman R, Kuemmel P, Tellis V, Sniderman K, Sos T, Cheigh JS, and Stubenbord W Jr.: Percutaneous transluminal angioplasty for transplant renal artery stenosis. Transplant Proc 15: 1089-1091, 1983.

96. *Matas AJ, Sibley RK, Mauer SM, Sutherland DER, Simmons RL, and Najarian JS: The value of needle renal allograft biopsy. I. A retrospective study of biopsies performed during putative rejection episodes. Ann Surg 197: 226-237, 1983.

97. *Sutherland DER, Morrow CE, Florak G, Kretschmer G, Bumgardner G, Matas AJ, and Najarian JS: Cold storage preservation of islet and pancreas grafts as assessed by in vitro function after transplantation to diabetic hosts. Cryobiology 20: 138-150, 1983.

98. Matas AJ, Miller JB, Schneider PD, Sutherland DER, Simmons RL, and Najarian JS: Assessment of 215 consecutive posttransplant hospital readmissions for renal allograft recipients at a single institution. Transplant Proc 15: 1702-1704, 1983.

99. *Matas AJ, Tellis VA, Veith FJ, Kuemmel P, Mollenkopf F, Karwa G, and Soberman R: The fate of the patient returned to hemodialysis after losing a renal transplant. JAMA 250: 1053-1056, 1983.

100. Matas AJ, Nehlsen-Cannarella SL, Tellis VA, Kuemmel P, Soberman RJ, and Veith FJ: Renal transplantation in patients having positive crossmatch with historical sera. Surg Forum 34: 415-416, 1983.

101. *Payne WD, Sutherland DER, Matas AJ, and Najarian JS: Successful long-term cryopreservation of neonatal rat islet tissue. Cryobiology 20: 226-229, 1983.

102. *Matas AJ, Nehlsen-Cannarella S, Tellis VA, Kuemmel P, Soberman R, and Veith FJ: Successful kidney transplantation with current sera negative/historical sera positive T cell crossmatch. Transplantation 37: 111-112, 1984.

103. *Kamholz S, Veith FJ, Mollenkopf F, Montefusco C, Nehlsen-Cannarella S, Kaleya R, Pinsker K, Tellis V, Soberman R, Sablay L, Matas A, Gliedman M, Goldsmith J, Fell S, Brodman R, Merav A, Shander A, Hollinger I, and Nagashima H: Single lung transplantation in paraquat intoxication. NY State J Med 84: 82-84, 1984.

104. *Dunn DL, Matas AJ, Fryd DS, Simmons RL, and Najarian JS: Association of concurrent herpes simplex virus and cytomegalovirus with detrimental effects after renal transplantation. Arch Surg 119: 812-817, 1984.

105. *Matas AJ, Sablay L, Tellis VA, Kuemmel P, Soberman R, Veith FJ: The value of renal allograft biopsy. II. Reflection of acute rejection changes throughout the kidney by percutaneous biopsy. Transplantation 38: 92-93, 1984.

106. *Matas AJ and Veith FJ: Presumed consent for organ donation. Theor Med 5: 155-166, 1984.

107. Matas AJ, Tellis V, Quinn T, Glicklich D, Soberman R, Veith F: Renal transplant rejection treatment - a cost effective approach. Transplant Proc 17: 189-190, 1985.

108. *Matas AJ: Death with dignity. A personal look into a major moral conflict for the physician in today's society. Minn Med 68: 209, 1985.

109. *Tellis VA, Matas AJ, Glicklich D, Quinn T, Soberman R, Weiss R, Veith FJ: Cyclosporine: preliminary experience in 79 renal transplants. NYS J Med 85: 531-534, 1985.

110. *Matas AJ, Arras J, Muyskens J, Tellis VA, Veith FJ: A proposal for cadaver organ procurement: Routine removal with right of informed refusal. J Health Politics, Policy and Law 10: 231-244, 1985.

111. *Matas AJ, Tellis VA, Sablay L, Quinn T, Soberman R, Veith FJ: The value of needle renal allograft biopsy III. A prospective study. Surgery 98: 922-926, 1985.

112. *Matas AJ, Tellis VA, Quinn T, Karwa G, Glicklich D, Soberman R and Veith FJ: Treatment of renal transplant rejection episodes in patients receiving prednisone and azathioprine - a cost effective approach. Transplantation 40: 35-39, 1985.

113. Tellis VA, and Matas AJ: Transplantation Surgery. In: Gold MS, Scher LA and Weinberg G (eds): General Surgery Board Review. New York: Raven Press, 1986, pp 138-151

114. *Wengerter K, Matas AJ, Tellis VA, Quinn T, Soberman R and Veith FJ: Transplantation of pediatric donor kidneys to adult recipients - is there a critical donor age? Ann Surg 204: 172-175, 1986.

115. *Matas AJ, Tellis VA, Gupta SK, Quinn T, Soverman R, Veith FJ: An integrated microcomputer system for transplant data retrieval and analysis. Dialysis and Transplantation 15: 309-311, 1986.

116. *Matas AJ, Tellis VA, Quinn T, Glicklich D, Soverman R, Weiss R, Veith FJ: ALG treatment of steroid resistant rejection in patients receiving cyclosporine. Transplantation 41: 579-582, 1986.

117. *Odenheimer D, Matas AJ, Tellis VA, Quinn T, Glicklich D, Soberman R, Veith FJ: Donor cultures reported positive following renal transplantation - a clinical dilemma. Transplant Proc 18: 465-466, 1986.

118. Wengerter K, Matas AJ, Tellis VA, Quinn T, Soberman R, Veith FJ: Which pediatric donor kidneys should be transplanted to adults? Transplant Proc 18: 475-476, 1986.

119. Matas AJ, Tellis VA, Quinn T, Soberman R, Veith FJ: Definition, Diagnosis and Management of Rejection in the Second to Sixth Months Posttransplant - An Overview. Transplant Proc 18: 11: 141-147, 1986.

120. *Gordon JV, White R, Matas AJ, Tellis VA, Glicklich D, Quinn T, Soberman R, Veith FJ: Renal transplantation in patients with a history of heroin abuse. Transplantation 42: 556-557, 1986.

121. Matas AJ and Veith FJ: Presumed consent - A more humane approach to cadaver organ donation. In: Kutscher AH (ed): Positive approaches to living with end stage renal disease: Psychosocial aspects for the patient family, staff, and community, 1987.

122. Matas AJ and Simmons RL: Sepsis following kidney transplantation. In: Santiago-Delpin E, Ruiz-Speare O and Chavez, Peon R (eds): Transplante De Organos, Salvat, 1987.

123. *Glicklich D, Matas AJ, Sablay LG, Senitzer D, Tellis VA, Soberman R, and Veith FJ: Recurrent membranoproliferative glomerulonephritis type 1 in successive renal transplants. Am J Nephrol 7: 143-149, 1987.

124. Neiberger RE, Weiss RA, Greiffer I, Tellis VA and Matas AJ: Elimination kinetics of cyclosporine following oral administration to children with renal transplants. Transplant Proc 19: 1525, 1987.

125. Tellis VA, Matas AJ, Quinn TA, Glicklich D, Weiss R, Soberman R and Veith FJ: Antilymphoblast globulin treatment of steroid resistant rejection in cyclosporine immunosuppressed renal transplant recipients. Transplant Proc 19: 1892, 1987.

126. *Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R and Veith FJ: Timing of cyclosporine administration in patients with posttransplant ATN. J Surg Res 43: 489-494, 1987.

127. *Matas AJ, Tellis VA, Karwa GL, Quinn TA, Hershman J, Soberman R, Bard R, Veith FJ: Comparison of posttransplant urologic complications following extravesical ureteroneocystostomy by a "single stitch" or "mucosal" anastomosis. Clin Transplantation 1: 159-163, 1987.

128. *Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ: Does race affect renal transplant results? - a single institution study. Clin Transplantation 1: 261-264, 1987.

129. Tellis VA, Matas AJ and Veith FJ: Vascular complications in transplantation. In: Cerilli, G.J, Lippincott, J.B, (eds): Organ Transplantation and Replacement, 1988, pp 423-433

130. *Tellis VA, Weiss P, Matas A and Veith FJ: Skin-flap coverage of polytetrafluorethylene vascular access graft exposed by previous infection. Surgery 103: 118-121, 1988.

131. Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman RJ, Veith FJ: The effect of referring dialysis center on transplant outcome. Transplant Proc 20 (Suppl.1): 375-376, 1988.

132. Senitzer D, Matas AJ, Tellis VA, Veith FJ, Soberman R: Do shared HLA antigens between present and past donors adversely affect graft survival in recipients with a past positive donor crossmatch? Transplant Proc 20 (Suppl.1): 34-36, 1988.

133. *Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ: Individualization of immediate posttransplant immunosuppression - the value of ALG in patients with delayed graft function. Transplantation 45: 406-409, 1988.

134. *Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ: Successful transplantation of highly sensitized patients without regard to HLA matching. Transplantation 45: 338-342, 1988.

135. Perez LM, Matas AJ, Tellis VA: Organ donation in three United States cities by race/ethnicity. Transplant Proc 20: 815, 1988.

136. *Matas AJ, Quinn TA, Tellis VA, Glicklich D, Soberman R, Veith FJ: Referring dialysis center affects renal transplant results. Transplantation 45: 894-898, 1988.

137. *Glicklich D, Seegmiller JE, Matas AJ, Tellis VA, Quinn TA, Karwa G, Kenner K, Finley K, Gruber HE, Soberman R, Veith FJ: 2,8-dihydroxyadenine urolithiasis: Report of a case first diagnosed following renal transplantation. Quart J Med 69: 785-793, 1988.

138. *Stein M, Matas AJ, Tellis VA, Quinn TA, Karwa GL, Glicklich D, Soberman RJ, Veith FJ: When is further ALG administration futile? Transplantation 46: 464-466, 1988.

139. *Perez LM, Matas AJ, Tellis VA, Schulman B, Davis F, Olson L: Organ donation in three major American cities with large latino and black populations. Transplantation 46: 553-557, 1988.

140. *Matas AJ, Tellis VA, Glicklich D, Soberman R, Veith FJ: Transplantation with past positive crossmatch and cyclosporine immunosuppression - A five year experience. Clin Transplantation 2: 336-340, 1988.

141. Fryd DS, Canafax DM, Matas AJ, Dunn D, Payne WD, Sutherland DER, Najarian JS: A comparison of two cyclosporine protocols at the University of Minnesota. In: Terasaki P (ed): Clinical Transplants 1988, Los Angeles: UCLA Tissue Typing Laboratory, 1988, pp 79-90.

142. Tellis V, Matas A, Soberman R, Principe A, Quinn T, Mallis M, Veith F: Long-term patient survival after cadaver renal transplantation. Transplant Proc 21: 2186, 1989.

143. Quinn T, Louis P, Mallis M, Senitzer DS, Tellis V, Matas A: A past positive crossmatch does not affect allograft survival for cyclosporine immunosuppressed primary and secondary renal transplant recipients. Transplant Proc 21: 704, 1989.

144. Matas A, Tellis V, Quinn T, Mallis M, Glicklich D, Senitzer DS, Soberman R: Long-term results of O-antigen match cadaver transplants - A single institution study. Transplant Proc 21: 682, 1989.

145. *Tellis VA, Matas AJ, Senitzer DS, Louis P, Glicklich D, Soberman R, Veith F: Successful transplantation after conversion of a positive crossmatch to negative by dissociation of IgM antibody. Transplantation 47: 127-129, 1989.

146. Reisfeld D, Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman RJ, Bakal C, Sprayragen S, Veith FJ: Late follow-up of percutaneous transluminal angioplasty for treatment of transplant renal artery stenosis. Transplant Proc 21: 1955-1956, 1989.

147. *Gruber S, Chavers B, Payne W, Fryd D, Canafax D, Simmons R, Najarian J, Matas A: Allograft renal vascular thrombosis: Lack of increase with cyclosporine immunosuppression. Transplantation 47: 475-478, 1989.

148. Gruber SA, Burke BA, Canafax DM, Hrushesky WJM, Cipolle RJ, Erdmann GR, Matas A, Simmons RL, Najarian JS: Feasibility of vascular catheter placement for intrarenal infusion in a canine autotransplant model. Transplant Proc 21: 1125-1126, 1989.

149. Gruber SA, Chavers B, Payne WD, Fryd DS, Canafax DM, Simmons RL, Najarian JS, Matas A.: Frequency of allograft renal vascular thrombosis under three immunosuppressive regimens at a single institution. Transplant Proc 21: 2139-2140, 1989.

150. *Matas AJ, Tellis VA, Quinn T, Principe A, Mallis M, Glicklich D, Veith F: Short- and long-term graft survival with O antigen-matched first cadaver renal transplants - A single institution study. Clin Transplantation 3: 22-26, 1989.

151. *Matas A, Fryd D: Renal transplantation - The importance of well designed single institution and multicenter studies. Clin Transplantation 3: 63-65, 1989.

152. Louis P, Senitzer D, Tellis V, Matas A: Successful transplantation after conversion of a positive crossmatch to negative by dissociation of IgM antibody. Transplant Proc 21: 764-765, 1989.

153. Glicklich D, Tellis VA, Matas AJ, Mallis M, Quinn T, Soberman R, Veith FJ: No association between posttransplant erythrocytosis, thromboembolic events, and cyclosporine therapy. Transplant Proc 21: 2141-2142, 1989.

154. *Canafax DM, Min DI, Gruber SA, Fryd DS, Matas AJ, Payne WD, Dunn DL, Sutherland DER, Simmons RL, Najarian JS: Immunosuppression of cadaveric renal allograft recipients: A risk-factor matched comparison of the Minnesota randomized trial with an antilymphoblast globulin, azathioprine, cyclosporine, and prednisone protocol. Clin Transplantation 3: 110-119, 1989.

155. *Gruessner RWG, Matas AJ, Lloveras G, Fryd DS, Dunn DL, Payne WD, Sutherland DER, Najarian JS: A comparison of single and double pediatric cadaver donor kidneys for transplantation. Clin Transplantation 3: 209-214, 1989.

156. *Gruber SA, Venkataram S, Canafax DM, Cipolle RJ, Bowers L, Elsberry D, McGuiggan M, Hynes PE, Ritz JA, Gould FH, Matas A, Hrushesky WJM, Rahman YE: Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine. Pharm Res 6: 601-607, 1989.

157. Bumgardner GL, Ascher NL, Chen S, Cunningham TR, Payne WD, Matas AJ: Immunosuppressive factor in hepatocyte and liver cytosol. Surg Forum 40: 391-393, 1989.

158. Fasola C, Matas A, Payne W, Najarian J: Reversal of acute hepatic failure in a large animal model by autologous hepatocyte transplantation. Surg Forum 40: 347-349, 1989.

159. *Tzardis PJ, Gruessner RWG, Matas AJ, Fryd DS, Payne WD, Dunn DL, Sutherland DER, Najarian JS: Renal transplantation in patients with polycystic kidney disease: a single center experience. Clin Transplantation 3: 325-330, 1989.

160. *Gruessner RWG, Matas AJ, Lloveras G, Fryd DS, Dunn DL, Payne WD, Sutherland DER, Najarian JS: Pediatric donors - a risk factor in renal retransplantation. Clin Transplantation 3: 349-354, 1989.

161. *Gruber SA, Hrushesky WJM, Cipolle RJ, Erdmann GR, Burke BA, Skjei KL, Mueller RP, Fryd DS, Matas AJ, Simmons RL, Canafax DM: Local immunosuppression with reduced systemic toxicity in a canine renal allograft model. Transplantation 48: 936-943, 1989.

162. *Gruber SA, Hrushesky WJM, Canafax DM, Cipolle RJ, Burke BA, Matas AJ, Ascher NL, Simmons RL: Local prednisolone infusion of canine renal allografts. Transplantation 48: 1072-1075, 1989.

163. *Matas AJ, Sutherland DER, Payne WD, Dunn DL, Perry E, Najarian JS: New approaches to living donor renal transplantation. Minn Med 72: 589-592, 1989.

164. Chavers BM, Matas AJ, Nevins TE, Mauer SM, Sutherland DER, Payne W, Dunn D, Gillingham K, Najarian JS: Results of pediatric kidney transplantation at the University of Minnesota. In Clinical Transplants 1989, Terasaki P (ed) Los Angeles, CA: UCLA Tissue Typing Laboratory, 1989, pp 253-266.

165. *Gruber SA, Canafax DM, Cipolle RJ, Erdmann GR, Burke BA, Matas AJ, Simmons RL, Hrushesky WJM: Local immunosuppression of the vascularized graft. Surgery 107: 210-214, 1990.

166. *Gruber SA, Cipolle RJ, Tzardis P, Skjei KL, Jossart G, Abed JF, Canafax DM, Burke BA, Matas AJ, Hrushesky WJM: Pharmacodynamics of local heparin infusion in a canine renal allograft model. J Pharmacol Exp Ther 252: 733-738, 1990.

167. *Greenstein SM, Schechner RS, Louis P, Senitzer D, Matas AJ, Veith FJ, Tellis VA: Evidence that zero antigen-matched cyclosporine-treated renal transplant recipients have graft survival equal to that of matched recipients. Transplantation 49: 332-336, 1990.

168. *Bumgardner GL, Matas AJ, Chen S, Cahill D, Cunningham TR, Payne WD, Bach FH, Ascher NL.: Comparison of in vivo and in vitro immune response to purified hepatocytes. Transplantation 49: 429-436, 1990.

169. *Chan GLC, Erdmann GR, Gruber SA, Matas AJ, Canafax DM: Azathioprine metabolism: Pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 30: 358-363, 1990.

170. Wrenshall L, Matas AJ, Payne WD, Sutherland DER, Bolman RM, Cerra F: Critical care of the transplant patient. In: Berk JL and Sampliner JE (eds): Handbook of Critical Care, Boston: Little, Brown and Company, 1990, pp 729-752.

171. Schechner RS, Schlumpf R, Tellis VA, Greenstein SM, Matas AJ: Receipt of shared organs at two geographically separate centers-the impact of UNOS. Transplant Proc 22: 305, 1990.

172. Gruessner RWG, Matas AJ, Dunn DL, Lloveras, G, Payne WD, Sutherland DER, Najarian JS: A comparison of pediatric versus adult cadaver donor kidneys for transplantation. Transplant Proc 22: 361-362, 1990.

173. Dunn DL, Schlumpf RB, Gruessner RWG, Morel P, Mayoral JL, Payne WD, Matas AJ, Sutherland DER, Moudry-Munns KC, Najarian JS: Maximal use of liver and pancreas from cadaveric organ donors. Transplant Proc 22: 423-424, 1990.

174. Gruessner RWG, Dunn DL, Tzardis PJ, Tomadze G, Moudry-Munns KC, Matas AJ, Najarian JS, Sutherland DER: Simultaneous pancreas and kidney transplants versus single kidney transplants and previous kidney transplants in uremic patients and single pancreas transplants in nonuremic diabetic patients: comparison of rejection, morbidity, and long-term outcome. Transplant Proc 22: 622-623, 1990.

175. *Tzardis PJ, Gruessner RWG, Matas AJ, Payne WD, Dunn DL, Sutherland DER, Najarian JS: Long-term follow-up of renal transplantation for Wegener's disease. Clin Transplantation 4: 108-111, 1990.

176. *Tellis VA, Reisfeld D, Matas AJ, Sprayragen S, Bakal C, Soberman R, Glicklich D, Veith FJ: Long-term results of percutaneous transluminal angioplasty for treatment of renal artery stenosis. Dial and Transpl 19: 22-28, 1990.

177. *Fabrega A, Matas AJ, Payne WD, Fryd DS, Dunn DL, Sutherland DER, Najarian JS: Ten- to 20-year follow-up of 123 consecutive HLA-identical living-related kidney transplants from the pre-cyclosporine era. Clin Transplantation 4: 145-152, 1990.

178. *Gruessner RWG, Tzardis PJ, Matas AJ, Dunn DL, Payne WD, Sutherland DER, Najarian JS: Ileal and colon conduits in renal transplantation. Clin Transplantation 4: 125-128, 1990.

179. *Matas AJ, Brayman KL, Gillingham KJ: Presentation of renal transplant graft survival data - where should "death with a functioning graft" be included? Clin Transplantation 4: 142-144, 1990.

180. Fischel RJ, Bolman RM, Platt JL, Najarian JS, Bach FH, Matas AJ: Removal of IgM anti-endothelial antibodies results in prolonged cardiac xenograft survival. Transplant Proc 22: 1077-1078, 1990.

181. *Canafax DM, Seifeldin R, Gruber SA, Hadsall RS, Miles CJ, Najarian JS, Matas AJ, Cipolle RJ: The pharmacoeconomics of organ transplantation: increased drug costs with decreased hospitalization costs. Pharmacotherapy 10: 205-210, 1990.

182. *Wrenshall LE, Matas AJ, Canafax DM, Min DI, Sibley RJ, Dunn DL, Payne WD, Sutherland DER, Najarian JS: An increased incidence of late acute rejection episodes in recipients of cadaver renal allografts given azathioprine, cyclosporine and prednisone. Transplantation 50: 233-237, 1990.

183. Tzardis PJ, Gruessner RWG, Matas AJ, Fryd DS, Payne WD, Dunn DL, Sutherland DER, Najarian JS: Renal transplantation in patients with polycystic kidney disease: a single center experience. In Golematis (ed): Chrysophillis, Athens, Greece, May, 1990, pp 395-406.

184. Chavers BM, Matas AJ, Nevins TE, Mauer SM, Sutherland DER, Payne WD, Dunn DL, Gillingham K, Najarian JS: Present status of kidney transplantation in children at the University of Minnesota. In Golematis (ed): Chrysophillis, Athens, Greece, May, 1990, pp 601-612.

185. Najarian JS, Frey DJ, Matas AJ, Gillingham KJ, So SSK, Cook M, Chavers B, Mauer SM, Nevins TE: Renal transplantation in infants. Ann Surg 212: 353-357, 1990.

186. *Matas AJ, Frey DJ, Gillingham KJ, Noreen HJ, Reinsmoen NL, Payne WD, Dunn DL, Sutherland DER, Najarian JS: The impact of HLA matching on graft survival and on sensitization after a failed transplant - evidence that failure of poorly matched renal transplants does not result in increased sensitization. Transplantation 50: 599-607, 1990.

187. Fasola CG, Kim YS, Manivel JC, Cerra FB, Matas AJ, Payne WD: Reversal of acute hepatic failure in pigs by xenogeneic hepatocyte (HC) transplantation and by injection of supernatant from xenogeneic HC cultures. Surg Forum 51: 374-375, 1990.

188. Frey DJ, Matas AJ: Renal transplantation. In: Cerra F (ed): Critical Care Clinics, 6: 4: pp 899-910, 1990 (October).

189. *Tzardis PJ, Gruessner RWG, Matas AJ, Payne WD, Dunn DL, Sutherland, DER: Fate of native polycystic kidneys left in situ after renal transplantation. Clin Transplantation 4: 309-310, 1990.

190. *Canafax DM, Min DI, Matas AJ, Amend WJC, Ptachcinski RJ, Hakala TR, Grevel J, Houghton D, Kahan BD, Simmons RL, Najarian JS, Cipolle RJ: The effects of initial cyclosporine dose and timing on long-term creatinine levels in cadaver renal transplantation. Clin Transplantation 4: 321-328, 1990.

191. *Gruessner RWG, Schechner R, Heil J, Matas AJ, Sutherland DER: En-bloc simultaneous pancreas and kidney allotransplantation in the pig. J Surg Res 49: 366-370, 1990.

192. *Reinsmoen NL, Kaufman D, Matas AJ, Sutherland DER, Najarian JS, Bach FH: A new in vitro approach to determine acquired tolerance in long-term kidney allograft recipients. Transplantation 50: 783-790, 1990.

193. *Fischel R, Kim W, Cahill D, Bolman R, Matas A: Cellular immunity in species with variable rejection of vascularized grafts. J Surg Res 49: 302-305, 1990.

194. Fischel RJ, Kim W, Cahill D, Matas AJ: The cellular response to xenotransplantation. Curr Surg 47: 345-347, 1990.

195. *Bumgardner GL, Matas AJ, Payne WD, Dunn DL, Sutherland DER, Najarian JS: Renal transplantation in patients with paraproteinemias. Clin Transplantation 4: 399-405, 1990.

196. Almond PS, Bumgardner GL, Chen S, Cunningham T, Payne W, Matas AJ: Correlation of Class I antigen expression with immunogenicity. Current Surgery 47: 262-264, 1990.

197. *Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, Bach FH: Transplantation of discordant xenografts: a review of progress. Immunol Today 11: 450-456, 1990.

198. *So SKS, Gillingham K, Cook M, Mauer SM, Matas AJ, Nevins TE, Chavers BM, Najarian JS: The use of cadaver kidneys for transplantation in young children. Transplantation 50: 979-983, 1990.

199. Bumgardner GL, Chen S, Almond PS, Ascher NL, Payne WD, Matas AJ: Role of macrophages in the immune response to hepatocytes. J Surg Res 48: 568-572, 1990.

200. Sutherland DER, Gruessner RWG, Matas AJ, Lloveras G, Fryd DS, Dunn DL, Payne WD, Najarian JS: Transplantation of single and double kidneys from pediatric donors. In: Abouna GM, Kumar MSA and White AG (eds): Organ Transplantation 1990, Dordrecht: Kluwer Academic Publishers, 1990, 201-202.

201. *Dunn DL, Mayoral JL, Gillingham KJ, Loeffler CM, Brayman KL, Kramer MA, Erice A, Balfour HH, Fletcher CV, Bolman RM, Matas AJ, Payne WD, Sutherland DER, Najarian JS: Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 51: 98-106, 1991.

202. *Frey DJ, Matas AJ: Allocation of cadaver kidneys: a survey of the American Society of Transplant Surgeons. Clin Transplantation 5: 1-2, 1991.

203. Bumgardner GL, Almond PS, Chen SC, Matas AJ: Memory T cells generated in vitro to MHC class I+, II- hepatocytes. Transplant Proc 23: 104-105, 1991.

204. Chen S, Almond PS, Bumgardner GL, Bach FH, Matas AJ: The role of antigen presenting cells in secondary mixed lymphocyte hepatocyte cultures. Transplant Proc 23: 106-107, 1991.

205. Almond PS, Bumgardner GL, Chen S, Platt JL, Payne WD, Matas AJ: Immunogenicity of Class I+, Class II- hepatocytes. Transplant Proc 23: 108-109, 1991.

206. Reinsmoen NL, Matas AJ, Kaufman D, Sutherland DER, Najarian JS, Bach FH: Acquired donor-specific hyporesponsiveness in long-term kidney allograft recipients. Transplant Proc 23: 141-142, 1991.

207. Fischel RJ, Matas AJ, Platt JL, Perry E, Manivel C, Bach FH, Najarian JS, Bolman RM: Prolonged survival of a discordant cardiac xenograft in a rhesus monkey. Transplant Proc 23: 589-590, 1991.

208. Schlumpf R, Morel P, Loveras JJ, Condie RM, Matas AJ, Kurle J, Fasola CG, Najarian JS, Sutherland DER: Dextran 40 successfully replaces the non-essential hydroxyethylstarch in the UW solution for 72-hours simple cold storage of the canine kidney. Transplant Proc 23: 657-659, 1991.

209. Wrenshall LE, Platt JL, Chopek MW, Fischel R, Matas AJ: ABO-incompatible transplantation in pigtail macaque monkeys. Transplant Proc 23, 703-704, 1991.

210. Bumgardner GL, Almond PS, Chen SC, Matas AJ: Indirect antigen presentation of hepatocyte (HC) MHC class I antigen in HC-sponge matrix allografts. Transplant Proc 23: 835-836, 1991.

211. Morel P, Kaufman DB, Platt J, Brayman K, Field MJ, Lloveras JK, Almond PS, Fasola C, Kyriakides P, Tzardis P, Schlumpf R, Matas AJ, Sutherland DER: Islet xenotransplantation in a pre-clinical large animal model. Transplant Proc 23: 875-876, 1991.

212. Canafax DM, Graves NM, Hilligoss DM, Careleton BC, Gardner MJ, Matas AJ: Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study. Transplant Proc 23: 1041-1042, 1991.

213. Frey DJ, Matas AJ, Gillingham KJ, Canafax DM, Payne WD, Dunn DL, Sutherland DER, Najarian JS: MALG vs OKT3 following renal transplantation - a randomized prospective trial. Transplant Proc 23: 1048-1049, 1991.

214. Gruber SA, Skjei KL, Sothern RB, Robison L, Tzardis P, Moss A, Gillingham K, Canafax DM, Matas AJ, Dunn DL: Cancer development in renal allograft recipients treated with conventional and cyclosporine immunosuppression. Transplant Proc 23: 1104-1105, 1991.

215. Almond PS, Troppmann C, Escobar F, Frey DJ, Matas AJ: Economic impact of delayed graft function. Transplant Proc 23: 1304, 1991.

216. Fasola CG, Kim YS, Morel P, Dunn DL, Sutherland DER, Payne WD, Matas AJ, Najarian JS: Kidney retransplantation: patients with a failed second kidney transplant should be considered for a third one. Transplant Proc 23: 1336, 1991.

217. Fischel RJ, Matas AJ, Payne WD, Gillingham KJ, Dunn DL, Sutherland DER, Najarian JS: Long-term outcome in 1-year graft survivors: comparison of diabetic and nondiabetic populations. Transplant Proc 23: 1337, 1991.

218. Troppmann C, Almond PS, Escobar FS, Morel, Ph, Papalois AE, Dunn DL, Payne WD, Sutherland DER, Matas AJ, Najarian JS: Donor age and cause of death affect cadaver renal allograft outcome. Transplant Proc 23: 1365-1366, 1991.

219. Gruber SA, Chavers B, Skjei KL, Sothern RB, Robinson L, Tzardis P, Moss A, Gillingham K, Canafax DM, Najarian JS, Matas AJ, Dunn DL: De novo cancer after pediatric kidney transplantation. Transplant Proc 23: 1373-1374, 1991.

220. Almond PS, Morel Ph, Matas AJ, Gillingham KJ, Chau KS, Brown A, Kashtan CE, Mauer SM, Chavers B, Nevins TE, Dunn DL, Sutherland DER, Payne WD, Najarian JS: Transplanted children with long-term graft function have an excellent quality of life. Transplant Proc 23: 1380-1381, 1991.

221. Najarian JS, Frey DJ, Matas AJ, So SKS, Cook M, Mauer SM, Chavers BM, Kashtan C, Gillingham KJ, Nevins TE: Successful kidney transplantation in infants. Transplant Proc 23: 1382-1383, 1991.

222. Almond PS, Morel Ph, Troppmann C, Matas AJ, Najarian JS, Chavers B: Progression of infantile cystinosis after renal transplantation. Transplant Proc 23: 1386, 1991.

223. *Fischel RJ, Payne WD, Gillingham KJ, Dunn DL, Sutherland DER, Matas AJ, Najarian JS: Long-term outlook for renal transplant recipients with one-year function: "Doctor, what are my chances?". Transplantation 51: 118-122, 1991.

224. *Mayoral JL, Loeffler CM, Fasola CG, Kramer MA, Orrom WJ, Matas AJ, Najarian JS, Dunn DL: Diagnosis and treatment of cytomegalovirus disease in transplant patients based upon gastrointestinal tract manifestations. Arch Surg 126: 2: 202-206, 1991.

225. *Schweitzer E, Matas AJ: A unique presentation of an anastomotic pseudoaneurysm. Vascular Surgery 25: 2: 131-135, 1991.

226. *Gruber SA, Chan GLC, Canafax DM, Matas AJ: Immunosuppression in renal transplantation; I. cyclosporine and azathioprine. Clin Transplantation 5: 65-85, 1991.

227. *Stephanian E, Gruber SA, Dunn DL, Matas AJ: Posttransplant lymphoproliferative disorders. Transplantation Reviews 5(2): 120-129, 1991.

228. *Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ: Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 51: 1014-1018, 1991.

229. *Gruber SA, Chan GLC, Canafax DM, Matas AJ: Immunosuppression in renal transplantation; II. cortisone, ALG and OKT3. Clin Transplantation 5: 219-232, 1991.

230. *Colon EA, Popkin MK, Matas AJ, Callies AL: Overview of noncompliance in renal transplantation. Transplantation Reviews 5: 3: 175-180, 1991.

231. *Morel Ph, Sutherland DER, Almond PS, Stoblen, F, Matas AJ, Najarian JS, Dunn DL: Assessment of renal function in type I diabetic patients after kidney, pancreas, or combined kidney-pancreas transplantation. Transplantation 51: 1184-1189, 1991.

232. *Morel Ph, Kaufmann, D, Matas AJ, Tzardis P, Field MJ, Lloveras JK, Sutherland DER: Total pancreatectomy in the pig for islet transplantation. Transplantation 52: 11-15, 1991.

233. *Morel Ph, Almond PS, Matas AJ, Gillingham KJ, Chau C, Brown A, Kashtan CE, Mauer SM, Chavers B, Nevins TE, Dunn DL, Sutherland DER, Payne WD, Najarian JS: Long-term quality of life after kidney transplantation in childhood. Transplantation 52: 47-53, 1991.

234. Perez R, Matas AJ, Gillingham KJ, Payne WP, Dunn DL, Gores PF, Sutherland DER, Najarian JS: Lessons learned and future hopes: three thousand renal transplants at the University of Minnesota. In: Terasaki, P. (ed): Clinical Transplants 1990, Los Angeles: UCLA Tissue Typing Laboratory, 1991, pp 217-231.

235. Matas AJ, Najarian JS: Therapeutic approaches to renal transplantation. In: Lichenstein, L.M. and Fauci, A.S. (eds): Current Therapy in Allergy Immunology and Rheumatology, B.C. Decker, Inc, 1991.

236. Boyle EM, Fischel RJ, Johnson EM, Leventhal J, Matas AJ, Bolman RM: Depletion of natural antibody following pretransplant cyclophosphamide allows prolonged xenograft survival. Current Surg 48: 463-465, 1991.

237. Najarian JS, Matas AJ: The present and future of kidney transplantation. Transplant Proc 23: 2075-2082, 1991.

238. *Gruber SA, Canafax DM, Cipolle RJ, Erdmann GR, Burke BA, Simmons RL, Hrushesky WJM, Matas AJ: Intraarterial infusion of immunosuppressants. Minerva Chir 46: 1: 75-79, 1991.

239. *Almond PS, Matas AJ, Gillingham KJ, Troppmann C, Payne WD, Dunn DL, Sutherland DER, Najarian JS: Risk factors for second renal allografts immunosuppressed with cyclosporine. Transplantation 52: 253-258, 1991.

240. *Modena FM, Hostetter TH, Salahudeen AK, Najarian JS, Matas AJ, Rosenberg ME: Progression of kidney disease in chronic renal transplant rejection. Transplantation 52: 239-244, 1991.

241. Matas AJ: Long-term kidney transplant outcome -- where do we go from here? Contemp Dialysis & Neph 12: 18-21, 1991.

242. *Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FJ: Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 52: 214-220, 1991.

243. *Morel Ph, Troppmann C, Almond PS, Schlumpf R, Gillingham KJ, Sutherland DER, Dunn DL, Payne WD, Matas AJ, Najarian JS: Multiorgan procurement does not affect the immediate outcome of kidney transplants. Clin Transplantation 5: 381-385, 1991.

244. *Almond PS, Matas AJ, Canafax DM: Fixed-rate reimbursement fails to cover costs for patients with delayed graft function. Pharmacotherapy 11: 5: 126S-129S, 1991.

245. Boyle EM, Fischel RJ, Johnson EM, Leventhal J, Matas AJ, Bolman RM: Depletion of natural antibody after pretransplant cyclophosphamide administration allows prolonged xenograft survival. Curr Surg 48: 463-465, 1991.

246. Schlumpf R, Morel Ph, Loveras JJ, Condie RM, Matas A, Kurle J, Najarian JS, Sutherland DER: Examination of the role of the colloids hydroxyethylstarch, dextran, human albumin, and plasma proteins in a modified UW solution. Transplant Proc 23: 2362-2365, 1991.

247. Brayman KL, Almond PS, Moss AA, Chen SC, Nakhleh R, Sutherland DER, Najarian JS, Matas AJ: Intermittent Rapamycin administration prevents autoimmune diabetes. Surg Forum 52: 405-407, 1991.

248. Almond PS, Chen S, Matas AJ: Cytotoxic T lymphocyte development requires IL-2 but not antigen processing. Surg Forum 52: 417-418, 1991.

249. *Schweitzer EJ, Matas AJ, Gillingham KJ, Payne WD, Gores PF, Dunn DL, Sutherland DER, Najarian JS: Causes of renal allograft loss: Progress in the '80s, Challenges for the '90s. Ann Surg 214: 6: 679-688, 1991.

250. *Almond PS, Matas AJ, Gillingham K, Moss, A, Mauer SM, Chavers B, Nevins T, Kashtan C, Dunn DL, Payne WD, Sutherland DER, Gores PF, Najarian JS: Pediatric renal transplants -- results with sequential immunosuppression. Transplantation 53: 46-51, 1992.

251. *Gruber SA, Erdmann GR, Burke BA, Moss A, Bowers L, Hrushesky WJM, Cipolle RJ, Canafax DM, Matas AJ: Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. Transplantation 53: 12-19, 1992.

252. Boyle EM, Fischel RJ, Johnson EM, Leventhal J, Matas AJ, Bolman RM: Depletion of natural antibody after pretransplant cyclophosphamide administration allows prolonged xenograft survival. Curr Surg 48: 463-465, 1991.

253. Almond PS, Gillingham KJ, Sibley R, Moss A, Melin M, Leventhal J, Manivel C, Kyriakides P, Payne WD, Dunn DL, Sutherland DER, Gores PF, Najarian JS, Matas AJ. Renal transplant function after ten years of cyclosporine. Transplantation 53(2):316-323, 1992.

254. *Brayman KL, Stephanian E, Matas AJ, Schmidt W, Payne WD, Sutherland DER, Gores PF, Najarian JS, Dunn DL: Analysis of infectious complications occurring after solid-organ transplantation. Arch Surg 127: 38-48, 1992.

255. *Stephanian E, Matas AJ, Gores P, Sutherland DER, Najarian JS Retransplantation as a risk factor for lymphocele formation. Transplantation 53: 676-678, 1992.

256. *Stephanian E, Matas AJ, Mauer SM, Chavers B, Nevins T, Kashtan C, Sutherland DER, Gores P, Najarian JS: Recurrence of disease in patients retransplanted for focal segmental glomerulosclerosis. Transplantation 53: 755-757, 1992.

257. *Bumgardner GL, Almond PS, Chen S, Ascher NL, Matas AJ: Cell subsets responding to purified hepatocytes and evidence of indirect recognition of hepatocyte major histocompatibility complex class I antigen. I. The role of L3T4+ T cell in the development of allospecific cytotoxicity in hepatocyte-sponge matrix allografts. Transplantation 53: 857-862, 1992.

258. *Bumgardner GL, Almond PS, Chen S, Ascher NL, Matas AJ: Cell subsets responding to purified hepatocytes and evidence of indirect recognition of hepatocyte major histocompatibility complex class I antigen. II. In vitro-generated "memory" cells to class I+ class II- hepatocytes. Transplantation 53: 863-868, 1992.

259. *Matas AJ, Payne WD, Gillingham KJ, Dunn DL, Sutherland DER, Najarian JS: Optimizing the immediate posttransplant prednisone dose -- A prospective randomized trial. Clin Transplantation 6: 73-76, 1992.

260. Moss AA, Almond PS, Chen SC, Fischel RJ, Salazar AJ, Matas AJ: Sublethal irradiation and syngeneic bone marrow transplant prolongs thyroid xenograft survival. Transplant Proc 24: 505, 1992.

261. Fischel RJ, King NJ, Boyle EM, Almond PS, Chen S, Bolman RM, Matas AJ: Evaluation of xenogeneic thyroid transplants as a model of cell-mediated response. Transplant Proc 24: 535-536, 1992.

262. Leventhal JR, Platt JL, Flores HC, Gruber SA, Matas AJ, Bolman RM: Inhibition of natural antibody synthesis by cyclophosphamide or 15-deoxyspergualin fails to prevent xenograft rejection in the guinea pig-to-rat model. Transplant Proc 24: 551, 1992.

263. Fischel RJ, Matas AJ, Perry E, Dalmasso A, Noreen H, Bolman RM: Plasma exchange, organ perfusion and immunosuppression reduce "natural" antibody levels as measured by binding to xenogeneic endothelial cells and prolong discordant xenograft survival. Transplant Proc 24: 574, 1992.

264. Boyle EM, Fischel RJ, Johnson EM, Leventhal J, Matas AJ, Bolman RM: Examination of the clonal deletion theory in the guinea pig to Lewis rat cardiac xenograft model. Transplant Proc 24: 632, 1992.

265. Brayman KL, Morel P, Field J, Lloveras JJ, Leventhal J, Nakhleh R, Jessurun J, Platt J, Matas AJ, Najarian JS, Gores PF, Sutherland DER: A comparison of mice and rats as recipients for canine islet xenografts. Transplant Proc 24: 651-652, 1992.

266. Leventhal J, Flores H, Gruber SA, Matas AJ, Bolman RM: Inhibition of natural antibody production by a combination of 15- deoxyspergualin, mizoribine, cyclophosphamide and splenectomy. Transplant Proc 24: 687, 1992.

267. Boyle EM, Fischel RJ, Johnson EM, Leventhal J, Matas AJ, Bolman RM: Pretransplant donor antigen and cyclophosphamide in the evaluation of the clonal deletion theory in the hamster to Lewis rat cardiac xenograft model. Transplant Proc 24: 698, 1992.

268. Johnson EM, Fischel RJ, Boyle EM, Matas AJ, Bolman RM: Plasma exchange, splenectomy, and cyclophosphamide for natural antibody removal: kinetics and xenograft survival. Transplant Proc 24: 701, 1992.

269. Flores HC, Leventhal JR, Gruber SA, Figueroa J, Platt JL, Manivel C, Bach FH, Matas AJ: Natural antibody production can be inhibited by 15-deoxyspergualin in a discordant xenograft model. Transplant Proc 24: 714, 1992.

270. Fischel RJ, King NJ, Manivel C, Almond PS, Chen S, Bolman RM, Matas AJ: The histopathologic appearance of rejected xenografts in the neovascularized and primarily vascularized rodent system. Transplant Proc 24: 631, 1992.

271. Flores H, Leventhal J, Gruber SA, Schaffer M, Bolman RM, Matas AJ: Mizoribine inhibits natural antibody production in a discordant xenograft model. Transplant Proc 24: 717, 1992.

272. Tzardis PJ, Gruber SA, Matas AJ, Golematis BCh, Najarian JS: Intrarenal infusion of immunosuppression through implantable pump in a canine auto and allotransplant model. Acta Chirurgica Hellenica 64: 1: 1992.

273. Tzardis PJ, Gruessner RWG, Matas AJ, Sutherland DER, Najarian JS: Renal transplantation for polycystic kidney disease. Long-term follow-up of the transplanted and the native kidneys. Acta Chirurgica Hellenica 64: 1: 1992.

274. Morel Ph, Moss A, Schlumpf R, Nakhleh R, Lloveras JK, Field MJ, Condie R, Matas AJ, Sutherland DER: 72-hour preservation of the canine pancreas: successful replacement of hydroxyethylstarch by dextran-40 in UW solution. Transplant Proc 24: 791-794, 1992.

275. Cheung AHS, Sutherland DER, Dunn DL, Moudry-Munns KC, McHugh L, Gillingham K, Najarian JS, Matas AJ: Morbidity following simultaneous pancreas-kidney transplants vs kidney transplants alone in diabetic patients. Transplant Proc 24: 866-868, 1992.

276. Morel Ph, Kaufman DB, Field MJ, Lloveras JK, Matas AJ, Sutherland DER: Detrimental effect of prednisone on canine islet autograft function. Transplant Proc 24: 1048-1050, 1992.

277. *Bumgardner GL, Matas AJ: Transplantation and pregnancy. Transplant Rev 6: 3: 139-162, 1992.

278. *Najarian JS, Almond PS, Mauer SM, Chavers B, Nevins T, Kashtan C, Matas AJ: Renal transplantation in the first year of life: The treatment of choice for infants with end-stage renal disease. J Am Soc Neph 2: 3: S228-S233, 1992.

279. *Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, Dunn DL, Sutherland DER, Najarian JS: Sequential therapy - A prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 54: 50-56, 1992.

280. *Leventhal J, Flores H, Gruber SA, Figueroa J, Platt JL, Manivel JC, Bach FH, Matas AJ, Bolman RM: Evidence that 15-deoxyspergualin inhibits natural antibody production but fails to prevent hyperacute rejection in a discordant xenograft model. Transplantation 54: 26-31, 1992.

281. Kaufman DB, Jones J, Matas AJ: New immunosuppressive agents: FK506, rapamycin, RS-61443, 15-deoxyspergualin. J Transplant Coordination 2: 20-27, 1992.

282. *Najarian JS, Chavers B, McHugh L, Matas AJ: 20 years or more of living donors. Lancet 340: 807-810, 1992.

283. *Fischel RJ, Matas AJ, Platt JL, Perry E, Noreen H, Shumway SJ, Bolman RM: Cardiac xenografting in the pig-to-rhesus monkey model: manipulation of antiendothelial antibody prolongs survival. J Heart Transplantation 2: 965-73, 1992.

284. *Dunn DL, Mayoral JL, Gillingham KJ, Sawyer MD, Kramer MA, Statz CL, McHugh L, Matas AJ, Gores PF, Payne WD, Sutherland DER, Najarian JS: Simultaneous treatment of concurrent rejection and tissue invasive cytomegalovirus disease without detrimental effects upon patient or allograft survival. Clin Transplantation 6: 413-420, 1992.

285. Almond PS, Gillingham K, Sibley R, Manivel C, Najarian JS, Matas AJ: The impact of cyclosporine and cyclosporine nephrotoxicity on long-term renal allograft function. Dialysis & Transplantation 21: 682-684, 1992.

286. *Basadonna G, Matas AJ, Najarian JS: Kidney transplantation in diabetic patients: The University of Minnesota experience. Kidney Int 42: S193-S196, 1992.

287. *Reinberg Y, Matas AJ, Manivel C, Gonzalez R, Gillingham K, Pryor JL: Outcome of renal transplantation or dialysis in patients with a history of renal cancer. Cancer 70:1564-1567, 1992.

288. *Cheung AHS, Sutherland DER, Gillingham KJ, McHugh LE, Moudry-Munns KC, Dunn DL, Najarian JS, Matas AJ: Simultaneous pancreas-kidney (SPK) transplant versus kidney transplants alone (KTA) in diabetic patients. Kidney Int 41: 924-929, 1992.

289. *Almond PS, Bumgardner GL, Chen S, Matas AJ. Pretransplant sensitization with major histocompatibility complex Class I+ and Class II- hepatocytes leads to accelerated skin graft rejection. J Surg Res 53: 182-187, 1992.

290. Basadonna G, Matas AJ, Gillingham K, Sutherland DER, Payne WD, Dunn DL, Gores PF, Gruessner RWG, Arrazola L, Najarian JS: Kidney transplantation in patients with type I diabetes: 25-year experience at the University of Minnesota. In: Terasaki, P. (ed): Clinical Transplants 1992, Los Angeles: UCLA Tissue Typing Laboratory, 1992, pp 227-237.

291. *Matas AJ: Hepatitis B positivity may not rule out kidney transplantation. J Critical Illness 8: 15-16, 1993.

292. *Almond PS, Matas AJ, Nakhleh R, Morel Ph, Troppmann C, Najarian JS, Chavers B: Renal transplantation for infantile cystinosis: long-term follow-up. J Ped Surg 28: 232-238, 1993.

293. *Schweitzer EJ, Canafax DM, Gillingham KJ, Najarian JS, Matas AJ: Phenytoin administration in renal allograft recipients on cyclosporine immunosuppression. Clin Transplantation 7: 9-13, 1993.

294. Flores HC, Cromwell JW, Leventhal JR, Najarian JS, Matas AJ: Does previous breast feeding affect maternal donor renal allograft outcome? A single institution experience. Transplant Proc 25: 212, 1993.

295. Farney AC, Noreen HJ, Sutherland DER, Reinsmoen N, Segall M, Gillingham K, Schmidt WJ, Matas AJ: Effect of reexposure to mismatched major histocompatibility complex on renal retransplant allograft survival. Transplant Proc 25: 213, 1993.

296. Leventhal JR, Dalmasso AP, Cromwell JW, Manivel CJ, Bolman RM III, Matas AJ: Complement depletion prolongs discordant cardiac xenograft survival in rodents and non-human primates. Transplant Proc 25: 398-399, 1993.

297. Moss A, Almond PS, Matas AJ, Gillingham K, Najarian JS: Predictors of improved outcome in second pediatric renal transplant recipients. Transplant Proc 25: 597, 1993.

298. Almond PS, Moss A, Nakhleh RE, Melin M, Chen S, Salazar A, Shirabe K, Matas AJ: Rapamycin in a porcine renal transplant model. Transplant Proc 25: 716, 1993.

299. Troppmann C, Almond PS, Payne WD, Dunn DL, Gores PF, Gruessner RWG, Sutherland DER, Matas AJ, Najarian JS: Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes. Transplant Proc. 25: 905, 1993.

300. Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DER, Gores PF, Gruessner RWG, Najarian JS: Relationship between early vs late acute rejection and onset of chronic rejection in kidney transplantation. Transplant Proc 25: 910-911, 1993.

301. Almond PS, Matas AJ, Gillingham K, Dunn DL, Payne WD, Gores, P, Gruessner R, Najarian JS: Predictors of chronic rejection in renal transplant recipients. Transplant Proc 25: 936, 1993.

302. Jones JW, Hunter DR, Matas AJ: Successful percutaneous treatment of ureteral stenosis after renal transplantation. Transplant Proc 25: 1038, 1993.

303. Cheung AHS, Matas AJ, Gruessner RG, Dunn DL, Moudry-Munns KC, Najarian JS: Should uremic diabetic patients who want a pancreas transplant receive a simultaneous cadaver kidney-pancreas transplant or a living related donor kidney first followed by cadaver pancreas transplant? Transplant Proc 25: 1184, 1993.

304. Matas AJ, Gillingham KJ, Sutherland DER: How "death with function" should be considered when calculating renal transplant outcome. Transplant Proc 25: 1309, 1993.

305. Basadonna GP, Arrazola L, Matas AJ, Gruessner R, Schmidt W, Sutherland DER: Morbidity, mortality and long-term allograft function in kidney transplantation alone and simultaneous pancreas-kidney in diabetic patients. Transplant Proc 25: 1321, 1993.

306. Jones JW, Matas AJ, Gillingham KJ, Gores PF, Payne WD, Gruessner RWG, Sutherland DER, Najarian JS: Employment and disability after renal transplantation. Transplant Proc 25: 1368, 1993.

307. Kaufman DB, Matas AJ, Arrazola, L, Gillingham KJ, Sutherland DER, Payne WD, Dunn DL, Gores PF, Najarian JS: Transplantation of kidneys from zero haplotype-matched living donors and from distantly related and unrelated donors in the cyclosporine era. Transplant Proc 25: 1530, 1993.

308. Canafax DM, Carleton BC, Matas AJ, Payne WD, Dunn DL, Sutherland DER, Najarian JS: Effects of three immunosuppressive drug protocols on cadaver renal transplantation costs after 4 years of therapy. Transplant Proc 25: 1692, 1993.

309. *Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 55: 752-757, 1993.

310. *Matas AJ, Gillingham KJ, Sutherland DER: Half-life and risk factors for kidney transplant outcome-importance of death with function. Transplantation 55: 757-760, 1993.

311. *Leventhal JR, Dalmasso AP, Cromwell JW, Platt JL, Manivel CJ, Bolman RM, Matas AJ: Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55: 857-865, 1993.

312. *Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DER, Gores PF, Gruessner RWG, Najarian JS: Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 55: 993-995, 1993.

313. *Reinsmoen NL and Matas AJ: Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity. Transplantation 55: 1017-1023, 1993.

314. *Jones JW, Hunter DW, Matas AJ: Percutaneous treatment of ureteral strictures after renal transplantation.
Transplantation 55: 1193-1194, 1993.

315. *Jones JW, Payne WD, Matas AJ: The living donor--risks, benefits, and related concerns. Transplant Reviews 7: 115-128, 1993.

316. *Leventhal JR, Matas AJ, Sun LH, Reif S, Bolman III RM, Dalmasso AP, Platt JL: The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 56: 1-8, 1993.

317. *Almond PS, Moss A, Nakhleh RE, Melin M, Chen S, Salazar A, Shirabe K, Matas AJ: Rapamycin: immunosuppression, hyporesponsiveness, and side effects in a porcine renal allograft model. Transplantation 56: 275-281, 1993.

318. *Najarian JS, Almond PS, Gillingham KJ, Mauer SM, Chavers BM, Nevins TE, Kashtan CE, Matas AJ: Renal transplantation in the first five years of life. Kidney Int 44: S-40-S-44, 1993.

319. *Matas AJ: Is MHC matching as a primary criterion in kidney allocation justified? Nature Genetics 5: 210-213, 1993.

320. *Jones JW, Gruessner RWG, Gores PF, Matas AJ: Hypoaldosteronemic hyporeninemic hyperkalemia after renal transplantation. Transplantation 56: 1013-1015, 1993.

321. Sutherland DER, Gores P, Farney A, Wahoff DC, Matas AJ, Dunn DL, Gruessner RWG, Najarian JS: Evolution of kidney, pancreas, and islet transplantation for diabetes at the University of Minnesota. Am J Surgery 166: 456-492, 1993.

322. *Gruessner RWG, Nakhleh R, Tzardis P, Platt JL, Schechner R, Gruessner A, Tomadze G, Matas A, Najarian JS, Sutherland DER: Rejection in single versus combined pancreas and kidney transplantation in pigs. Transplantation 56: 1053-1062, 1993.

323. Jones JW, Acton BE, Granger DK, Matas AJ: Pregnancy following kidney donation. Transplant Proc 25: 3082, 1993.

324. Jones JW, Halldorson J, Elick B, Granger DK, Matas AJ: Unrecognized health problems diagnosed during living donor evaluation: a potential benefit. Transplant Proc 25: 3083, 1993.

325. Reinsmoen NL, Hertz MI, Kubo S, Bolman RM, Matas AJ: Immune factors correlating with improved long-term graft outcome in kidney, lung, and heart transplants. Transplant Proc 25:3277-3278, 1993.

326. Matas AJ, Najarian JS: The role of HLA matching in kidney transplantation: 30 years after, In: Terasaki, P. (ed): Clinical Transplants, 1993. Los Angeles, CA, UCLA Tissue Typing Laboratory, p. 428-430, 1993.

327. Nevins TE and Matas AJ: Living-related kidney donation in (ed) Tejani AH and Fine RN, Pediatric Renal Transplantation, Wiley & Sons, Inc, New York, 1993.

328. Jones JW, Matas AJ, Najarian JS: Surgical Techniques in (ed) Tejani AH and Fine RN, Pediatric Renal Transplantation, Wiley & Sons, Inc, New York, 1993.

329. Gruber SA, Gillingham KJ, Sothern RB, Stephanian E, Chavers B, Matas AJ, Dunn DL. Cancer development in pediatric primary renal allograft recipients. Transplant Proc 26:3-4.

330. Fasola CG, Gillingham KJ, Troppmann C, Gruessner RWG, Gores PF, Dunn DL, Payne WD, Sutherland DER, Matas AJ, Najarian JS. Kidney transplant or retransplant can effectively treat congenital nephrotic syndrome: a single-center experience. Transplant Proc 26:9, 1994.

331. Troppmann C, Almond PS, Fasola CG, Benedetti E, Gruessner RWG, Dunn DL, Gores PF, Payne WD, Matas AJ, Najarian JS. Effect of Minnesota Antilymphocyte Globulin on T-lymphocytes and their subsets during induction therapy in pediatric renal transplantation. Transplant Proc 26:26-27, 1994.

332. Fasola CG, Gillingham KJ, Troppmann C, Gruessner RWG, Gores PF, Dunn DL, Payne WD, Sutherland DER,
Matas AJ, Najarian JS. Pediatric kidney retransplantation: 30 years of experience at a single institution. Transplant Proc 26:48, 1994.

333. Jones JW, Nevins T, McHugh L, Matas AJ, Najarian JS. Nutrition and growth in pediatric renal transplant recipients. Transplant Proc 26:62-63, 1994.

334. Granger DK, Burd RS, Schmidt WJ, Dunn DL, Matas AJ. Incidence and timing of infections in pediatric renal transplant recipients in the cyclosporine era. Transplant Proc 26:64, 1994.

335. Fryer JP, Benedetti E, Gillingham KJ, Najarian JS, Matas AJ. Steroid-related complications in pediatric kidney transplant recipients in the cyclosporine era. Transplant Proc 26:91-92, 1994.

336. Matas AJ. Trend towards long-term reduction in cyclosporin levels:a risk factor for chronic graft rejection? In: Salaman J (ed.) Long-Term Cyclosporine Therapy and Risk of Chronic Rejection: A Discussion. New York: Royal Society of Medicine Press, 1994: 11-18.

337. Jones JW, Gillingham KJ, Sutherland DER, Payne WD, Dunn DL, Gores PF, Gruessner RWG, Najarian JS, Matas AJ: Successful long-term outcome with 0-haplotype-matched living related kidney donors. Transplantation 57: 512-15, 1994.

338. *Gruessner RWG, Nakhleh R, Tzardis P, Schechner R, Gruessner AC, Matas AJ, Najarian JS, Sutherland DERS. Rejection patterms after simultaneous pancreasticoduodenal-kidney transplants in pigs. Transplantation 57: 756-60, 1994.

339. *Chavers BM, Eun-Mi K, Matas AJ, Gillingham KJ, Najarian JS. Causes of kidney allograft loss in a large pediatric population at a single center. Ped Neph 8: 57-61, 1994.

340. *Matas AJ, Burke JF, DeVault GA, Monaco A, Pirsch JD. Chronic rejection. J Am Soc Nephr 4: S23-30, 1994.

341. *Najarian JS, Gillingham KJ, Sutherland DER, Reinsmoen NL, Payne WD, Matas AJ. The impact of the quality of initial graft function on cadaver kidney transplants. Transplantation 57: 812-816, 1994.

342. *Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode0 on long-term renal allograft survival (t1/2). Transplantation 57: 857-859, 1994.

343. *Dunn DL, Gillingham KJ, Kramer MA, Schmidt WJ, Erice A, Balfour HH, Gores PF, Gruessner RWG, Matas AJ, Payne WD, Sutherland DER, Najarian JS. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 57: 876-884, 1994.

344. *Leventhal JR, Sakiyalak P, Witson J, Simone P, Matas AJ, Bolman RM, Dalmasso AP. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation 57: 974-978, 1994.

345. *Leventhal JR and Matas AJ: Xenotransplantation in rodents: A review and reclassification. Transplantation Rev 8: 80-92, 1994.

346. *Matas AJ, Gores PF, Kelley SL, Bielefield-Skrokov M, Kinaszczuk M, Gruessner RWG, Najarian JS. Pilot evaluation of 15-Deoxyspergualin for refractory acute renal transplant rejection. Clin Transplantation 8: 116-119, 1994.

347. *Matas AJ. Chronic rejection - Definition and correlates. Clin Transplant 8: 162-167, 1994.

348. *Fryer JP, Matas AJ. How to identify the best candidates for kidney transplantation. Protocols for making the best use of scarce donor organs. J Crit Illness 9: 362-375, 1994.

349. *Kim EM, Striegel J, Kim Y, Matas AJ, Najarian JS, Mauer SM. Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. Kidney Int 45: 1440-1445, 1994.

350. Matas AJ. Trend towards long-term reduction in cyclosporin levels: a risk factor for chronic graft rejection? Clin Exp Pers Sandimmun Ther 4: 3-5, 1994.

351. Troppmann C, Gruessner RWG, Matas AJ, Dunn DL, Stevens RB, Najarian JS, Sutherland DER: Results with renal transplants performed after previous solitary pancreas transplants. Transplant Proc 26: 448-449, 1994.

352. *Matas AJ: Chronic rejection in renal transplant recipients - risk factors and correlates. Clin Transplantation 8: 332-336, 1994.

353. *Fryer JP, Granger DK, Leventhal JU, Gillingham KJ, Najarian JS, Matas AJ. Steroid related complications in the cyclosporine era. Clin Transplantation 8:224-229, 1994.

354. *Sharma AK, Myers TA, Hunninghake DB, Matas AJ, Kashtan CE. Hyperlipidemia in long-term survivors of pediatric renal transplantation. Clin Transplantation 8:252-257, 1994.

355. *Granger DK, Jenkins M, Moss AA, Chen S, Almond P, Matas AJ. Prolonged survival without posttransplant immunosuppression in a large animal model. Surgery 116 (2): 236, 1994.

356. *Gruber SA, Gillingham K, Sother RB, Stephanian E, Matas AJ, Dunn DL. De Novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplantation 8:388-395, 1994.

357. *Benedetti E, Fryer J, Matas AJ, Sutherland DER, Payne WD, Dunn DL, Gores PF, Gruessner RWG, Najarian JS: Kidney transplant outcome with and without right renal vein extension. Clin Transplantation 8: 416-417, 1994.

358. *Gruber SA, Hewitt HM, Sorenson AL, Barber DL, Bowers L, Rynders G, Arrazola L, Matas AJ, Rosenberg ME, Canafax DM. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol 34;859-864, 1994.

359. *Scherrer L, Leventhal JR, Matas AJ, Dalmasso AP. Evidence that rat xenoreactive antibodies recognize multiple protein antigens on guinea pig endothelial cells and platelets. Transplantation 58:458-465, 1994.

360. *Fryer JP, Leventhal JR, Dalmasso AP, Chen S, Simone PA, Jessurun J, Sun LH, Reinsmoen NL, Matas AJ. Cellular rejection in discordant xenografts when hyperacute rejection is prevented: Analysis using adopted and passive transfer. Transplant Immun 1994; 2: 87-93.

361. *Gruber SA, Matas AJ. Etiology and pathogenesis of tumors occurring after organ transplantation. Transplantation Science 4:87-104, 1994.

362. *Matas AJ. "A cost-outcome analysis of retransplantation: The need for accountability" - A response. Transplantation Rev 8: 207-209, 1994.

363. *Benedetti E, Matas AJ, Hakim N, Fasola C, Gillingham K, McHugh L, Najarian JS. Renal transplantation for patients 60 years of age or older. Annals of Surgery 220:445-460, 1994.

364. Leventhal JR, Berry B, Simone P, Dalmasso AP, Bolman RM, Matas AJ. Study of the pathogenesis of delayed xenograft rejection in the guinea pig-to-rat model. Surgical Forum 65: 450-452, 1994.

365. Granger DK, Amin NB, Sorenson AL, Gillingham KJ, Canafax DM, Matas AJ. Cyclosporine levels impact early rejection episodes. Transplant Proc 26:2513-2515, 1994.

366. Reinsmoen NL, Hertz MI, Kubo SH, Bolman RM, Matas AJ. Reduced incidence of chronic rejection in cyclosporine-treated solid organ recipients with donor antigen-specific hyporeactivity. Transplant Proc 26: 2558-2559, 1994.

367. Benedetti E, Hakim NS, Matas AJ, Payne WD, Mauer SM, Nevins T, Kashten C, Chavers B, Najarian JS. Renal transplantation in cyclosporine immunosuppressed infants and children. Transplant Proc 26: 2766-2767, 1994.

368. Sorenson AL, Lovdahl M, Hewitt JM, Granger DK, Almond PS, Russlie HQ, Barber D, Matas AJ, Canafax DM. Effects of ketoconazole on cyclosporine metabolism in renal allograft recipients. Transplant Proc 26: 2822, 1994.

369. *Fryer JP, Benedetti E, Perry EH, Matas AJ. Antibody mediated rejection of an HLA identical, ABO incompatible kidney transplant after two failed cadaver transplants. Transplantation 58: 723-725, 1994.

370. *Reinsmoen NL, Bolman RM, Savik K, Butters K, Matas AJ, Hertz MI. Improved long-term graft outcome in lung transplantation recipients who develop donor antigen-specific hyporeactivity. J Heart Lung Transplant 13(1):30, 1994.

371. *Gruessner RWG, Dunn DL, Gruessner AC, Matas AJ, Najarian JS, Sutherland DER: Recipient risk factors have an impact on technical failure and patient and graft survival rates in bladder-drained pancreas transplants. Transplantation 57(11) 1598-1606, 1994.

372. Matas AJ: Chronic Allograft Rejection - Definition, and Clinical Laboratory Correlates, In: Lieberman R and Morris R. (eds): Principles of Immunosuppressive Drug Development. CRC Press. 1994.

373. *Hakim NS, Benedetti E, Pirenne J, Gillingham K, Payne WD, Dunn DL, Sutherland DER, Gruessner RW, Gores PF, Matas AJ, Najarian JS: Complications of ureterovesical anastomosis in kidney transplant patients: The Minnesota experience. Clin Transplantation 8:504-507, 1994.

374. *Fryer JP, Leventhal JR, Dalmasso AP, Chen SC, Simone PA, Goswitz JJ, Reinsmoen NL, Matas AJ. Beyond hyperacute rejection: Acclerated rejection in a discordant xenograft model by adoptive transfer of specific cell subsets. Transplantation 59: 171-176, 1994.

375. *Granger DK, Cromwell JW, Chen SC, Goswitz JJ, Morrow DT, Beierle FA, Sehgal SN, Canafax DM, Matas AJ. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 59: 183-186,1994.

376. *Leventhal JR, Ranjit J, Fryer JP, Witson JC, Dalmasso AP, Derlich JM, Remiszewski J, Matas AJ, Bolman RM, III. Removal of baboon and human anti-porcine IgG and IgM natural antibodies by immunoadsorption: results of in vitro and in vivo studies. Transplantation 59: 294-300,1994.

377. *Wahoff DC, Matas AJ, Papalois BE, Everett JE, Nelson LA, Sutherland DER. Reactive oxygen scavenger dimethylthiourea does not improve canine renal graft survival after 72-hour cold storage. Research in Surgery, 6:51-53,1994.

378. Nevins TE, Matas AJ. Live related kidney donation. In: Tejani AH and Fine RN (eds.): Pediatric Renal Transplantation. Wiley-Liss, Inc., New York, 137-143, 1994.

379. Jones JW, Matas AJ, Najarian JS. Surgical Technique. In: Tejani AH and Fine RN (eds): Pediatric Renal Transplantation. Wiley-Liss, Inc., New York, 187-200, 1994.

380. *Troppmann C, Benedetti E, Gruessner RWG, Payne WD, Sutherland DER, Najarian JS, Matas AJ. Retransplantation after renal allograft loss due to noncompliance: Indications, outcome, and ethical concerns. Transplantation 59:467-471, 1994.

381. Troppmann C, Almond PS, Matas AJ, Najarian JS, Gruessner RWG. Die Nierentransplantation als Therapie der chronischen Niereninsuffizienz bei Kindern unter 1 Jahr - Ergebnisse von 30 Transplantationen zwishcen 1970 und 1992. (Kidney transplantation is the treatment of choice in children below one year of age with end stage renal disease - results of 30 transplants performed between 1970 and 1992.) Zentralbl. Kinderchir. 3: 10-21, 1994.

382. Troppmann C, Matas AJ, Najarian JS, Gruessner RWG. Ulcer conplications in the upper gastrointestinal tract after 1034 kidney transplantations: Localization, incidence and effects on the survival rates of transplants and patients. Lagenbecks Arch Chir suppl. 359-362, 1994..

383. *Chavers BM, Matas AJ, Gillingham KJ, Schmidt WJ, Najarian JS. Pediatric renal transplantation at the University of Minnesota: The cyclosporine years. Terasaki and Cecka, Eds. UCLA Tissue Typing Laboratory. Clin Transplant, pg 203, 1994.

384. *Matas AJ, Najarian JS. Kidney transplantation - The living donor. Terasaki and Cecka, Eds. UCLA Tissue Typing Laboratory. Clinical Transplants pg 372, 1994.

385. *Troppmann C, Gillingham K, Benedetti E, Almond PS, Gruessner RWG, Najarian JS, Matas AJ. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation - A multivariate analysis. Transplantation 59, 962-968, 1995.

386. *Fryer JP, Leventhal JR, Matas AJ. The emergence of xenotransplantation. Transplant Immunol, 3(1): 21-31, 1995.

387. *Benedetti E, Troppmann C, Gillingham KJ, Hakim NS, Gutowski K, Najarian JS, Sutherland DER, Payne WD, Dunn DL, Gores PF, Matas AJ, Gruessner RWG. Short- and long-term outcome of kidney transplants with multiple renal arteries. Ann Surg, 221 (4): 406-414, 1995.

388. Matas AJ, Dosificacion de Mantenimiento de sandimmun y Evolucion a Largo Plazo en el Trasplante Renal. Symposium Report. pg 47-53. Sevilla, Spain, 1995.

389. Najarian JS, Matas AJ. Organs should be shared on the basis of matching - CON. Transplant Proc 27 (1): 100-101, 1995

390. Reinsmoen NL, McSherry C, Jackson AJ, Hertz MI, Bolman RM, Matas AJ. Circulating donor antigen and response to donor antigen as predictors of long-term lung and kidney transplant success. Transplant Proc 27(1): 205-206, 1995

391. *Gruessner RWG, Fasola C, Benedetti E, Foshager MC, Gruessner AC, Matas AJ, Najarian JS, Goodale RL. Laparoscopic drainage of lymphoceles after kidney transplantation: Indications and limitations. Surgery 117: 288-95, 1995.

392. *Troppmann C, Papalois BE, Chiou A, Benedetti E, Dunn DL, Matas AJ, Najarian JS, Gruessner RWG. Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. J Am Coll Surg, 180: 433-443, 1995.

393. Reinsmoen NL, McSherry C, Jackson AJ, Hertz MI, Bolman RM, Matas AJ. Circulating donor antigen and response to donor antigen as predictors of long-term lung and kidney transplant success. Transplant Proc 27: 205-206, 1995.

394. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas AJ. Phase II FK506 multicenter concentration control study: One-year follow-up. Transplant Proc 27: 809-811, 1995.

395. Cooperative Clinical Trials in Transplantation (CCTT) Research Group. Murine OKT4A mmunosuppression in cadaver donor renal allograft recipients: A cooperative pilot study (report 1). Transplant Proc 27: 863, 1995.

396. Troppmann C, Benedetti E, Gruessner RWG, Najarian JS, Matas AJ. Should patients with renal allograft loss due to noncompliance be retransplanted? Transplant Proc 27: 1093, 1995.

397. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas AJ. Phase II FK506 multicenter concentration control study: One-year follow-up. Transplant Proc 27 (1): 809-811, 1995.

398. Troppmann C, Benedetti E, Gruessner RWG, Najarian JS, Matas AJ. Should patients with renal allograft loss due to noncompliance be retransplanted? Transplant Proc 27(1): 1093, 1995

399. *Pirenne J, Benedetti E, Kashtan CE, Giedo-Garcia E, Hakim N, Schroeder CH, Cook M, Sutherland DER, Matas AJ, Najarian JS. Kidney transplantation in the absence of the infrarenal vena cava. Transplantation, 59: 1739-1742, 1995.

400. *Agarwal A, Mauer SM, Matas AJ, Nath KA. Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: Current concepts and management. JASN 6: 1160, 1995.

401. *Reinsmoen NL, McSherry C, Chavers B, Hertz MI, Matas AJ. Correlation of donor antigen-specific hyporeactivity with allogeneic microchimerism in kidney and lung recipients. Pediatric Nephrology, 9:S35-S39, 1995.

402. *Matas AJ, Almond PS, Moss A, Gillingham KJ, Sibley R, Payne WD, Dunn DL, Gruessner RWG, Sutherland DER, Manivel C, Najarian JS. Effect of cyclosporine on renal function in kidney transplant recipients -- Twelve-year follow-up. Clinical Transplantation, 9: 450-453, 1995.

403. *McSherry C, Hertz MI, Jackson AM, Butters K, Diko M, Matas AJ, Bolman RM, Reinsmoen NL. Allogeneic microchimerism and donor antigen-specific hyporeactivity in lung transplant recipients. Clinical Transplantation 9: 442-449, 1995.

404. *Reinsmoen NL, Jackson A, McSherry C, Ninova D, Wiesner RH, Krom RAF, Hertz MI, Bolman RM, Matas AJ. Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients. Transplantation, 60: 1546-1554, 1995.

405. *Matas AJ, Knatterud ME. What, precisely, is "induction therapy"? A plea to standardize the term. Transplantation, 60: 1375-1377, 1995.

406. *Burke BA, Chavers BM, Gillingham KJ, Kashtan CE, Manivel JC, Mauer SM, Nevins TE, Matas AJ. Chronic renal allograft rejection in the first 6 months posttransplant. Transplantation, 60: 1413-1417, 1995.

407. *Kroshus TJ, Dalmasso AP, Leventhal JR, John R, Matas AJ, and Bolman RM. Antibody removal by column immunoabsorption prevents tissue injury in an ex vivo model of pig-to-human xenograft hyperacute rejection. J. Surg. Res. 59: 43-50, 1995.

408. *Hakim NS, Pirenne J, Benedetti E, Matas AJ. A technique of removal of the Tenckhoff peritoneal dialysis catheter. J Am Coll Surg, 180: 350-2, 1995.

409. Benedetti E, Hakim NS, Perez EM, Matas AJ. Renal transplantation. Acad Radiol 2(2):159-66, 1995.

410. *Matas AJ, Chavers BM, Nevins TE, Mauer SM, Kashtan CE, Cook M, Najarian JS. Recipient evaluation, preparation, and care in pediatric transplantation: The University of Minnesota protocols. Kidney International, 49: S99-S102, 1996.

411. *Agarwal A, Kim Y, Matas AJ, Alam J, Nath KA. Gas-generating systems in acute renal allograft rejection in the rat. Transplantation, 61: 93-98, 1996

412. *Farney AC, Matas AJ, Noreen HJ, Reinsmoen NL, Segall M, Schmidt WJ, Gillingham K, Najarian JS, Sutherland DER. Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival? Clinical Transplantation, 10: 147-156, 1996.

413. Fryer J, Chen S, Simone P, Matas A. The role of macrophages in delayed vascular xenograft rejection. Am College of Surgeons - Surgical Forum 46: 396-397, 1995

414. Matas AJ. Chronic allograft rejection: definition and clinical laboratory correlates. In: R Lieberman and A Mukherjee, eds., Principles of Drug Development and Autoimmunity, Austin, Texas: R.G. Landes Co., 1996.

415. Johnson EM, Leventhal J, Dalmasso AP, Goswitz J, Simone P, Chen S, Moyle M, Matas AJ. Inactivation of C3 and C5 Prolongs Cardiac Xenograft Survival and Decreases Leukocyte Infiltration in a Model of Delayed Xenograft Rejection. Transplantation Proceedings. Vol. 28, no. 2 (April), 1996: p 603.

416. Johnson EM, Leventhal J, Dalmasso AP, Goswitz J, Simone P, Chen S, Moyle M, Matas AJ. Use of a Novel CD11b/CD18 Inhibitory Agent in a C6 Deficient Rat to Evaluate Delayed Xenograft Rejection. Transplantation Proceedings, Vol. 28, no. 2 (April), 1996: p 728.

417. *F. Vincenti, D.A. Laskow, J.F. Neylan, R. Mendez, A.J. Matas. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. Transplantation, Vol. 61, no.11 (June), 1996: p 1576-1581.

418. *West M, Sutherland DERS, Matas AJ. Kidney transplant recipients who die with functioning grafts: serum creatinine level and cause of death. Transplantation 62(7):1029-1030, 1996.

419. *Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label concentration-ranging trial of FK506 in primary kidney transplantation. Transplantation 62:900-905, 1996.

420. *Benedetti E, Pirenne J, Troppmann C, Hakim N, Moon C, Gruessner RWG, Sharp H, Matas AJ, Payne WD, Najarian JS. Combined liver and kidney transplantation. Transplant International 9:486-491, 1996.

421. Troppmann C, Papalois BE, Gruessner AC, Moon C, Matas AJ, Sehgal SN, Nakhleh RE, Gruessner RW. Perioperative immunosuppression as a critical determinant of early outcome after discordant xenoislet transplantation: a comparative study. Trans Proc 28(2):981-983, 1996.

422. Troppmann C, Papalois BE, Gruessner AC, Moon C, Matas AJ, Nakhleh RE, Gruessner RW. Impact of antipassenger lymphocyte globulin on functional graft survival of discordanta xenoislet grafts from a large animal donor. Trans Proc 28(2):842-844, 1996.

423. *Troppmann C, Gillingham KJ, Gruessner RW, Dunn DL, Payne WD, Najarian JS, Matas AJ. Delayed graft function in the absence of rejection has no long-term impact. A study of cadaver kidney recipients with good graft function at 1 year after transplantation. Transplantation 61(9):1331-1337, 1996.

424. *Troppmann C, Gruessner AC, Papalois BE, Sutherland DE, Matas AJ, Benedetti E, Gruessner RW. Delayed endocrine pancreas graft function after simultaneous pancreas-kidney transplantation. Incidence, risk factors, and impact on long-term outcome. Transplantation 61(9):1323-30, 1996.

425. Johnson EM, Zimmerman J, Duderstadt K, Chambers J, Sorenson AL, Granger DK, Almond PS, Fryer JP, Leventhal JR, Scarola J, Matas AJ, Canafax DM. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Trans Proc 28(2):987, 1996.

426. Granger DK, Cromwell JW, Canafax DM, Matas AJ. Combined rapamycin and cyclosporine immunosuppression in a porcine renal transplant model. Trans Proc 28(2):984, 1996.

427. Johnson EM, Canafax DM, Gillingham K, Schmidt W, Pandian K, Najarian JS, Matas AJ. Do early cyclosporine levels affect the incidence of acute rejection in renal transplant recipients? Trans Proc 28(2):879, 1996.

428. Fryer JP, Chen S, Johnson EM, Simone P, Sun LH, Goswitz JJ, Matas AJ. Prolonged survival of discordant xenografts in a subset of complement-depleted rats. Trans Proc 28(2):700, 1996.

429. Fryer JP, Chen S, Johnson EM, Sun LH, Matas AJ. The different influences of allosensitization and xenosensitization on cellular rejection. Trans Proc 28(2):674, 1996.

430. Fryer JP, Chen S, Johnson EM, Simone P, Matas AJ. The role of macrophages in endothelial cell injury--a possible mechanism for delayed xenograft rejection. Trans Proc 28(2):626, 1996.

431. *Slovut DP, Benedetti E, Matas AJ. Babesiosis and hemophagocytic syndrome in an asplenic renal transplant recipient. Transplantation 62: 537-539, 1996.

432. Matas AJ. Elderly patients. In Medical roundtable on optimal immunosuppression in high-risk renal patients (Henry M, Ed). Medical Education Network, 1996, pp. 17-18.

433. *Matas AJ, Gillingham KJ, Chavers BM, Nevins T, Kashtan C, Mauer SM, Payne WD, Gruessner RWG, Najarian JS. The importance of early cyclosporine levels in pediatric kidney transplantation. Clin Trans 10: 482-486, 1996.

434. *Matas AJ. A third kidney transplant: Cost-effective treatment for end-stage renal disease? Clin Trans 10: 516-520, 1996.

435. *Wrenshall LE, McHugh L, Felton P, Dunn DL, Matas AJ. Pregnancy after donor nephrectomy. Transplantation 62: 1934-1936, 1996.

436. *Ingulli E, Matas AJ, Nevins TE, Kashtan CE, Mauer SM, Gillingham K, Chavers BM. Impact of age on renal allograft survival in children after the first rejection episode. Pediatric Nephrol 10: 474-478, 1996.
437. Garcia EL, Pirenne J, Hakim NS, Benedetti E, Kashtan CE, Cook M, Sutherland DE, Matas AJ, Najarian JS, Fernandez HC. Technical options of renal transplant in the absence of a viable ilio-caval venous circuit. Presentation of a case and review of the literature. Actas Urol Esp 20(6): 577-581, 1996.

438. Kerr S, Johnson E, Pandian K, Gillingham K, Matas AJ. Psychological impact of a failed kidney transplant.
Transplant Proc 29: 1573, 1997.

439. *CCTT Research Group (Cooperative Clinical Trials in Transplantation). Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study. Transplantation 63: 1087, 1997.

440. *Pirenne J, Lledo-Garcia E, Benedetti E, Hakim NS, Sutherland DER, Gruessner RWG, Najarian JS, Matas AJ. Colon perforation after renal transplantation: A single-institution review. Clin Transplantation 11: 88-93, 1997.
441. *Matas AJ, Lawson W, McHugh L, Gillingham K, Payne WD, Dunn DL, Gruessner RWG, Sutherland DER, Najarian JS. Employment patterns after successful kidney transplantation. Transplantation, 61: 729-33, 1996.

442. Matas AJ. Living donor transplantation. In: Hakim N, editor: Introduction to organ transplantation, Imperial College Press, London, 53-60, 1997.

443. West MS, Sutherland DER, Matas AJ. Considering death with function as a graft loss in kidney transplant recipients. Transplant Proc 29: 239, 1997.

444. *Chavers BM, Gillingham KJ, Matas AJ. Complications by age in primary pediatric renal transplant recipients. Pediatr Nephrol 11(4): 399-403, 1997.

445. *Matas AJ, Gillingham KJ, Elick BA, Dunn DL, Gruessner RW, Payne WD, Sutherland DE, Najarian JS. Risk factors for prolonged hospitalization after kidney transplants. Clin Transplant 11(4): 259-264, 1997.

446. *Birk PE, Matas AJ, Gillingham KJ, Mauer SM, Najarian JS, Chavers BM. Risk factors for chronic rejection in pediatric renal transplant recipients--a single center experience. Pediatr Nephrol 11(4): 395-398, 1997.

447. Humar AP, Leone JP, Matas AJ. Kidney transplantation: A brief review. Front Biosci 2: E41-E47, 1997.

448. Miller RB, Burke BA, Schmidt WJ, Gillingham KJ, Matas AJ, Mauer M, Kashtan CE. Recurrence of haemolytic uraemic syndrome in renal transplants: a single-centre report. Nephrol Dial Transplant 12(7): 1425-1430, 1997.

449. *Johnson EM, Remucal MJ, Gillingham KJ, Dahms RA, Najarian JS, Matas AJ. Complications and risks of living donor nephrectomy. Transplantation 64(8): 1124-1128, 1997.

450. *Nyberg SL, Manivel JC, Cook ME, Gillingham KJ, Matas AJ, Najarian JS. Grandparent donors in a living-related renal transplant program. Clin Transplantation 11(5) part 1: 349-353, 1997.

451. *Johnson EM, Canafax DM, Gillingham KJ, Humar A, Pandian K, Kerr SR, Najarian JS, Matas AJ. Effect of early cyclosporine levels on kidney allograft rejection. Clin Transplantation 11(6): 552-557, 1997.

452. *Humar A, Johnson EM, Payne WD, Wrenshall L, Sutherland DER, Najarian JS, Gillingham KJ, Matas AJ. Effect of initial slow graft function on renal allograft rejection survival. Clin Transplatation 11(6): 623-627, 1997.

453. Stevens RB, Matas AJ. Renal retransplantation: the Minnesota experience. Transplant Immunol Letter 13 (4):4-10, 1997.

454. Matas AJ. Should pediatric kidneys be used for pediatric patients? Pediatr Transplantation 1(2): 102-103, 1997.

455. *Jackson A, McSherry C, Butters K, Diko M, Almond PS, Matas AJ, Reinsmoen NL. Pretransplant exposure to donor HLA-DR antigen in random transfusion units and the development of donor antigen-specific hyporeactivity. Hum Immunol 55:148-155, 1997.

456. Johnson, EM, Najarian JS, Matas AJ. Living kidney donation: donor risks and quality of life. In: Clinical Transplants 1997, Cecka and Terasaki, Eds. UCVA Press, 1997, pp. 231-240.

457. *Humar A, Johnson EM, Gillingham KJ, Sutherland DE, Payne WD, Dunn DL, Wrenshall LE, Najarian JS, Gruessner RW, Matas AJ. Venous thromboembolic complications after kidney and kidney-pancreas transplantation. Transplantation 65(2): 229-234, 1998.

458. *Humar A, Johnston EM, Payne WD, Dunn DL, Wrenshall LE, Najarian JS, Gruessner RWG, Matas AJ. The acutely ischemic extremity after kidney transplant: an approach to management. Surgery 123(3): 344-350, 1998.

459. *Jacobs C, Johnson E, Anderson K, Gillingham K, Matas AJ. Kidney transplants from living donors: how donation affects family dynamics. Adv Renal Replacement Therapy 5(2): 89-97, 1998.

460. *Matas AJ. Chronic allograft dysfunction: clinical definitions and risk factors. Graft 1(2)(Suppl.II): 48-51, 1998.

461. *Reinsmoen NL, Gillingham K, Jackson A, Butters K, McSherry C, Diko M, Hertz MI, Kubo S, Matas AJ. Can cellular assays predict chronic rejection? Graft 1(2)(Suppl. II): 60-65, 1998.

462. *Matas AJ, McHugh L, Payne WD, Wrenshall LE, Dunn DL, Gruessner RWG, Sutherland DER, Najarian JS. Long-term quality of life after kidney and simultaneous pancreas-kidney transplantation. Clin Transplantation 12: 233-242, 1998.

463. *Matas AJ. Risk factors for chronic rejection-a clinical perspective. Transplant Immunology 6: 1-11, 1998.

464. Matas AJ, Najarian JS. Kidney Transplantation. In: O'Neill JA, Rowe MI, Grosfiell JL, Fonkalsrud EW, Coran AG, (eds), Pediatric Surgery. Mosby, St. Louis, 1998, pp. 563-581.

465. Sutherland DER, Gillingham KJ, Cecka M, Najarian JS, Payne WD, Gruessner RWG, Matas AJ. Living donors in kidney transplantation. In: Touraine JL, Traeger J, Betuel H, Dubernard JM, Revillard JP, Dupuy C, (eds), Retransplantation. Kluwer Academic Publishers, London, 1997, pp. 251-259.

466. *Humar A, Nevins TE, Remucal M, Cook ME, Matas AJ, Najarian JS. Kidney transplantation in children younger than 1 year using cyclosporine immunosuppression. Ann Surg 228(3): 421-428, 1998.

467. Matas AJ. Acute rejection is a major risk factor for chronic rejection. Transplant Proc 5:1766-8, 1998.

468. *Humar A, Grubbs B, Zapzalka D, Nazarian W, Hunter D, Matas AJ. Isolated iliac artery stenosis as a cause of kid.ney graft dysfunction posttransplant. Clin Transplantation 12(5):406-8, 1998.

469. *Matas AJ, Sutherland DER. Kidney transplantation without a final crossmatch. Transplantation 66(12):1835-1836, 1998.

470. *Hakim NS, Benedetti E, Payne WD, Gruessner R, Gores P, Sutherland DE, Najarian JS, Matas AJ. Pre-emptive renal transplantation. Int Surg 83(4):330-332, 1998.

471. *Vincenti F, Kirkman R, Light S, Bumgardner G. Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H. Gaston R, Backman L, Burdick J for Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338(3):161-5, 1998.

472. *Monaco AP, Burke JF, Ferguson RM, Halloran PF, Kahan BD, Light JA, Matas AJ, Solez K. Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am J Kidney Dis 33(1):150-160, 1999.

473. *Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Matas AJ. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 67(1): 94-97, 1999.

474. *Reinsmoen NR, Matas AJ, Donaldson L, Carter S, Cooperative Clinical Trial in Transplant Research Group. Impact of transfusions and acute rejection on posttransplant donor antigen-specific responses in two study populations. Transplantation 67(5):697-702, 1999.

475. *Johnson EM, Anderson JK, Jacobs C, Suh G, Humar A, Suhr BD, Kerr SR, Matas AJ. Long-term follow-up of living kidney donors: Quality of life after kidney donation. Transplantation 67(5):717-721, 1999.

476. *Kerr SR, Dalmasso AP, Apasova EV, Chen SS, Kirschfink M, Matas AJ. Mouse-to-rabbit xenotransplantation: a new small animal model of hyperacute rejection mediated by the classical complement pathway. Transplantation 67(3):360-5, 1999.

477. Troppmann C, Gruessner AC, Gillingham KJ, Sutherland DER, Matas AJ, Gruessner RWG. Impact of delayed function on long-term graft survival after solid organ transplantation. Transplant Proc 31:1290-1292, 1999.

478. Humar A, Kerr S, Hassoun A, Granger D, Suhr B, Matas A. The association between acute rejection and chronic rejection in kidney transplantation. Transplant Proc 31:1302-1303, 1999.

479. Matas AJ. The impact of acute rejection on chronic rejection: The adult experience. Graft (Supp II) 2(2):S44-S47, 1999.

480. *Matas AJ. Noncompliance and late graft loss: Implications for long-term clinical studies. Transplant Reviews 13(2): 78-82, 1999.

481. *Kerr SR, Matas AJ. Living donors >55 years: to use or not to use? Transplantation 67(7):999-1004, 1999.

482. *Kahan BD, Rajagopalan PR, Hall M for United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monocolonal antibody. Transplantation 67(2):276-84, 1999.

483. *Kandaswamy R, Kamps M, Matas AJ. Administration of OKT3 as a two-hour infusion does not attenuate first-dose side effects. Letter to the Editor, Transplantation 68(5):709-710, 1999.

484. *Matas AJ, Humar A, Payne WD, Gillingham KJ, Dunn DL, Sutherland DER, Najarian JS. Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann Surg 230(4):493-500, 1999.

485. *West M, Pirenne J, Chavers B, Gillingham K, Sutherland DER, Dunn DL, Matas AJ. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplantation 13:318-323, 1999.

486. *Alexander JW, Light JA, Donaldson LA, Delmonico FL, Diethelm AG, Wilkinson A, Rosenthal JT, Thistlethwaite JR, Hunsicker LG, Matas AJ, First MR, Reinsmoen NL, Rose SM. Cooperative Clinical Trials in Transplant Research Group. Evaluation of pre- and post-transplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Transplantation 68(8):1117-1124, 1999.

487. *Humar A, Kerr S, Gillingham KJ, Matas AJ. Features of acute rejection that increase risk for chronic rejection. Transplantation 68(8):1200-1203, 1999.

488. *Humar A, Gillingham KJ, Kandaswamy R, Payne WD, Dunn DL, Sutherland DER, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 68:1879-1883, 1999.

489. *Ahsan N, Hricik, Matas A, Rose S, Tomlanovich S, Wilkinson A, Ewell M, McIntosh M, Stablein D, Hodge E for Steroid withdrawal study group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Transplantation 68:1865-1874, 1999.

490. *Humar A, Hassoun A, Kandaswamy R, Payne WD, Sutherland DER, Matas AJ. Immunologic factors: the major risk for decreased long-term renal allograft survival. Transplantation 68:1841-1846, 1999.

491. *Matas AJ, Gillingham KJ, Humar A, Dunn DL, Sutherland DER, Najarian JS. Immunologic and nonimmunologic factors-different risks for cadaver and living-donor transplantation. Transplantation 69(1):54-58, 2000.

492. *Matas AJ, Gillingham K, Payne WD, Humar A, Dunn DL, Sutherland DER, Najarian JS. Should I accept this kidney? Clin Transplant 14(1):90-95, 2000.

493. *Koushik RS, Matas AJ, Rosenberg ME. Iliac artery stenosis masquerading as diuretic resistant congestive heart failure. Clin Transplant 14(1):11-13, 2000.

494. Matas AJ. Essay 10. Noncompliance with immunosuppressive regimens. In: Stuart FP, Abecassis MM, Kaufman DB (eds). Handbook of Organ Transplantation. Lances Bioscience, Georgetown, TX, 2000, pp. 484-489.

495. Matas AJ. Essay 13. Relationship between acute and chronic rejection. In: Stuart FP, Abecassis MM, Kaufman DB (eds). Handbook of Organ Transplantation. Lances Bioscience, Georgetown, TX, 2000, pp. 514-516.

496. *Kronson J, Gillingham K, Sutherland DER, Matas A. Renal transplantation in Type II diabetic patients compared with Type I diabetic patients and patients over 50 years old: A single-center experience. Clin Transplant 14:226-234, 2000.

497. *Doyle SE, Matas AJ, Gillingham K, Rosenberg ME. Predicting clinical outcome in the elderly renal transplant recipient. Kidney Int 57(5):2144-50, 2000.

498. Matas AJ. Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients. Pediatr Transplantation 4:92-99, 2000.

499. *Humar A, Gillingham K, Payne WD, Sutherland DER, Matas AJ. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 70(2):310-313, 2000.

500. *Matas AJ, Garvey CA, Jacobs CL, Kahn JP. Nondirected donation of kidneys from living donors. NEJM 343(6):433-436, 2000.

501. *Humar A, Payne WD, Sutherland DER, Matas AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 69(11):2357-2360, 2000.

502. *Suhr BD, Guzman-Paz M, Apasova EP, Matas AJ, Dalmasso AP. Induction of accommodation in the hamster-to-rat model requires inhibition of the membrane attack complex of complement. Transplant Proc 32(5):976, 2000.

503. *Papalois VE, Moss A, Gillingham KJ, Sutherland DER, Matas AJ, Humar A. Pre-emptive transplants for patients with renal failure: an argument against waiting until dialysis. Transplantation 70(4):625-31, 2000.

504. *Kahan BD for The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 356:194-201, 2000.

505. *Humar A, Durand B, Gillingham K, Payne WD, Sutherland DE, Matas AJ. Living unrelated donors in kidney transplants: better long-term results than with non-HLA-identical living related donors? Transplantation 69(9):1942-5, 2000.

506. Arrazola L, Sozen H, Humar A, Papalois V, Uknis M, Matas AJ. Increasing incidence of steroid resistant rejection in kidney transplantation. Transplant Proc 32(7):1767, 2000.

507. Arrazola L, Sozen H, Humar A, Papalois V, Uknis M, Matas AJ. Both immunologic and nonimmunologic factors are risks for long-term graft survival-a multivariate analysis. Transplant Proc 32(7):1831, 2000.

508. Arrazola L, Sozen H, Humar A, Uknis M, Papalois V, Matas AJ. Death with function: the next major hurdle. Transplant Proc 32(7):1832, 2000.

509. Arrazola L, Sozen H, Humar A, Papalois V, Uknis M, Matas AJ. Kidney transplant using pediatric donors-effect on long-term graft and patient survival. Transplant Proc 32(7):1839, 2000.

510. Reinsmoen NL, Jackson AM, DeOliveira A, Matas AJ, Gillingham K, Ward FE. Cellular immunology markers posttransplantation predictive of long-term graft outcome. Ann Transplantation 5(2):50-60, 2000.

511. Papalois VE, Matas AJ. Long-term follow-up of living kidney donors. Curr Opin Organ Transplant 5(4):319-323, 2000.

512. Humar A, Key N, Ramcharan T, Payne WD, Sutherland DER, Matas AJ. Kidney retransplants after initial graft loss to vascular thrombosis. Clin Transplantation 15:6-10, 2001.

513. Sutherland DER, Gruessner RWG, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 233(4):463-501, 2001.

514. Kandaswamy R, Gillingham K, Humar A, Payne WD, Dunn DL, Sutherland DE, Najarian JS, Matas AJ. Impact of HLA-ABDR match on chronic rejection in kidney transplants. Transplant Proc 33(1-2):1292, 2001.

515. Kandaswamy R, Sutherland DE, Humar A, Payne WD, Gruessner RW, Matas AJ. Transplantation without a final crossmatch-it can be done. Transplant Proc 33(1-2):1234, 2001.

516. Kandaswamy R, Humar A, Payne WD, Dunn DL, Sutherland DE, Matas AJ. Risk factors for kidney transplant acute rejection: a multivariate analysis. Transplant Proc 33(102):1112, 2001.

517. Arrazola L, Sutherland DE, Sozen H, Hunter DW, Payne WD, Najarian JS, Matas AJ. May-Thurner syndrome in renal transplantation. Transplantation. 2001 Mar 15;71(5):698-702.

518. Matas AJ, Solez K. Editorial-From first principles-tubulitis in protocol biopsies and learning from history. Amer J Transplant 1:4-5, 2001.

519. Moss A, Najarian JS, Sutherland DER, Payne WD, Gruessner RWG, Humar A, Kandaswamy R, Gillingham KJ, Dunn DL, Matas AJ. 5,000 kidney transplants-a single-center experience. In: Cecka and Terasaki, Eds. Clinical Transplants 2000, UCLA Immunogenetics Center, Los Angeles, CA, 2001.

520. Humar A, Kerr SR, Ramcharan T, Gillingham KJ, Matas AJ. Peri-operative cardiac morbidity in kidney transplant recipients: incidence and risk factors. Clin Transplant 15:154-158, 2001.

521. Nyberg SL, Matas AJ, Rogers M, Harmsen WS, Velosa JA, Larson TS, Prieto M, Ishitani MB, Sterioff S, Stegall MD. Donor scoring system for cadaveric renal transplantation. Amer J Transplantation 1:162-170, 2001.

522. Matas AJ. Expected clinical outcomes-risk factors in kidney transplantation. In: Norman DJ and Turka LA, Eds. Primer on Transplantation, 2nd Ed. American Society of Transplantation, Mt. Laurel, NJ, pp. 485-489, 2001.

523. Matas AJ, Humar A, Kandaswamy R, Payne WD, Gruessner RWG, Sutherland DER. Kidney and pancreas transplantation without a crossmatch in select circumstances-it can be done. Clin Transplant 15:236-239, 2001.

524. Matas AJ, Payne WD, Sutherland DER, Humar A, Gruessner RWG, Kandaswamy R, Dunn DL, Gillingham KJ, Najarian JS. 2,500 Living donor kidney transplants-A single-center experience. Ann Surg 234(2):149-164, 2001.

525. *Kandaswamy R, Matas AJ.  Laparoscopic donor nephrectomy: The University of Minnesota experience.  Minnesota Med 84:43-45, 2001.

526. *Humar A, Arrazola L, Mauer M, Matas AJ, Najarian JS.  Kidney transplantation in young children: should there be a minimum age? Pediatr Nephrol 16(12):941-5, 2001.

527. *Humar A, Ramcharan T, Denny R, Gillingham KJ, Payne WD, Matas AJ.  Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation 72(12):1920-3, 2001. 

528. Humar A, Matas AJ.   Immunosuppressive drugs.   In:  Hakim N and Danovitch G (eds).  Transplantation Surgery, 2001.  Springer-Verlag, New York.  pp. 373-393.

529. *Matas AJ, Kasiske B, Miller L. Proposed guidelines for re-evaluation of patients on the waiting list for renal cadaver transplantation.  Transplantation 73(5):811-812, 2002.

530. *Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 13(5):1358-64, 2002.

531. *Matas AJ, Halbert RJ, Barr ML, Helderman JH, Hricik DE, Pirsch JD, Schenkel FA, Siegal BR, Liu H, Ferguson RM. Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. Clin Transplant 16(2):113-21, 2002.

532. *Khan K, Schwarzenberg SJ, Sharp HL, Matas AJ, Chavers BM.  Morbidity from congenital hepatic fibrosis after renal transplantation for autosomal recessive polycystic kidney disease.  Am J Transplant 2:360-365, 2002.

533. *Ishani A, Erturk S, Herta MI, Matas AJ, Savik K, Rosenberg ME.  Predictors of renal function following lung or heart-lung transplantation.  Kidney Int 61(6):2228-34, 2002.

534. Matas AJ.  Steroid sparing after kidney and pancreas transplantation.  Graft 5(4):232-236, 2002.

535. *Five preventable causes of kidney graft loss in the 1990s: A single-center analysis.  Kidney International 62:704-714, 2002. 

536. *Bostom AD, Brown RS Jr, Chavers BM, Coffman TM, Cosio FG, Culver K, Curtis JJ, Danovitch GM, Everson GT, First MR, Garvey C, Grimm R, Hertz MI, Hricik DE, Hunsicker, LG, Ibrahim H, Kasiske BL, Kennedy M, Klag M, Knatterud ME, Kobashigawa J, Lake JR, Light JA, Matas AJ, McDiarmid SV, Miller LW, Payne WD, Rosenson R, Sutherland DE, Tejani A, Textor S, Valantine HA, Wiesner RH.   Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group.  Am J Transplant 2(6):491-500, 2002.

537. Adams PL, Cohen DJ, Danovitch GM, Edington RM, Gaston RS, Jacobs CL, Luskin RS, Metzger RA, Peters TG, Siminoff LA, Veatch RM, Rothberg-Wegman L, Bartlett ST, Brigham L, Burdick J, Gunderson S, Harmon W, Matas AJ, Thistlethwaite JR, Delmonico FL. The nondirected live-kidney donor: ethical considerations and practice guidelines: A National Conference Report. Transplantation 74(4):582-9, 2002.

538. Matas AJ.  Ethical incentives—not payment—for organ donation, Letter to editor.  NEJM 347(17):1282-3, 2002.

539. *Vats A, Gillingham K, Matas A, Chavers B.  Improved late graft survival and half-lives in pediatric kidney transplantation:  A single center experience.  Am J Transplant 2:939-945, 2002.

540. *Ramcharan T, Matas AJ.  Long-term (20- to 37-year) follow-up of living kidney donors.  Am J Transplant 2:959-964, 2002.

541. *Humar A, Ramcharan T, Kandaswamy R, Gillingham K, Payne WD, Matas AJ. Risk factors for slow graft function after kidney transplants: a multivariate analysis.  Clin Transplant 16(6):425-9, 2002.   

542. Preciado DA, Matas A, Adams GL.  Squamous cell carcinoma of the head and neck in solid organ transplant recipients.  Head Neck 24(4):319-25, 2002.

543. Kennedy M, Humar A, Matas AJ.  Immunosuppression in Solid-Organ Transplantation.  In: Irwin RS and Rippe JM (eds) Intensive Care Medicine, fifth ed. Lippincott Williams & Wilkins, Philadelphia, 2003, pp 1935-1945.

544. *Noreen HJ, McKinley DM, Gillingham KJ, Matas AJ, Segall M.  Positive remote crossmatch: Impact on short-term and long-term outcome in cadaver renal transplantation.  Transplantation 75(4):501-505, 2003.

545. *Ramcharan T, Kasiske B, Matas AJ.  Living donor kidney transplants:  The difficult decisions.  Transplantation Reviews 17(1):3-10, 2003.

546. *Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ.  Diabetes mellitus after kidney transplantation in the United States.  Am J Transplant 3:178-185, 2003.

547. *Matas AJ, Humar A.  Why study kidney transplant risk factors.  Commentary on Multivariate analysis of donor risk factors for graft survival in kidney transplantation.  Transplantation 75(3):266-7, 2003.

548. *Paraskevas S, Kandaswamy R, Humar A, Gillingham K, Gruessner RWG, Payne WD, Najarian JS, Dunn DL, Sutherland DER, Matas AJ.  Predicting long-term kidney graft survival: Can new trials be done?  Transplantation 75(8):1256-1259, 2003. 

549. *Nyberg SL, Matas AJ, Kremers WK, Thostenson JD, Larson TS, Prieto M, Ishitani MB, Sterioff S, Stegall MD.  Improved scoring system to assess adult donors for cadaver renal transplantation.  Am J Transplant 3(6):715-21, 2003.

550. *Asolati M, Matas AJ.  Risks versus benefits of living kidney donation.  Curr Opin Organ Trans 8:155-159, 2003.

551. *Matas AJ, Bartlett ST, Leichtman AB, Delmonico FL. Morbidity and mortality after living kidney donation, 1999-2001: Survey of United States transplant centers. Am J Transplant 3(7):830-834, 2003.

552. Papalois VE, Matas AJ.  The history of the concept of brain death and organ preservation.  In: Hakim NS and Papalois VE (eds) History of Organ and Cell Transplantation, Imperial College Press, London, UK, 2003, pp 64-75.

553. Humar A, Matas AJ:  Immunosuppressive Drugs.  In:  Hakim NS and Danovitch GM (eds) Transplantation Surgery, Springer, London, UK, 2003, pp 373-393.

554. Collins AJ, Kasiske B, Herzog C, Chen SC, Everson S, Constantini E, Grimm R, McBean M, Xue J, Chavers B, Matas A, Manning W, Louis T, Pan W, Liu J, Li S, Roberts T, Dalleska F, Snyder J, Ebben J, Frazier E, Sheets D, Johnson R, Li S, Dunning S, Berrini D, Guo H, Solid C, Arko C, Daniels F, Wang X, Forrest B, Gilbertson D, St Peter W, Frederick P, Eggers P, Agodoa L.  Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States.  Am J Kidney Dis 42(6 Suppl 5):A5-7, 2003.

555. *Matas AJ.  What's new and what's hot in transplantation: clinical science ATC 2003.  Am J Transplant 3(12):1465-73, 2003.

556. *Burnette AD, Mohler K, McHugh L, Matas A, Savik K, Reinsmoen NL.  Ten year overview of defining a chronic rejection-free state by donor antigen-specific hyporeactivity.  Hum Immunol 64(10 Suppl):S40, 2003.

557. *Barr ML, Schenkel FA, Van Kirk A, Halbert RJ, Helderman JH, Hricik DE, Matas AJ, Pirsch JD, Siegal BR, Ferguson RM, Nordyke RJ.  Determinants of quality of life changes among long-term cardiac transplant survivors: results from longitudinal data.  J Heart Lung Transplant 22(10):1157-67, 2003.

558. *Humar A, Denny R, Matas AJ, Najarian JS.  Graft and quality of life outcomes in older recipients of a kidney transplant.  Exp Clin Transplant 2:69-72, 2003.

559. Matas AJ.  Essay 7.  Noncompliance with immunosuppressive regimens.  In:  Stuart FP, Abecassis MM, Kaufman DB (eds).  Organ Transplantation, 2nd ed..  Lances Bioscience, Georgetown, TX, 2003, pp. 539-545.

560. Matas AJ.  Essay 8.  Relationship between acute and chronig rejection.  In:  Stuart FP, Abecassis MM, Kaufman DB (eds).  Organ Transplantation, 2nd ed..  Lances Bioscience, Georgetown, TX, 2003, pp. 546-550.

561. Manual of Kidney Transplant Medical Care.  Matas A, ed.  Fairview Publications, Minneapolis, 2003.

562. *Matas AJ, Schnitzler M.  Payment for living donor (vendor) kidneys: a cost-effectiveness analysis. Am J Transplant. 4(2):216-21, 2004.

563. Nevins TE, Matas AJ.  Medication noncompliance: another iceberg's tip.  Transplantation 77(5):776-778, 2004.

564. Matas AJ, Sutherland DER, Najarian JS.  Evolution of immunosuppression at the University of Minnesota.  Transplant Proc 36(suppl 2S), 64S-70S, 2004.

565. *Khwaja K, Asolati M, Harmon J, Melancon JK, Gillingham K, Kandaswamy R, Humar A, Gruessner R, Payne W, Najarian J, Dunn D, Sutherland E, Matas A.  Outcome at 3 years with a prednisone-free maintenance regimen: A single-center experience with 349 kidney transplant recipients.  Am J Transplant 4(6):980-7, 2004.

566. *Tsai MY, Aras O, Sozen H, Hanson NQ, Woll PS, Arends VL, Hunninghake DB, Matas AJ.  Plasma homocysteine levels in living kidney donors before and after uninephrectomy.  J Lab Clin Med 143(6):340-3, 2004.

567. Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, Kupiec-Weglinski J, Matas A, Montgomery RA, Nickerson P, Platt JL, Rabb H, Thislethwaite R, Tyan D, Delmonico FL.  Meeting Report.  National Conference to Assess Antibody-Mediated Rejection in Solid Organ Transplantation.  Am J Transplant 4(7):1033, 2004.

568. *Jacobs CL, Roman D, Garvey C, Kahn J, Matas AJ.  Twenty-two nondirected kidney donors:  An update on a single center’s experience.  Am J Transplant 4(7):1110, 2004.

569. *Hariharan S, Kasiske B, Matas A, Cohen A, Harmon W, Rabb H.  Surrogate markers for long-term renal allograft survival.  Am J Transplant 4:1179-1183, 2004.

570. Jacobs CL, Garvey C, Roman D, Kahn J, Matas AJ.  Chapter 27.  Evolution of a nondirected kidney donor program:  lessons learned.  In:  Cecka and Terasaki, Eds. Clinical Transplants 2003.  UCLA Immunogenetics Center, Los Angeles, 2004, pp. 283-291.

571. *Matas AJ, Kandaswamy R, Humar A, Payne WD, Dunn DL, Najarian JS, Gruessner RWG, Gillingham KJ, McHugh LE, Sutherland DER. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 240(3):510-517, 2004.

572. *Bock A, Bliss RL, Matas A, Little JA.  Human leukocyte antigen type as a risk factor for nonmelanomatous skin cancer in patients after renal transplantation.  Transplantation 78(5):775-778, 2004.

573. *Matas AJ.  The case for living kidney sales: rationale, objections and concerns.  Am J Transplant 4:2007-2017, 2004.

574. *Khwaja K, Asolati M, Harmon JV, Melancon JK, Dunn TB, Gillingham KJ, Kandaswamy R, Humar A, Gruessner RWG, Payne, WD, Najarian JS, Dunn DL, Sutherland DER, Matas AJ.  Rapid discontinuation of prednisone in higher-risk kidney transplant recipients.  Transplantation 78(9):1397-1399, 2004. 

575. Matas AJ, Jacobs CL, Kahn JP, Garvey CA.  Nondirected kidney donation at the University of Minnesota.  In:  T. Gutmann, AS Daar, RA Sells, W Land (Eds) Ethical, Legal, and Social Issues in Organ Transplantation, Pabst Science Publishers, Lengerich, 2004, pp. 195-200.

576. Matas AJ, Schnitzler M, Daar AS.  Payment for living kidney donors (vendors) is not an abstract ethical discussion occurring in a vacuum.  Letter to the Editor.  Am J Transplant  4(8): 1380, 2004.

577. *Woodle ES, Vincenti F, Lorder M, Gritsch A, Hricik D, Washburn K, Matas A, Gallichio M, Neylan J, The Rapamune Early Corticosteroid Cessation Study Group.  A multicenter pilot study of early (4 day) steroid cessation in renal transplant recipients under Simulect, tacrolimus and sirolimus therapy.  Am J Transplant 5:157-166, 2005.

578. *Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM.  Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients:  A single-center report.  Transplantation 79(8):958-963, 2005.

579. *Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J, Rush D.  Long-term deterioration of kidney allograft function.  Am J Transplant 5:1405-14, 2005.

580. *Kandaswamy R, Melancon JK, Dunn T, Tan M, Casingal V, Humar A, Payne WD, Gruessner WG, Dunn DL, Najarian JS, Sutherland DER, Gillingham KJ, Matas A.  A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients—an interim analysis.  Am J Transplant 5:1529-1536, 2005.

581. Jie T, Matas AJ, Gillingham KJ, Sutherland DER, Dunn DL, Humar A.  Mycobacterial infections after kidney transplant.  Trans Proc 37:937-9, 2005.

582. McKay DB, Josephson MA, Armenti VT, August P, Coscia LA, Davis CL, Davison JM, Easterling T, Friedman JE, Hou S, Karlix J, Lake KD, Lindheimer M, Matas AJ, Moritz MJ, Riely CA, Ross LF, Scott JR, Wagoner LE, Wrenshall L, Adams PL, Bumgardner GL, Fine RN, Goral S, Krams SM, Martinez OM, Tolkoff-Rubin N, Pavlakis M, Scantlebury V; Women's Health Committee of the American Society of Transplantation.  Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation.

Am J Transplant 5(7):1592-9, 2005.

583. Matas AJ, Jacobs CL, Garvey CA.  Nondirected living donors.  In:  Gaston RS and Wadström J (eds).  Living Donor Kidney Transplantation.  Current Practices, Emerging Trends and Evolving Challenges.  Taylor & Francis, London, 2005, pp. 151-155.

584. *Matas AJ, Kandaswamy R, Gillingham KJ, McHugh L, Ibrahim H, Kasiske B, Humar A.  Prednisone-free maintenance immunosuppression-a 5-year experience.  Am J Transplant 5(10):2473-8, 2005.

585. *Matas AJ, Sutherland DE.  The importance of innovative efforts to increase organ donation.  JAMA 294(13):1691-3, 2005. 

586. *Koushik R, Matas AJ.  Focal segmental glomerular sclerosis in kidney allograft recipients:  an evidence-based approach.  Transplantation Reviews 19(2):78-87, 2005.

587. Matas AJ.  Minimisation strategies in kidney transplant.  Hospital Pharmacy Europe 22:45-47, 2005.

588. *Humar A, Matas AJ.   Surgical complications after kidney transplantation.  Semin Dial. 18(6):505-10, 2005.

589. *Koushik R, Garvey C, Manivel JC, Matas AJ,Kasiske BL.  Persistent, asymptomatic, microscopic hematuria in prospective kidney donors.   Transplantation 80(10):1425-9, 2005.

590. Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle K, Fitzsimmons W, First MR.  Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.  Transplant Proc 37(2):867-70, 2005.

591.  *Ibrahim H, Rogers T, Casingal V, Sturdevant M, Tan M, Humar A, Gillingham K, Matas A.  Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol.  Transplantation 81(2):214-219, 2006.

592. *Matas AJ.  Transplantation using marginal living donors.  Editorial. Am J Kidney Dis 47(2):353-355, 2006.

593. *Oetting WS, Rogers TB, Krick TP, Matas AJ, Ibrahim HN. Urinary beta2-microglobulin is associated with acute renal allograft rejection.  Am J Kidney Dis 47(5):898-904, 2006.

594. *Ibrahim H, Rogers T, Tello A, Matas A.  The performance of three serum creatinine-based formulas in estimating GFR in former kidney donors.  Am J Transplant 6:1479-1485, 2006.

595. Pruett TL, Tibell A, Alabdulkareem A, Bhandari M, Cronin DC, Dew MA, Dib-Kuri A, Gutmann T, Matas A, McMurdo L, Rahmel A, Rizvi SA, Wright L, Delmonico FL. The ethics statement of the Vancouver Forum on the live lung, liver, pancreas, and intestine donor.  Transplantation 81(10):1386-7, 2006.

596. *Casingal V, Glumac E, Tan M, Sturdevant M, Nguyen T, Matas AJ.  Death on the Kidney Waiting List-Good Candidates or Not?  Am J Transplant 6:1953-1956, 2006.

597. *Kandaswamy R, Kasiske B, Ibrahim H, Matas AJ.  Living or deceased donor kidney transplants for candidates with significant extrarenal morbidity.  Clin Transplant 20(3):346-50, 2006.

598. Humar A, Matas AJ.  Kidney Transplantation.  In:  Humar A, Matas AJ, Payne WD (eds):  Atlas of Organ Transplantation.  Springer-Verlagm, London, 2006, pp. 91-131.

599. *Gaston RS, Danovitch GM, Epstein RA, Kahn JP, Matas AJ, Schnitzler MA. Limiting Financial Disincentives in Live Organ Donation: A Rational Solution to the Kidney Shortage.  Am J Transplant 6(11):2548-55, 2006.

600. Matas AJ.  Recurrent disease after kidney transplantation—it is time to unite to address this problem!  Editorial, Am J Transplant 6(11):2527-8, 2006.

601. Kennedy M, Humar A, Matas AJ.  Immunosuppression in Solid-Organ Transplantation.  In: Irwin RS and Rippe JM (eds) Intensive Care Medicine, sixth ed. Lippincott Williams & Wilkins, Philadelphia, 2006, pp

602. Matas AJ.  Why we should develop a regulated system of kidney sales—a call for action!  Editorial. Clin J Am Soc Nephrol 1(6):1129-32, 2006.

603. Matas AJ, Kandaswamy R.  The current role of calcineurin inhibitors in posttransplant immunosuppression?  Am J Transplant 6:2827-2829, 2006.

604. Paraskevas S, Kandaswamy R, Humar A, Gillingham KJ, Gruessner RW, Payne WD, Najarian JS, Sutherland DER, Matas AJ.  Risk factors for rising creatinine in renal allografts with 1 and 3 yr survival.  Clin Transplant 20:667-672, 2006. 

605. Adrogue HE, Matas A, McGlennon RC, Key NS, Gruessner A, Gruessner RW, Humar A, Sutherland DER, Kandaswamy R.  Do inherited hypercoagulable states play a role in thrombotic events affecting kidney/pancreas transplant recipients?  Clin Transplant 21(1):32-37, 2007.

606. Gaston RS, Danovitch GM, Epstein RA, Kahn JP, Matas AJ, Schnitzler MA.  Letter to the editor.  Must all living donor compensation be viewed as valuable consideration?  Amer J Transplant 7(5):1309-10, 2007. 

607. Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ.  Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.  Transplantation 83(6):722-6, 2007.

608. John R, Lietz K, Huddleston S, Matas A, Liao K, Shumway S, Joyce L, Bolman RM.  Perioperative outcomes of cardiac surgery in kidney and kidney-pancreas transplant recipients.  J Thorac Cardiovasc Surg 133(5):1212-9, 2007.

609. Matas AJ, Ibrahim H.  Chapter 8.  Long-term outcomes for the donor.  In:  Tan HP, Marcos A and Shapiro R (eds) Living Donor Transplantation, Informa Healthcare USA, New York, 2007, pp 87-100.

610. Matas AJ, Ibrahim H.  Chapter 35.  Ethics of paid living-unrelated donation: the case for a regulated system of kidney sales.  In:  Tan HP, Marcos A and Shapiro R (eds) Living Donor Transplantation.  Informa Healthcare USA, New York, 2007, pp 417-429. 

611. Humar A, Gillingham K, Kandaswamy R, Payne W, Matas A.  Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode.  Am J Transplant 7(8):1948-53, 2007.

612. Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle K, Fitzsimmons W, First MR.  Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.  Transplantation  83(12):1648-51, 2007.

Top of page

ABSTRACTS:

1. Matas AJ, Simmons R, Buselmeier T, Najarian J, and Kjellstrand C: Mortality after bilateral nephrectomy splenectomy (BNS) in hemodialyzed patients. Kidney Int 6: 74A, 1974.

2. Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Insulin and amylase content of human neonatal pancreata. Fed Proc 34: 864, 1975.

3. Matas AJ, Najarian JS, and Simmons RL: Increased incidence of cancer in the uremic patient. Amer Coll Phys, 1975.

4. Matas AJ, Simmons RL, Goetz FC, Sutherland DER, Kjellstrand CM, and Najarian JS: Elevated serum creatinine in association with hyperglycemia in the diabetic. Transpl Surg, 1975.

5. Matas AJ, Najarian JS, and Simmons RL: Increased cancer in uremic patients. Am Assoc Cancer Res, 1975.

6. Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Human neonatal pancreas: Suitability for transplantation. Diabetes 24 (Suppl. 2): 421, 1975.

7. Buselmeier TJ, Simmons RL, Duncan DA, Toledo LH, Johnson FA, Mauer SM, Mazas MF, Matas AJ, Najarian JS, and Kjellstrand CM: Intraperitoneal steroid injection for dialysis patients with intractable ascites. Western Dialysisand Transplant Society, 1975.

8. Matas AJ, Simmons RL, Buselmeier TJ, Kjellstrand CM, and Najarian JS: Death more than three years after renal transplantation. Kidney Int 8: 499, 1975.

9. Simmons RL, Matas AJ, Buselmeier TJ, Kjellstrand CM, and Najarian JS: Renal transplantation in patients with a previous history of malignancy. Kidney Int 8: 502, 1975.

10. Scheinman JI, Matas AJ, Rattazzi L, and Simmons RL: Immunopathologic studies of the ruptured renal allograft.

11. Buselmeier TJ, Simmons RL, Duncan DA, Toledo LH, Mauer SM, Matas AJ, Najarian JS, and Kjellstrand CM: Local steroid treatment of intractable ascites in dialysis patients. Kidney Int 8: 423, 1975.

12. Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Minimal collagenase digestion: Amelioration of diabetes with a single neonatal rat pancreas. Fed Proc 35: 689, 1976.

13. Sutherland DER, Matas AJ, Steffes MW, and Najarian JS: Culture of adult pancreas: An improved technique for

14. Najarian JS, Mauer SM, Simmons RG, Simmons RL, Haymond MR, Matas AJ, Kennedy WR, Buselmeier TJ, Kjellstrand CM, Sutherland DER, and Goetz FC: Rehabilitation and recurrence after 100 kidney transplants to diabetics. Diabetes 25: 349, 1976.

15. Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Neonatal islet transplantation following minimal collagenase digestion. Diabetes 25: 376, 1976.

16. Sutherland DER, Buls J, Matas AJ, Simmons RL, and Najarian JS: Gastrointestinal bleeding in renal transplant recipients. Program of Clinical Dialysis and Transplant Forum, 1976.

17. Matas AJ, Simmons R, Najarian J, and Kjellstrand C: Factors mimicking acute rejection episodes in renal transplant recipients. Program of Clinical Dialysis and Transplant Forum, p. 20, 1976.

18. Kjellstrand C, Buselmeier T, Simmons R, Matas A, and Najarian J: Risk factors in dialysis and transplantation. Program of Clinical Dialysis and Transplant Forum, p. 20, 1976.

19. Payne WD, Matas AJ, Simmons RL, and Najarian JS: Perfusion nephropathy. N Engl J Med, 296: 514, 1976.

20. Matas AJ, Payne WD, Sutherland DER, Steffes MW, Kretschmer GJ, and Najarian JS: Optimal transplant site for minimal quantities of islet tissue. Ann Royal Coll Phys Surg Canada, p. 50, January 1977.

21. Sutherland DER, Payne WD, and Matas AJ: Successful transplantation of cultured pancreatic fragments from single adult rat donors treated with DL-ethionine. Europ Soc Surg Res 9: 99, 1977.

22. Kretschmer GJ, Sutherland DER, Matas AJ, and Najarian JS: Autotransplantation of pancreatic fragments in totally pancreatectomized dogs. A study comparing the splenic pulp vs. the portal vein as a site for tissue implantation. Europ Soc Surg Res 9: 100, 1977.

23. Sutherland DER, Numata M, Matas AJ, Simmons RL, and Najarian JS: Liver cell isografts and allografts in drug
induced experimental hepatitis in rats. Europ Soc Surg Res 9: 167, 1977.

24. Payne WD, Sutherland DER, Matas AJ, and Najarian JS: DL-ethionine treatment of pancreatic donors. Fed Proc 36: 279, 1977.

25. Matas AJ, Sutherland DER, Payne WD, Steffes MW, Kretschmer GJ, and Najarian JS: Successful transplantation of neonatal rat islet tissue preserved up to 63 hours. Trans Amer Soc Artif Int Organs 6: 55, 1977.

26. Sutherland DER, Kretschmer GJ, Matas AJ, and Najarian JS: Experience with transplantation of pancreatic fragments to the spleen of totally pancreatectomized dogs. Trans Amer Soc Artif Int Organs 6: 85, 1977.

27. Sutherland DER, Matas AJ, Kretschmer GJ, Payne WD, and Najarian JS: Recent advances in experimental islet
transplantation. 10th Europ Congress Int Coll Surg, 1977.

28. Sutherland DER, Matas AJ, Steffes MW, and Najarian JS: Liver cysts in streptozotocin treated rats. Transplantation 24: 162-163, 1977.

29. Hertel BF, Matas AJ, and Simmons RL: Lymphoproliferative disorders in transplant recipients. Amer Soc Transpl Surg, 1977.

30. Kretschmer GL, Sutherland DER, Matas AJ, and Najarian JS: Autotransplantation Langerhans ischer inselin ohne trennung von exo-und endokrinem gewebe an total pankreatektomiert en Hudden.

31. Matas AJ, Sutherland DER, Steffes MW, and Najarian JS: Transplantation of neonatal rat islets after warm and cold ischemia. Ann. Royal Coll Phys Surg Canada, 11, 40 (1978).

32. Steffes MW, Brown DM, Matas AJ, and Mauer SM: Islet transplantation and urinary albumin excretion in intact and uninephrectomized rats with diabetes mellitus. Diabetes 27 (Suppl. 2): 506, 1978.

33. Matas AJ, Sutherland DER, Payne WD, and Najarian JS: Transplantation of neonatal rat islet tissue after in situ and cold ischemia. Diabetes 27 (Suppl. 2): 440, 1978.

34. Sutherland DER, Matas AJ, Goetz FC, and Najarian JS: Autotransplantation of dispersed pancreatic islet tissue to the portal vein after near total pancreatectomy for chronic pancreatitis. Amer Panc Assoc, Inc, Chicago, November, 1978.

35. Lum CT, Sutherland DER, Matas AJ, Eckhardt J, and Najarian JS: Prolongation of mouse pancreatic islet cell allo grafts by inhibition of adenosine deaminase (ADA). Assoc Acad Surg, 1978.

36. Brown DM, Mauer SM, Bassan J, Matas AJ, and Steffes MW: Glomerular basement membrane thickness following islet transplantation. Amer Soc Nephrol, 1978.

37. Sutherland DER, Najarian JS, Matas AJ, and Goetz FC: Human autotransplantation of dispersed pancreas after
pancreatectomy. Clin Res 26: 707A, 1978.

38. Sutherland DER, Najarian JS, Matas AJ, and Goetz FC: Human islet autotransplantation. 10th Congress of the International Diabetes Foundation. Excerpta Medica 481: 226, 1979.

39. Steffes MW, Brown DM, Bassan J, Matas AJ, and Mauer SM: Alterations in mesangial matrix and cytoplasmic components with islet transplantation and uninephrectomy. 10th Congress of the International Diabetes Foundation. Excerpta Medica 481: 223, 1979.

40. Dunn DL, Matas AJ, Simmons RL, and Najarian JS: The effect of herpes simplex virus infection on renal transplant recipients. Amer Soc Transpl Surg, 1980.

41. Hong JH, Shirani K, Arshad A, Parsa I, Matas AJ, Adamsons R, and Butt K: Influence of cadaver donor age on the success of kidney transplants. Amer Soc Transpl Surg, 1981.

42. Matas AJ, Sibley RK, Mauers SM, Kim Y, Sutherland DER, Simmons RL, and Najarian JS: Routine two week posttransplant (predischarge) kidney biopsy does not predict subsequent course. Assoc Acad Surg, Chicago, 1981.

43. Sutherland DER, Matas AJ, Goetz FC, and Najarian JS: Islet cell transplantation - Clinical experience. International Symposium on Pancreas-Islet Cell Transplantation and Mechanical Pancreas, Detroit, 1981.

44. Payne WD, Matas AJ, Frenzel E, Sutherland DER, and Najarian JS: Transplantation of cryopreserved neonatal rat pancreas. Soc Cryobiol, 1981.

45. Tellis V, Matas AJ, Mollenkopf F, Kuemmel P, Soberman R, and Veith FJ: Survival of patients returning to dialysis after a failed transplant. Amer J Kidney Dis CDT Forum, 1982, P. 33.

46. Tellis VA, Kuemmel PJ, Veith FJ, Soberman RJ, Matas AJ, Weiss PJ, and Mollenkopf F: Skin flap coverage of exposed previously infected Polytetrafluorethylene grafts for hemodialysis. Trans Am Soc Artific Int Organs.

47. Matas AJ and Veith FJ: Presumed consent - A more humane approach to cadaver organ donation? Arch Foundation Thanatology, Vol 10 2: 45-6, 1983.

48. Matas A, Sablay L, Tellis V, Kuemmel P, Soberman R, and Veith FJ: Allograft biopsy (Bx) is representative of rejection (R) throughout the kidney. Amer J Kidney Dis. 13th Annual Meeting National Kidney Foundation 1983, p. 19.

49. Matas A, Tellis V, Gupta S, Kuemmel P, and Veith F: An ideal software package for transplant patient data collection and retrieval. Amer J Kidney Dis. 13th Annual Meeting National Kidney Foundation 1983, P. 20.

50. Matas A, Kuemmel P, Tellis V, Soberman R, and Veith F: Treatment of renal transplant rejection - a cost effective approach. Amer J Kidney Dis 13th Annual Meeting, National Kidney Foundation 1983, P. 20.

51. Matas A, Kuemmel P, Tellis V, Soberman R, and Veith F: Renal allograft biopsy. A prospective study. Amer J Kid Dis 13th Annual Meeting, National Kidney Foundation 1983, P. 20.

52. Matas AJ, Tellis VA, Veith FJ, Kuemmel P, Mollenkoph F, Karwa G, and Soberman R: The fate of the patient returned to hemodialysis after losing a renal transplant, Modern Medicine of Canada 1984.

53. Matas AJ, Tellis VA, Quinn T, Glicklich D, Soberman R, Veith FJ: Renal transplant rejection treatment - a cost effective approach. Abst 10th Int Congress of The Transplantation Society, p. 326, 1984.

54. Matas AJ: Splenectomy and death in renal transplant patients. Arch Surg 119: 486, 1984.

55. Matas AJ, Sibley RK, Mauer SM, Sutherland DER, Simmons RL and Najarian JS: The value of needle renal allograft biopsy. A retrospective study of biopsies performed during putative rejection episodes. Year Book of Pathology, 1984.

56. Matas AJ, Tellis VA, Quinn T, Sablay B, Weiss R, Soberman R, Veith FJ: ALG for steroid resistant rejection in
renal transplant recipients on cyclosporine. Amer J Kid Dis 14th Annual Meeting National Kidney Foundation, A 15, 1984.

57. Matas AJ, Tellis VA, Quinn T, Glicklich D, Soberman R, Weiss, R and Veith FJ: ALG treatment of steroid resistant rejection in patients receiving cyclosporine. XIth Annual Meeting, American Society of Transplant Surgeons, Chicago, 1985.

58. Wengerter K, Matas A, Tellis V, Quinn T, Soberman R and Veith F: Which pediatric donor kidneys should be transplanted to adults? Second International Symposium on Organ Procurement. October, 1985.

59. Odenheimer D, Matas A, Tellis V, Quinn T, Soberman R and Veith F: Donor cultures reported positive following renal transplantation - a clinical dilemma. Second International Symposium on Organ Procurement. October, 1985.

60. Wengerter K, Matas A, Tellis V, Quinn T, Soberman R and Veith F: Transplantation of Pediatric Donor Kidneys to Adults Recipients - What is the Critical Age? Presented at Association of Academic Surgery, 1985.

61. Odenheimer D, Matas A, Tellis V, Quinn T, Soberman R and Veith F: Does race affect renal transplant results - a single institution study. Presented at 15th Annual Meeting National Kidney Foundation. Amer J Kidney Dis 6: A14, 1985.

62. Matas AJ, Tellis VA, Perez L, Quinn T, Karwa G, Glicklich D, Soberman R and Veith FJ: Timing of cyclosporine administration in patients with posttransplant ATN. Amer J Kid Dis 6: A12, 1985.

63. Neiberger RE, Weiss RA, Greiffer I, Tellis VA and Matas AJ: Elimination of cyclosporine following oral administration to children with renal transplants. Amer Soc Transplant Physicians 5th Annual Meeting, May 1985.

64. Tellis V, Matas A, Soberman R, Quinn T, Glicklich D and Veith F: Safe renal transplantation in patients over 50. Amer J Kidney Dis, 1986.

65. Matas A, Tellis V, Quinn T, Glicklich D, Soberman R and Veith F: Selective early immunosuppression after renal transplantation - The value of ALG. Amer J Kidney Dis, 1986.

66. Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ: Timing of cyclosporine administration in patients with posttransplant ATN. Assoc for Acad Surg. Twentieth Annual Meeting, Washington, DC, 1986.

67. Matas AJ, Tellis VA, Quinn TA, Glicklich D, Principe A, Soberman R, Veith FJ: Individualization of immediate posttransplant immunosuppression - the value of ALG in patients with delayed graft function. Amer Soc Transpl Physicians, 6th Annual Meeting, Chicago, 1987.

68. Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ: Successful transplantation of highly sensitized patients without regard to HLA matching. Amer Soc Transpl Surgeons, 13th Annual Meeting, Chicago, 1987.

69. Matas A, Tellis V, Glicklich D, Soberman R and Veith F: The effect of referring dialysis center on transplant results. Intl Organ Transplant Forum. Pittsburgh, 1987.

70. Perez L, Matas A, Tellis V: Organ donation in three major cities by race/ethnicity. National Kidney Foundation, Inc. Annual Scientific Meeting, Washington, DC 1987.

71. Matas A, Tellis V, Glicklich D, Soberman R and Veith F: The effect of referring dialysis center on transplant results. National Kidney Foundation Annual Scientific Meeting, Washington, D.C. 1987.

72. Matas A and Tellis V: Selection of kidney recipients. JAMA, 258: 1328-1329, 1987.

73. Senitzer D, Louis PM, Matas AJ, Tellis VA, Soberman R, Veith FJ: Performed reactive antibody and the stimulation index are not predictors of post-donor specific transfusion sensitization. 13th Annual Meeting of American Society for Histocompatibility and Immunogenetics, New York, 1987.

74. Senitzer D, Matas AJ, Tellis VA, Soberman R, Veith FJ: Effect of a positive noncurrent serum donor crossmatch on early renal graft loss. 13th Annual Meeting of American Society of Histocompatibility and Immunogenetics, New York, 1987.

75. Matas AJ, Tellis VA, Senitzer D, Louis P, Glicklich D, Soberman R, Veith FV: Transplantation with Past Positive Crossmatch and Cyclosporine - A Five-year Experience. American Society Transplant Physicians 7th Annual Meeting, 1988.

76. Stein M, Matas AJ, Tellis VA, Karwa G, Quinn T, Glicklich D, Soberman R, Veith FJ. When is Continued ALG Administration Futile? American Society Transplant Physicians, 7th Annual Meeting, 1988.

77. Tellis VA, Matas AJ, Senitzer D, Louis P, Glicklich D, Soberman R, Veith F: Successful Transplantation after Conversion of a Positive Crossmatch to Negative by Dissociation of IgM antibody. American Society of Transplant Surgeons 14th Scientific Meeting, 1988.

78. Matas AJ, Tellis VA, Mallis M, Glicklich D, Senitzer D, Soberman R: Long-Term Results of O Ag Match Cadaver Transplants - A Single Institution Study. XIIth International Congress of the Transplantation Society, Australia 1988.

79. Quinn TA, Louis P, Senitzer D, Matas A: Transplantation with Past Positive Crossmatch and Cyclosporine - A Five- year Experience. XIIth International Congress of the Transplantation Society, Australia 1988.

80. Louis P, Senitzer D, Tellis V, Matas A: Successful Transplantation After Conversion of a Positive Crossmatch to Negative by Dissociation of IgM Antibody. XIIth International Congress of the Transplantation Society, Australia 1988.

81. Stein M, Karwa G, Quinn T, Matas A: When Should an Antilymphocyte Globulin (ALG) Course be Stopped? XIIth International Congress of the Transplantation Society, Australia 1988.

82. Reisfeld D, Matas A, Tellis V, Sprayragen S, Bakal C, Soberman R, Glicklich D, Veith F: Late Follow-up of Percutaneous Transluminal Angioplasty for Treatment of Transplant Renal Artery Stenosis. XIIth International Congress of the Transplantation Society, Australia 1988.

83. Tellis V, Matas A, Soberman R, Principe A, Quinn T, Mallis M, Veith F: Long-term Patient Survival After Cadaver Renal Transplantation. XIIth International Congress of the Transplantation Society, Australia 1988.

84. Perez L, Matas A, Tellis V: Minority Organ Donation in Three Major Cities. XIIth International Congress of the Transplantation Society, Australia 1988.

85. Senitzer D, Louis P, Tellis V, Glicklich D, Veith F, Matas A: Successful Transplantation of the Highly Sensitized Patient Does Not Require a Well Matched Kidney. XIIth International Congress of the Transplantation Society, Australia 1988.

86. Canafax DM, Sutherland DER, Matas AJ, Payne WP, Dunn DL, Najarian JS: Cyclosporine and immunosuppressive regimens in renal transplantation. (letter) N Engl J Med, 319: 1287-1288, 1988.

87. So SKS, Nevins TE, Cook M, Chang PN, Mauer SM, Matas AJ, Najarian JS: Renal transplantation in 20 infants under 1 year of age. Submitted to Amer Soc of Trans Physicians 8th Annual Meeting, May, 1989.

88. Wrenshall L, Matas A, Canafax D, Min D, Fryd D, Dunn D, Payne W, Sutherland D: Increased incidence of late rejection in cadaveric recipients receiving sequential therapy. Amer Soc Trans Physicians 8th Annual Meeting, May, 1989.

89. Bumgardner GL, Matas A, Payne W, Elick B, Dunn D, Fryd D, Sutherland D, Najarian J: Posttransplant pregnancy at a single center. Amer Soc Trans Physicians 8th Annual Meeting, May, 1989.

90. Bumgardner GL, Ascher NL, Cahill D, Chen S, Payne WD, Matas AJ: Analysis of the in vivo and in vitro immune response to purified hepatocytes. Amer Soc Trans Surgeons 15th Annual Meeting, June, 1989.

91. Fabrega A, Matas A, Payne W, Fryd D, Najarian J: Long term results of 123 consecutive HLA-identical living related transplants. Amer Soc Trans Surgeons 15th Annual Meeting, June, 1989.

92. Min DI, Canafax DM, Wrenshall L, Matas AJ, Fryd DS, Dunn DL, Payne WD, Sutherland DER, Najarian JS: An increased frequency of late rejection occurs in cadaveric renal allograft recipients receiving sequential immunosuppressive therapy. Am Coll of Clin Pharm 10th Annual Meeting, August, 1989.

93. Greenstein SM, Schechner RS, Louis P, Senitzer D, Matas AJ, Tellis V: Zero antigen matched cyclosporine treated renal transplant recipients have equal graft survival to matched recipients. Should "points be reevaluated? Amer Soc Trans Surgeons 15th Annual Meeting, June, 1989.

94. Bumgardner GL, Ascher NL, Chen S, Cunningham TR, Payne WD, Matas AJ: Immunosuppressive effects of epatocyte cytosol (HCC) is mediated by arginase. Am Coll of Surgeons, Atlanta, October, 1989.

95. Bumgardner GL, Payne WD, Cahill D, Chen S, Cunningham T, Matas AJ, Ascher NL: Purified hepatocytes stimulate allospecific cytotoxic response in vivo. Society of University Surgeons, Baltimore, MD, February 9-11, 1989.

96. Fasola C, Matas A, Payne W, Najarian J: Reversal of acute liver failure in a large animal by autologous hepatocyte transplantation. Am Coll of Surgeons, Atlanta, October, 1989.

97. Fischel R, Platt J, Dalmasso A, Fuad S, Vercellotti G, Bach F, Matas A: Antibody and complement reactions in discordant xenograft models. Am Coll of Surgeons, Atlanta, October, 1989.

98. Bumgardner G, Payne WD, Matas AJ, Cahill D, Chen S, Ascher NL: In vivo immunogenicity of purified MHC class I + hepatocytes. The FASEB Journal 3(4): A1125, 1989.

99. Gruessner RWG, Matas AJ, Fryd DS, Sutherland DER: A comparison of pediatric vs. adult cadaver donor kidneys for transplantation. 4th Intl Symposium on Organ Procurement and Preservation. Minneapolis, September, 1989.

100. Canafax DM, Matas AJ, Najarian JS: Management of the immunosuppressive drug therapy for recipients of a cadaveric renal allograft: a risk-factor matched comparison of the Minnesota randomized trial with an antilymphoblast globulin, azathioprine, cyclosporine, and prednisone protocol. Am Assoc of Coll of Pharm annual meeting, Portland, Oregon, July 10, 1989.

101. Fischel RJ, Kim W, Cahill D, Bolman RM III, Matas AJ: Cellular immunity in species with variable rejection of vascularized grafts. Assoc for Academic Surgery, Louisville, KY, November, 1989.

102. Stock PG, Bumgardner GL, Ascher NL, Cunningham T, Chen S, Matas AJ, Payne WD: Comparative antigenicity of parenchymal and lymphoid cells in vitro and in vivo. Am Coll of Surgeons, Atlanta, October, 1989.

103. Dunn D, Bumgardner GL, Chen S, Matas AJ: The effects of murine liver cytosol on the development of a humoral immunity. 30th Annual Meeting of the National Student Research Forum, Galveston, TX, April, 1989.

104. Gruessner RWG, Dunn DL, Tzardis PJ, Tomadze G, Payne WD, Matas AJ, Sutherland DER, Najarian JS: Simultaneous pancreas/kidney transplant versus kidney transplants alone in diabetic patients with nephropathy: comparison of outcome and morbidity. 4th Intl. Sym on Organ Procurement and Preservation and 2nd Intl Congress on Pancreatic and Islet Transplantation, Minneapolis, MN, September, 1989.

105. Bumgardner GL, Chen S, Ascher NL, Payne WD, Matas AJ,: Macrophages in immune response to hepatocytes. Assoc of Acad Surgery, Louisville, KY, 1989.

106. Fischel RJ, Bolman RM III, Platt JL, Turman MA, Fuad SA, Matas AJ, Bach FH: Removal of IgM antibodies against endothelial cells results in prolonged cardiac xenograft survival in a discordant model. IV Congress of the European Society for Organ Transplantation, Barcelona, Spain, November, 1989.

107. Fischel RJ, Matas AJ, Platt JL, Bach FH, Bolman RM: Removal of IgM antibodies against endothelial cells results in prolonged cardiac xenograft survival in a discordant model. American Heart Assn, 62nd Scientific Sessions, New Orleans, LA, November, 1989.

108. So SKS, Mauer SM, Matas A, Nevins T, Chavers B, Najarian JS: Should cadaver kidneys be used for transplantation in young children? National Kidney Foundation, 19th Annual Scientific Meeting, December, 1989.

109. Matas AJ, Letter to the Editor (re: HLA matching), ASHI Quarterly 13: #3, p.10, 1989.

110. Reinsmoen NL, Kaufman DB, Sutherland DER, Matas AJ, Najarian JS, Bach FH: Immunogenetic and cellular basis of long-term renal graft acceptance in patients with total lymphoid irradiation. First International Basic Sciences Symposium of the Transplant Society, Chateau Lake Louise, Alberta, Canada, October 1-4, 1989.

111. Fischel RJ, Bolman RM III, Platt JL, Turman MA, Fuad SA, Matas AJ, Bach FH: Removal of IgM antibodies against endothelial cells results in prolonged cardiac xenograft survival in a discordant model. IV Congress of the European Society for Organ Transplantation, Barcelona, Spain, November, 1989.

112. Fischel RJ, Matas AJ, Platt JL, Bach FH, Bolman RM: Removal of IgM antibodies against endothelial cells results in prolonged cardiac xenograft survival in a discordant model. American Heart Assn, 62nd Scientific Sessions, New Orleans, LA, November, 1989.

113. Schechner R, Schlumpf R, Tellis V, Matas A: Receipt of shared organs at 2 geographically separate centers - the impact (?) of UNOS. 4th Intl. Symposium on Organ Procurement and Preservation, Minneapolis, MN 1989.

114. Fischel RJ, Burdine J, Shumway SJ, Matas AJ, Platt JL, Bach FJ, Bolman RM: Pig to rhesus monkey cardiac xenografts - a preclinical model to study the prevention of humoral rejection . Intl. Soc. for Heart Transplantation, Fort Lauderdale, Florida, April 4-6, 1990.

115. Almond PS, Bumgardner GL, Cunningham T, Chen S, Payne WD, Matas AJ: Correlation of Class I antigen expression with immunogenicity. Resident's Program, The Society of University Surgeons 51st Annual Meeting, February 8-10, 1990.

116. Mayoral JL, Loeffler CM, Kramer MA, Matas AJ, Sutherland DER, Najarian JS, Dunn DL: Diagnosis of cytomegalovirus disease in transplant patients based upon gastrointestinal tract manifestations. Surgical Infection Society, 1990.

117. Fasola CG, Kim YS, Dunn DL, Payne WD, Sutherland DER, Matas AJ, Najarian JS: Kidney retransplantation at a single institution: prediction of the outcome of the third kidney transplant based on the patient's previous transplant history. American Society of Transplant Physicians, 1990.

118. Almond PS, Morel P, Mauer SM, Nevins T, Matas AJ, Najarian J, Chavers B: Long-term follow-up of infantile cystinosis patients post renal transplantation. American Society of Transplant Physicians, 1990.

119. Loeffler CM, Matas AJ, Kruse L, Mayoral JL, Payne WD, Dunn DL, Sutherland DER, Najarian JS: Patients with non HBsAg+ liver disease are not at increased risk for renal transplantation. American Society of Transplant Physicians, 1990.

120. Escobar FS, Troppmann C, Gillingham KJ, Almond PS, Matas AJ, Sutherland DER: Influence of pretransplant dialysis on renal allograft outcome. American Society of Transplant Physicians, 1990.

121. Wrenshall LE, Platt J, Fischel R, Bach F, Matas AJ: ABO incompatible transplantation in primates. American Society of Transplant Physicians, 1990.

122. Almond PS, Bumgardner GL, Chen S, Cunningham T, Platt JL, Matas AJ: Correlation of Class I antigen expression with immunogenicity. American Society of Transplant Physicians, 1990.

123. Almond PS, Matas AJ, Escobar FS, Troppmann C, Payne WD, Dunn DL, Sutherland DER, Gillingham KJ, Najarian JS: The effects of cyclosporine and non-immunologic loss of the primary renal allograft on second renal transplants. American Society of Transplant Physicians, 1990.

124. Reinsmoen NL, Matas A, Kaufman D, Sutherland DER, Najarian JS, Bach FH: A new in vitro approach to determine acquired tolerance in long-term kidney allograft recipients. American Society of Transplant Physicians, 1990.

125. Gruber SA, Tzardis P, Skjei KL, Sothern RB, Canafax DM, Matas AJ, Dunn DL: Incidence of malignancy in renal allograft recipients treated with conventional and cyclosporine immunosuppression at a single institution. American Society of Transplant Physicians, 1990.

126. Graves NM, Matas AJ, Hilligoss DM, Canafax DM: Managing the interaction of fluconazole and cyclosporine: results of a double-blind randomized pharmacokinetic and safety study. American Society of Transplant Physicians, 1990.

127. Canafax DM, Davis CL, Carleton BC, Matas AJ, Najarian JS: Results of 13 identical twin renal transplants performed at the University of Minnesota between 1963 and 1986. American Society of Transplant Physicians, 1990.

128. Bumgardner GL: Cell subsets responding to purified hepatocytes in vitro and in vivo and evidence for indirect "antigen" presentation. American Society of Transplant Surgeons, 1990.

129. Matas AJ, Gillingham KJ, Frey DJ: PRA increase after a failed transplant is not affected by donor source or antigen match. XIII International Congress of the Transplantation Society, 1990.

130. Chen SC, Almond PS, Bumgardner G, Bach FH, Matas AJ: Antigen presenting cell function in the mixed lymphocyte hepatocyte culture. XIII International Congress of the Transplantation Society, 1990.

131. Caplan A, Troppmann C, Matas AJ: "Equitable access" or "maximize results" - an ethical conflict in cadaver kidney allocation illustrated by results in patients > 90 kg. XIII International Congress of the Transplantation Society, 1990.

132. Escobar FS, Chen SC, Bumgardner G, Matas AJ: Mechanism of liver cytosol induced immunosuppression. XIII International Congress of the Transplantation Society, 1990.

133. Cunningham T, Almond PS, Bumgardner G, Chen SC: Immunogenicity of Class I+, Class II- Hepatocytes. XIII International Congress of the Transplantation Society, 1990.

134. Almond PS, Frey DJ: Transplantation of kidneys with ATN results in economic losses for hospitals with fixed rate reimbursement. XIII International Congress of the Transplantation Society, 1990.

135. Chavers B, Mauer SM, Nevins TE: Infantile cystinosis: Progression of the primary disease post renal transplant. XIII International Congress of the Transplantation Society, 1990.

136. Troppmann C, Nakhleh RE, Platt JL, Almond PS, Matas AJ, Najarian JS: Renal transplantation in sensitized miniature swine. Surgical Forum, 1990.

137. Fasola C, Kim YS, Manivel JC, Cerra F, Matas AJ, Payne WD: Reversal of acute hepatic failure in pigs by xenogeneic hepatocyte transplantation and by injection of supernatant from xenogeneic hepatocyte cultures. Surgical Forum, 1990.

138. Almond PS, Bumgardner GL, Chen SC, Matas AJ: The proliferative response to Class I+, Class II - hepatocytes. Surgical Forum, 1990.

139. Fischel RJ, Matas AJ, Burdine J, Perry E, Irwin E, Bolman RM: Cardiac xenografting in the pig to rhesus model: removal of anti-endothelial AB results in prolonged survival and evidence for accommodation to AB return. Surgical Forum, 1990.

140. Stoeblen F, Troppmann C, Payne WD, Dunn DL, Sutherland DER, Matas AJ, Najarian JS: The use of living related donors in kidney retransplantation. 4th U of M Research Poster Session: Basic and Applied Research in Academia and Industry, 1990.

141. Almond PS, Bumgardner GL, Chen SC, Matas AJ: Proliferative response to Class I+, Class II- hepatocytes. Am Acad of Pediatrics, 1990.

142. Almond PS, Morel P, Mauer SM, Nevins T, Matas AJ, Najarian JS, Chavers B: Renal transplantation for infantile cystinosis: long term follow-up. Am Acad of Pediatrics, 1990.

143. Almond PS, Troppmann C, Morel P, Matas AJ, Najarian JS: Incidental appendectomy in pediatric renal transplant recipients. Am Acad of Pediatrics, 1990.

144. Gruber SA, Hrushesky WJM, Canafax DM, Cipolle RJ, Erdmann GR, Burke BA, Simmons RL, Matas AJ: Local 6- mercaptopurine infusion prolongs renal allograft survival without systemic toxicity in a canine model. Am Coll of Surgeons, Atlanta, October, 1989.

145. Reddy RL, Perry EH, Chopek MW, Matas AJ: Effective removal of high titer anti-A by plasma exchange for ABO- incompatible renal transplantation. American Society for Apheresis, 1990.

146. Duffy BF, Phelan DL, Flye MW, Mohanakumar: Development of T-cell clonotypic auto-antibodies in liver-kidney transplant recipient. American Society for Histocompatibility and Immunogenetics 16th Annual Meeting 1990, p. 19.

147. Matas AJ, Frey DJ, Gillingham KJ, Noreen H, Reinsmoen N, Najarian JS: PRA increase after a failed transplant is not affected by donor source or antigen match. American Society for Histocompatibility and Immunogenetics 16th Annual Meeting 1990, p. 85.

148. Almond P, Bumgardner G, Chen S, Matas A: Class I+,II- hepatocytes stimulate the generation of "memory" cells in vivo. Assoc for Academic Surgery 24th Annual Meeting, 1990, p.155.

149. Almond PS, Bumgardner G, Chen S, Matas A: Class I+,II- hepatocytes (HC) stimulate the generation of "memory" cells in vivo. Association for Academic Surgery 24th Annual Meeting, 1990, p. 155.

150. Brayman KL, Morel P, Matas AJ, Sutherland DER, Dunn DL, Gores PF, Payne WD, Gillingham KJ: 375 renal transplants in the elderly - a single center experience. Central Surgical Association, 1991.

151. Moss A, Almond PS, Matas AJ, Gillingham K, Troppmann C, Payne WD, Dunn D, Sutherland DER, Najarian JS: Risk factors for second renal transplants immunosuppressed with cyclosporine. American Society of Transplant Physicians, 1991.

152. Troppmann C, Almond PS, Matas AJ, Najarian JS: Donor risk factors and acute tubular necrosis after cadaveric renal transplantation. American Society of Transplant Physicians, 1991.

153. Troppmann C, Caplan, A, Matas AJ, Najarian JS: "Equitable access" or "maximize results" - an ethical conflict in cadaver kidney allocation illustrated by results in patients 90 kg. American Society of Transplant Physicians, 1991.

154. Schweitzer EJ, Matas AJ, Gillingham KJ, Payne WD, Gores PF, Dunn DL, Sutherland DER, Najarian JS: Causes of renal allograft loss: progress in the '80s, challenges for the '90s. American Society of Transplant Physicians, 1991.

155. Gruber S, Moss A, Erdmann G, Burke B, Bowers L, Cipolle R, Canafax D, Matas A: Synergism of oral cyclosporine with local mizoribine infusion in a canine renal allograft model. American Society of Transplant Physicians, 1991.

156. Cheung AHS, Matas AJ, Dunn DL, Gillingham K, Najarian JS: Risk of cytomegalovirus in living-related donor renal transplants - a single center experience. American Society of Transplant Physicians, 1991.

157. Brayman KL, Vianello A, Xenos L, Gruber S, Gillingham K, Morel P, Matas AJ, Dunn DL, Gores PF, Payne WD, Sutherland DER, Najarian JS: Analysis of lethal and non-lethal pulmonary embolism in renal transplant recipients in the pre- and post-cyclosporine eras. American Society of Transplant Physicians, 1991.

158. Brayman KL, Gillingham KJ, Morel P, Matas AJ, Sutherland DER, Dunn DL, Gores PF, Payne WD, Najarian JS: Renal transplants in the elderly - the impact of patient death with a functioning graft. American Society of Transplant Physicians, 1991.

159. Stephanian E, Mauer SM, Chavers B, Nevins T, Kashtan C, Sutherland DER, Matas AJ, Najarian JS: Recurrence of disease in patients retransplanted for focal segmental glomerulosclerosis. American Society of Transplant Physicians, 1991.

160. Cheung AHS, Gillingham KJ, Matas AJ: Infection/Rejection--Revisited. American Society of Transplant Physicians, 1991.

161. Noreen HL, Olson D, Segall M, Gillingham KJ, Matas AJ: Is routine measurement of interleukin 2 receptor (IL-2R) useful? American Society of Transplant Physicians, 1991.

162. Perez R, Matas AJ, Payne WD, Dunn DL, Mauer SM, Chavers B, Nevins T, Kashtan C, Najarian JS: Infectious complications in pediatric renal transplant recipients. American Society of Transplant Physicians, 1991.

163. Almond PS, Matas AJ, Nevins T, Kashtan K, Chavers B, Najarian JS: Pediatric renal transplants: results with sequential immunosuppression. American Society of Transplant Physicians, 1991.

164. Cheung AHS, Matas AJ, Gillingham KJ, Dunn DL, McHugh L, Moudry-Munns K, Najarian JS, Sutherland DER: Morbidity and renal allograft survival in simultaneous cadaver pancreas/kidney versus kidney transplant alone in diabetic patients. American Society of Transplant Surgeons, 1991.

165. Chen SC, Almond PS, Matas AJ: Evidence for direct antigen recognition by CD8+ T cells in mixed lymphocyte hepatocyte culture. American Society of Transplant Surgeons, 1991.

166. Almond PS, Moss A, Melin M, Leventhal J, Gillingham K, Sibley R, Manivel C, Kyriakides P, Matas AJ, Najarian JS: Renal transplant function after 10 years of cyclosporine. American Society of Transplant Surgeons, 1991.

167. Leventhal J, Platt JL, Flores H, Figueroa J, Johnson E, Boyle E, Fischel R, Bach FH, Matas AJ, Bolman RM: Natural antibody and discordant xenograft rejection. American Society of Transplant Surgeons, 1991.

168. Fischel RJ, King NJ, Manivel C, Almond PS, Chen S, Bolman RM, Matas AJ: The histopathologic appearance of rejected xenografts in a neovascularized and primarily vascularized rodent system. First International Congress on Xenotransplantation, 1991.

169. Fischel RJ, Boyle EM, Manivel C, King NJ, Almond PS, Bolman RM, Matas AJ: Evaluation of xenogeneic thyroid transplants as a model of cell mediated response. First International Congress on Xenotransplantation, 1991.

170. Fischel RJ, Matas AJ, Platt JL, Noreen H, Bach FH, Bolman RM: Plasma exchange organ perfusion and immunosuppression reduce "natural" antibody levels as measured by binding to xenogeneic endothelial cells and prolong discordant xenograft survival. First International Congress on Xenotransplantation, 1991.

171. Moss A, Almond PS, Chen S, Fischel RJ, Salazar A, Matas AJ: Sublethal irradiation and syngeneic bone marrow transplant prolongs thyroid xenograft survival. First International Congress on Xenotransplantation, 1991.

172. Flores H, Leventhal J, Gruber SA, Figueroa J, Platt JL, Bach FH, Matas AJ, Bolman RM: 15-deoxyspergualin inhibits natural antibody production in a discordant xenograft model. First International Congress on Xenotransplantation, 1991.

173. Perez RR, Matas AJ: Acute rejection in a living related donor renal transplant recipient. Transplantation Science, 1991.

174. Troppmann C, Payne WD, Dunn DL, Sutherland DER, Matas AJ, Najarian JS: The long-term impact of donor risk
factors and acute tubular necrosis on cadaveric renal transplantation. European Society for Organ Transplantation, Maastricht, the Netherlands, 1991.

175. Fischel RJ, Matas AJ, Bolman RM: Immunosuppression, plasmapheresis and organ perfusion reduce xenogeneic antibody levels as measured by antiendothelial cell ELISA and prolong discordant xenograft survival, American College of Surgeons, 1991.

176. Cheung AHS, Sutherland DER, Dunn DL, Moudry-Munns KC, McHugh L, Gillingham K, Najarian JS, Matas AJ: Morbidity following simultaneous pancreas kidney transplants vs kidney alone in diabetic patients. Third International Congress on Pancreatic and Islet Transplantation Symposium on Artificial Insulin Delivery System. Lyon, France, 1991.

177. Perez R, Matas AJ, Payne WD, Dunn DL, Mauer SM, Chavers B, Nevins T, Kashtan C, Najarian JS: Infectious complications in pediatric renal transplant recipients. Organ transplants in children a perspective for the 90's, Philadelphia, PA, 1991.

178. Flores H, Leventhal J, Gruber SA, Schaffer M, Bolman RM, Matas AJ: Mizoribine inhibits natural antibody production in a discordant xenograft model. First International Congress on Xenotransplantation, 1991.

179. Leventhal J, Platt JL, Flores H, Figueroa J, Johnson E, Boyle E, Fischel R, Bach FH, Bolman RM, Matas AJ: Measurement of natural antibody in a discordant xenograft model. First International Congress on Xenotransplantation, 1991.

180. Leventhal J, Flores H, Gruber SA, Matas AJ, Bolman RM: Inhibition of natural antibody production by a combination of 15-deoxyspergualin, mizoribine, cyclophosphamide and splenectomy. First International Congress on Xenotransplantation, 1991.

181. Boyle EM, Fischel RJ, Johnson EM, Leventhal J, Matas AJ, Bolman RM: Pretransplant donor antigen and cyclophosphamide for evaluation of the clonal deletion theory in the hamster to Lewis rat xenograft model. First International Congress on Xenotransplantation, 1991.

182. Boyle EM, Fischel RJ, Johnson EM, Leventhal J, Matas AJ, Bolman RM: Examination of the clonal deletion theory in the guinea pig to Lewis rat cardiac xenograft model. First International Congress on Xenotransplantation, 1991.

183. Johnson EM, Fischel RJ, Boyle EM, Matas AJ, Bolman RM: Plasma exchange, splenectomy and cyclophosphamide for natural antibody removal; kinetics and xenograft survival. First International Congress on Xenotransplantation, 1991.

184. Cheung AHS. Morbidity following simultaneous -- Third International Congress on Pancreatic and Islet Transplantation and Symposium on Artificial Insulin Delivery Systems. Palais des Congres, Lyon, France, June, 1991.

185. Reinsmoen NL, Matas A, Bach FH: Acquired donor-specific hyporesponsiveness in kidney allograft recipients. Symposium on Tolerance Induction, Breckenridge, CO 1991, p 33.

186. Brayman KL, Morel Ph, Stevens B, Field J, Lloveras JJ, Matas AJ, Gores PF, Sutherland DER: Canine islet xenografts in rats and mice: differences in susceptibility to hyperacute rejection. Association for Academic Surgery, 25th Annual Meeting, Colorado Springs, CO, 1991.

187. Pryor J, Reinberg Y, Manivel JC, Matas A, Gillingham KJ, Woods W, Gonzalez R: Outcome of renal transplantation or dialysis in patients with a history of renal cancer. American Urological Association, Inc, Toronto, 1991.

188. Pryor J, Reinberg Y, Manivel JC, Matas A, Gillingham KJ, Woods W, Gonzalez R: American Urological Association, Inc, 1991 Annual Meeting-Toronto.

189. Werier J, Cheung AHS, Matas AJ: Anaphylactic hypersensitivity reaction after repeat OKT3 treatment. Lancet 337: 1351, 1991.

190. Almond PS, Moss A, Matas A, Gillingham K, Melin M, Flores H, Najarian J: Hemodynamics and hypertension: hypertension-clinical. J Am Soc Neph 2: 486, 1991.

191. Perez R, McHugh L, Frana P, Sinaiko A, Frey D, Matas AJ: Management of hypertension in renal transplantation. J Am Soc Neph 2: 494, 1991.

192. Kim EM, Mauer SM, Gillingham K, Matas A, Chavers B: Causes of kidney transplant loss in a large pediatric population at a single center. J Am Soc Neph 2: 804, 1991.

193. Reinsmoen NL, Najarian JS, Matas AJ: In vitro donor antigen-specific hyporesponsiveness correlates with improved late renal transplant outcome. Am Soc Neph 2: 814, 1991.

194. Schweitzer EJ, Canafax DM, Gillingham KJ, Najarian JS, Matas AJ: Phenytoin administration in kidney recipients on CSA immunosuppression. Am Soc Neph 2: 816, 1991.

195. Stephanian E, Frey D, Matas A, Najarian J: Randomized trial of ALG vs OKT3 in renal transplantation. Am Soc Neph 2: 818, 1991.

196. Almond P, Moss A, Nakhleh R, Melin M, Chen S, Cromwell J, Cunningham T, Salazar A, Shirabe K, Matas AJ: Rapamycin; a potent immunosuppressant for renal transplantation. Assn for Academic Surg, Colorado Springs, CO, November 1991.

197. Leventhal J, Flores H, Figueroa J, Johnson E, Boyle E, Fischel R, Platt J, Bach FH, Matas A, Bolman RM: Natural antibody and discordant xenograft rejection. Assn for Academic Surg, Colorado Springs, CO, November 1991.

198. Perez RV, Kertes P, Dunn D, Matas A: First Episode of cytomegalovirus (CMV) disease 8 to 17 years after renal transplantation. American Society of Transplant Physicians, Chicago, IL May 26-27, 1992.

199. Leventhal JR, Dalmasso AP, Cromwell JW, Manivel CJ, Bolman RM, and Matas AJ: Complement depletion in rodents and non human primates safely prolongs discordant cardiac xenograft survival. American Society of Transplant Surgeons, Chicago, IL, May 27-29, 1992.

200. Almond PS, Matas AJ, Gillingham KJ, Najarian JS: Risk factors for chronic renal transplant rejection. American Society of Transplant Surgeons, Chicago, IL, May 27-29, 1992.

201. Matas AJ, Gillingham KJ, Sutherland DER: T1/2 and risk factors for renal transplant outcome; importance of death with function. American Society of Transplant Surgeons, Chicago, IL, May 27-29, 1992.

202. Basadonna G, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DER, Najarian JS: Early vs. late rejection. Impact on graft loss to chronic rejection in kidney transplantation. American Society of Transplant Physicians, Chicago, IL May 26-27, 1992.

203. Cheung AHS, Matas AJ, Gruessner RWG, Dunn DL, Moudry-Munns K, Najarian JS, Sutherland DER: Uremic diabetic patients wanting a pancreas transplant -- simultaneous cadaver kidney/pancreas or living related donor kidney followed by cadaver pancreas transplant? American Society of Transplant Physicians, Chicago, IL May 26- 27, 1992.

204. Jones JW, Hunter DR, Matas AJ: Percutaneous transluminal dilatation of ureteral stenosis in renal transplant recipients. American Society of Transplant Physicians, Chicago, IL May 26-27, 1992.

205. Reinsmoen NL, Matas AJ: Improved late renal transplant outcome correlates with the development of in vitro donor antigen specific hyporeactivity. American Society of Transplant Physicians, Chicago, IL May 26-27, 1992.

206. Kaufman DB, Matas AJ: Incidence of steroid resistant rejection episodes according to severity of rejection on biopsy. American Society of Transplant Physicians, Chicago, IL May 26-27, 1992.

207. Reinsmoen NL, Bolman RM, Savik K, Butters K, Hertz MI: Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection. American Society of Transplant Physicians, Chicago, IL May 26-27, 1992.

208. Kaufman DB, Matas AJ, Najarian JS: Expanding the pool of living donors: transplantation of kidneys from 0 haplotype match donors, and distantly related and unrelated donors. American Society of Transplant Physicians, Chicago, IL May 26-27, 1992.

209. Kaufman DB, Matas AJ, Najarian JS: Transplantation of kidneys from zero-haplotype matched sibling donors, and distantly related and unrelated donors in the cyclosporine era. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

210. Leventhal J, Dalmasso A, Cromwell J, Manivel C, Bolman RM, Matas A: In rodents and non-human primates complement depletion prolongs discordant cardiac xenograft survival. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

211. N, Bolman RM, Savik K, Butters K: Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection? XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

212. Flores H, Cromwell J, Leventhal J, Najarian J, Matas A: Does previous breast feeding affect maternal donor renal allograft outcome? A single institution experience. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

213. Hunter D, Jones J, Matas A: Successful percutaneous treatment of ureteral stenosis after renal transplantation. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

214. Matas AJ, Gillingham KJ, Sutherland DER: Importance of death with function in analysis of t 1/2 and outcome of renal transplants. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

215. Granger D, Gillingham K, Sutherland D, Payne W, Gores P, Gruessner R, Najarian J, Matas A: Extra renal disease affects posttransplant patient and graft outcome in renal allograft recipients. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

216. Troppmann C, Almond PS, Matas A, Najarian J: Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

217. Basadonna G, Matas A, Gillingham K, Payne W, Dunn D, Sutherland D, Najarian J: Does early vs. late rejection affect renal transplant graft loss to chronic rejection? XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

218. Gruessner R, Almond PS, Gillingham K, Matas A: Predictors of chronic rejection in renal transplant recipients. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

219. Gores P, Kaufman D, Matas A: Treatment of renal rejection episodes according to histologic severity on biopsy. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

220. Moss A, Almond PS, Matas A, Gillingham K, Najarian J: Predictors of improved graft survival in second pediatric renal transplant recipients on sequential and conventional immunosuppression. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

221. Najarian J, Chavers B, McHugh L, Matas A: Long-term follow-up of living related kidney transplant donors. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

222. Payne W, Jones J, Dunn D, Gores P, Gruessner R, Najarian J, Matas A: Employment and disability after renal transplantation. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

223. Butters K, Matas A, Jackson A, Diko M, Reinsmoen N: Donor antigen-specific hyporeactivity correlates with improved late renal transplant outcome. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

224. Cheung A, Matas A, Gruessner R, Dunn D, Moudry-Munns K, Najarian J, Sutherland D: Should uremic diabetic patients who want a pancreas transplant receive a simultaneous cadaver kidney-pancreas transplant or living related donor kidney first followed by cadaver pancreas transplant? XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

225. Jones J, Chen S, Granger D, Almond P, Matas A: Donor specific hyporesponsiveness from intrasplenic injection of MHC class I+, II- allogeneic hepatocytes. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

226. Almond P, Moss A, Melin M, Salazar A, Nakhleh R, Shirabe K, Matas A: Rapamycin; immunosuppressive and tolerogenic effects in a porcine renal allograft model. XIVth International Congress of the Transplantation Society, Paris, France, August, 1992.

227. Sharma A, Myers T, Hunninghake D, Matas A, Kashtan C: Serum lipids in late survivors of pediatric renal transplantation. Am Soc Neph, 25th Annual Meeting, November, 1992.

228. Almond PS, Moss A, Nakhleh R, Melin M, Chen S, Salazar A, Shirabe K, Matas AJ: Rapamycin in a porcine renal transplant model. 3rd Intl Conf on Drug Research in Immunologic and Infectious Diseases. The New York Academy of Sciences, Third International Conference on Drug Research in Immunologic and Infectious Diseases. Immunomodulating Preclinical and Clinical Evaluation, 1992.

229. Granger DK, Gillingham KJ, Matas AJ: Pretransplant comorbidities effect allograft and patient survival. J Am Soc Neph 3: 861, 1992.

230. Jones JW, Halldorson J, Granger D, Elick B, Matas AJ: Unexpected morbidity discovered during living donor evaluation. J Am Soc Neph 3: 864, 1992.

231. Myers T, Hunninghake D, Matas A, Kashtan C: Serum lipids in late survivors of pediatric renal transplantation. J Am Soc Neph 3: 881, 1992.

232. Matas AJ, Sutherland DER, Najarian JS: The impact of HLA matching on graft survival. Letters to the Editor. Transplantation 54: 568-569, 1992.

233. Leventhal J, Rae E, Butters K, Reinsmoen N, Matas A, Bolman RM: Cytokine gene expression in non-hyperacutely rejected discordant cardiac xenografts. J Heart Lung Transplant 12: S78, 1993.

234. Reinsmoen NL, Hertz MI, Kubo S, Bolman RM, Matas AJ: Immune factors correlating with improved long-term graft outcome in kidney, lung and heart transplants (p. 286). American Society of Transplant Physicians, Houston, TX, May 1993.

235. Fryer JP, Granger DK, Leventhal JR, Gillingham K, Najarian JS, Matas AJ: Steroid related complications in the cyclosporine era (p. 207). American Society of Transplant Physicians, Houston, TX, May 1993.

236. Jones JW, Acton R, Elick E, Granger DK, Matas AJ: The effect of kidney donation on subsequent pregnancy (p. 279). American Society of Transplant Physicians, Houston, TX, May 1993.

237. Matas AJ, Gillingham K, Reinsmoen NL, Payne W, Dunn DL, Jones J, Gruessner R, Gores P, Najarian JS: The non- 6 antigen matched cadaver transplant - a single institution study (p. 326). American Society of Transplant Physicians, Houston, TX, May 1993.

238. Gruber S, Hewitt J, Sorenson A, Barber D, Bowers L, Arrazola L, Matas A, Rosenberg M, Canafax D: Pharmacokinetics of FK506 in patients awaiting renal transplantation. American Society of Transplant Physicians, Houston, TX, May 1993.

239. Gruber SA, Gillingham K, Sothern RB, Stephanian E, Matas AJ, Dunn DL: De novo cancer in cyclosporine-treated and non-CSA-treated adult primary renal allograft recipients (p.277). American Society of Transplant Physicians, Houston, TX, May 1993.

240. Aweeka FT, Mekki O, Hewitt J, Canafax D, Matas A, Tworek D, Lee C, Steinmuller D, Schecter P, Laskow D, Neyland J, Mendez R, Benet LZ, Gambertoglio JG, Vincenti F: Comparative pharmacokinetics of tacrolimus in pre and post renal allograft recipients following intravenous and oral administration. American Society of Transplant Physicians, Houston, TX, May 1993.

241. Canafax DM, Lovdahl M, Norman D, Hewitt JM, Granger D, Almond S, Mastoridis P, Russlie HQ, Barber DL, Matas AJ: Effects of ketoconazole on cyclosporine concentrations in renal allograft recipients. American Society of Transplant Physicians, Houston, TX, May 1993.

242. Jackson A, Donahue P, McSherry C, Santamaria P, Butters K, Reinsmoen NL: T cell receptor repertoire changes observed in the development of donor antigen-specific hyporeactivity. American Society of Transplant Physicians, Houston, TX, May 1993.

243. Chavers BM, Reinsmoen NL, Mauer SM, Najarian JS, Matas AJ: High incidence of histologically-defined renal allograft rejection in asymptomatic patients following treatment (p.261). American Society of Transplant Physicians, Houston, TX, May 1993.

244. Jones JJ, Gillingham KJ, Sutherland DER, Payne W, Dunn D, Gores P, Gruessner R, Najarian J, Matas AJ: Successful long-term outcome with 0 haplotype match living-related donors. (p. 87). American Society of Transplant Physicians, Houston, TX, May 1993.

245. Neylan J, Whelchel J, Laskow D, Mendez R, Vincente F, Matas AJ, Steinmuller D, Fitzsimmons B: Adverse events in the comparative dose finding trial of FK506 in primary renal transplantation (p.154). American Society of Transplant Physicians, Houston, TX, May 1993.

246. Fasola CG, Gillingham K, Gruessner R, Payne W, Najarian JS, Matas AJ: Elderly kidney donors successfully expand the donor pool. A single center experience in the CSA era (p.181). American Society of Transplant Physicians, Houston, TX, May 1993.

247. Vencenti F, Bretan P, Melzer J, Mendez R, Laskow D, Neylan J, Matas AJ, Steinmuller D, Fitzsimmons W: Analysis of the incidence and outcome of acute rejection in FK506 treated renal transplant recipients: results of a concentration controlled trial (p.197). American Society of Transplant Physicians, Houston, TX, May 1993.

248. Granger DK, Schmidt WJ, Chavers B, Dunn DL, Matas AJ: Infections after renal transplantation in CSA treated recipients (p.274). American Society of Transplant Physicians, Houston, TX, May 1993.

249. Matas AJ, Gores PF, Kelley SL, Skrokov-Bielefield M, Kinaszczuk M, Gruessner RWG, Najarian JS: Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. American Society of Transplant Surgeons, Houston, TX, May 1993.

250. Scherrer L, Leventhal J, Sun LH, Dalmasso AP, Matas AJ: Different antigens on guinea pig endothelial cells and platelets are recognized by rat xenoreactive antibodies in the guinea pig to rat discordant species combination. American Society of Transplant Surgeons, Houston, TX, May 1993.

251. Najarian JS, Gillingham K, Sutherland DER, Payne WD, Matas AJ: The importance of the quality of initial graft function in cadaver kidney transplantation. American Society of Transplant Surgeons, Houston, TX, May 1993.

252. Gillingham KJ, Payne WD, Najarian JS, Matas AJ: The impact of an acute rejection episode on long-term renal allograft survival (T1/2). American Society of Transplant Surgeons, Houston, TX, May 1993.

253. Fryer J, Leventhal J, Dalmasso A, Simone P, Chen S, Sun LH, Jessurun J, Reinsmoen N, Matas A: Cellular rejection in a discordant xenograft: analysis using adoptive and passive transfer. American Society of Transplant Surgeons, Houston, TX, May 1993.

254. Matas AJ, Gillingham K, Reinsmoen NL, Payne W, Dunn DL, Jones J, Gruessner R, Gores P, Najarian JS: The non- 6 antigen matched cadaver transplant - a single institution study. The Society for Organ Sharing 2nd International Congress, Vancouver, British Columbia, Canada, July 1993.

255. Fasola CG, Gillingham K, Gruessner R, Payne W, Najarian JS, Matas AJ: Elderly kidney donors successfully expand the donor pool. A single center experience in the CSA era. The Society for Organ Sharing 2nd International Congress, Vancouver, British Columbia, Canada, July 1993.

256. Matas A, Gillingham K, Gruessner R, Gores P, Sutherland D, Dunn D, Payne W, Najarian J: The importance of the quality of initial graft function in cadaver kidney transplantation. The Society for Organ Sharing 2nd International Congress, Vancouver, British Columbia, Canada, July 1993.

257. Jones JW, Sutherland DER, Payne WD, Najarian JS, Matas AJ: The value of the 0 haplotype match living-related donor. The Society for Organ Sharing 2nd International Congress, Vancouver, British Columbia, Canada, July 1993.

258. Jones JW, Halldorson J, Elick B, Granger DK, Matas AJ: Unrecognized health problems diagnosed during living donor evaluation: A potential benefit. The Society for Organ Sharing 2nd International Congress, Vancouver, British Columbia, Canada, July 1993.

259. Reinsmoen NL, Hertz MI, Kubo S, Bolman RM, Matas AJ: Immune factors correlating with improved long-term graft outcome in kidney, lung and heart transplants. The Society for Organ Sharing 2nd International Congress, Vancouver, British Columbia, Canada, July 1993.

260. Jones JW, Acton R, Elick B, Granger DK, Matas AJ: Pregnancy following kidney donation. The Society for Organ Sharing 2nd International Congress, Vancouver, British Columbia, Canada, July 1993.

261. Reinsmoen NL, Bolman RM, Savik K, Butters K, Matas AJ, Hertz MI: Improved long-term graft outcome in lung transplant recipients who develop donor antigen-specific hyporeactivity. J Heart Lung Transplant 12: S66, 1993.

262. Fryer J, Leventhal J, Simone P, Chen S, Dalmasso A, Sun LH, Jessurun J, Reinsmoen N, Matas A: Cellular rejection in a discordant xenograft: analysis using adoptive and passive transfer. Second International Congress on Xenotransplantation, Cambridge, England, September 1993.

263. Leventhal JR, Scherrer L, Sun LH, Dalmasso AP, Matas AJ: Antigens on guinea pig endothelial cells and platelets recognized by rat xenoactive antibodies. Second International Congress on Xenotransplantation, Cambridge, England, September 1993.

264. Moss A, Fryer JP, Leventhal JR, Simone P, Chen S, Jessurun J, Reinsmoen N, Matas A: Analysis of the human anti- pig cellular immune response using the Hu-Scid mouse-porcine skin graft model. Second International Congress on Xenotransplantation, Cambridge, England, September 1993.

265. Najarian JS, Benedetti E, McHugh L, Matas AJ: Kidney transplantation for patients > 60. The American Surgical Association, San Antonio, Texas, April, 1994.

266. Granger DK, Amin NB, Sorenson AL, Gillingham KJ, Canafax DM, and Matas AJ: Cyclosporine levels impact early rejection episodes. The Third International Congress on Cyclosporine, Seville, Spain, March, 1994.

267. Reinsmoen NL, Hertz M, Kubo S, Bolman RM, Matas AJ: Reduced incidence of chronic rejection in CSA-treated solid organ recipients with donor antigen-specific hyporeactivity. The Third International Congress on Cyclosporine, Seville, Spain, March, 1994.

268. McSherry C, Jackson AM, Hertz MI, Matas AJ, Bolman RM, Reinsmoen NL: Circulating donor antigen (allogeneic microchimerism) and response to donor antigen as predictors of long-term lung and kidney transplant success. American Society of Transplant Physicians, Chicago, Illinois, May, 1994.

269. Hakim NS, Benedetti E, Pirenne J, Payne WD, Gruessner RW, Gores P, Sutherland DER, Dunn DL, Najarian JS, Matas, AJ: Preemptive transplantation - a cost effective approach to the patient with renal failure. American Society of Transplant Physicians, Chicago, Illinois, May, 1994.

270. Troppmann C, Benedetti E, Chiou A, Gruessner RW, Dunn DL, Gores P, Payne WD, Matas AJ, Najarian JS: Upper gastrointestinal ulcer complications after 956 renal transplants - incidence, localization, outcome and impact on graft and patient survival. American Society of Transplant Physicians, Chicago, Illinois, May, 1994.

271. Benedetti E, Matas AJ, Payne WD, Dunn DL, Gores P, Sutherland DER, Gruessner RW, McHugh L, Najarian JS: Kidney transplantation is successful for patients > 60. American Society of Transplant Physicians, Chicago, Illinois, May, 1994.

272. Hakim NS, Benedetti E, Pirenne J, Gillingham K, Payne WD, Dunn DL, Sutherland DER, Gruessner RW, Matas AJ, Najarian JS: Urologic anastomotic complications after kidney transplantation - a single center experience with 3 anastomotic techniques. American Society of Transplant Physicians, Chicago, Illinois, May, 1994.

273. Troppmann C, Benedetti E, Gruessner RW, Najarian JS, Matas AJ: Should patients with renal allograft loss due to non-compliance be retransplanted? American Society of Transplant Physicians, Chicago, Illinois, May, 1994.

274. Reinsmoen NL, Granger D, Canafax D, Gillingham K, Matas AJ: Impact of cyclosporine levels and HLA match on early rejection episodes. American Society of Transplant Physicians, Chicago, Illinois, May, 1994.

275. Fryer JP, Ingulli E, Gillingham K, Gruessner RW, Sutherland DER, Matas AJ: Are all polyclonal antibody induction therapies equal? - ALG vs. ATG in primary kidney transplants. American Society of Transplant Physicians, Chicago, Illinois, May, 1994.

276. Kroshus TJ, Everett JE, Leventhal JR, John R, Solien EE, Andrade R, Matas AJ, Bolman RM. A modified ex-vivo isolated heart perfusion system. Academy of Surgical Research, 1994.

277. Benedetti E, Hakim N, Matas A, Payne W, Mauer SM, Nevins T, Kashtan C, Chavers B, Najarian J. Renal transplantation in cyclosporine immunosuppressed infants and children. The Third International Congress on Cyclosporine, Seville, Spain, March, 1994.

278. Delmonico F, Thistlethwaite R, Matas A, Lindblad A, Salomon D, Knowles R, Haverty T, Rose S. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: A cooperative pilot study. XVth World Congress of the Transplantation Society, Kyoto, Japan, August, 1994.

279. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas AJ. Phase II FK506 multicenter concentration control study: one-year follow-up. XVth World Congress of the Transplantation Society, Kyoto, Japan, August, 1994.

280. Miller, R, Burke,B, Matas A.J., Kashton, C. Recurrence (R) of Hemolutic Uremic Syndrome (HUS) in Renal Allografts: A Single Center Report. Submitted: Journal of the American Society of Nephrology 5:3:1024, 1994.

281. Miller R, Burke B, Matas A, Kashtan C. Recurrence of hymolytic uremic syndrome (HUS) in renal allografts: a single center report. JASN 5;3:1024, 1994.

282. Ingulli E, Matas A, Nevins T, Kashtan C, Mauer SM, Gillingham K, Najarian JS, Chavers BM. The impact of first rejection on renal allograft survival in children: a single center experience. American Society of Transplant Physicians 13th Annual Meeting, Chicago, IL, May, 1994.

283. Chavers BM, Mauer SM, Gillingham K, Najarian JS, Matas A. Comparison of posttransplant complications according to age in primary pediatric transplant recipients. American Society of Transplant Physicians 13th Annual Meeting, Chicago, IL, May, 1994.

284. Chavers BM, Mauer SM, Nevins T, Gillingham K, Najarian JS, Matas AJ. Young age is not a risk factor for graft failure in primary pediatric kidney transplant recipients. American Society of Transplant Physicians 13th Annual Meeting, Chicago, IL, May 1994.

285. Leventhal, Kim Y, Matas A, Alam J, Nath KA. Infiltration Macrophages Strongly Express Heme Oxugenaxe ( HO) In Acute Renal Allograft Rejection (AR) In: The Rat. Submitted to: Journal Of The American Society o Nephrology. September 5:3: 114 1994.

286. Sorenson AL, Canafax DM, Matas AJ. Single dose pharmacokinetic evluation of iohexol (IX) in renal transplant recipients. American Association of pharmaceutical scientists. May 1995.

287. Pirenne J, Moon C, Benedetti E, Gruessner AC, Hakim NS, Troppmann C, Bekersky I, Matas AJ, Uckun F, Gruessner RWG. Effect of donor-specific bone marrow administration on kidney allograft survival under FK506: A prospective randomized study in porcine model. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL, May 1995.

288. Troppmann C, Papalois BE, Moon C, Nakhleh RE, Gruessner A, Matas AJ, Gruessner RWG. Transplant site and islet mass as critical outcome determinants after discordant large-to-small animal xenoislet transplantation. Submitted to: American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL, May 1995, and 5th IPITA Congress, 1995.

289. Neylan JF, Laskow D, Vincenti F, Mendeaz R, Matas AJ, Seidler T. The safety of FK506 in renal transplant recipients: Two year follow-up of the U.S. Phase II trial. Submitted to: XIIIth International Congress of Nephrology.

290. Kershner R, Laskow D, Neylan J, Vincenti F, Mendez R, Mata sAJ. Correlation of FK506 blood concentrations to rejection and toxicity in cadaveric kidney transplant patients. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

291. Leichtman AB, Bennett WM, Curtis JJ, Halloran PF, Matas AJ, Monaco AP, Salomon DR. OG37-325 is similarly efficacious to cyclosporine A: Report of two, phase III multicenter trials. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

292. Fryer J, Chen S, Johnson E, LH Sun, Dalmasso A, Matas AJ. Macrophage role after xeno- vs. allosensitization. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

293. Burke BA, Chavers BM, Gillingham KJ, Kastan CE, Manivel JC, Mauer SM, Nevins TE, Matas AJ. Chronic renal allograft rejection in the first six months posttransplant - A reevaluation. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

294. Hakim NS, Benedetti E, Pirenne J, Payne WD, Gruessner RWG, Gores PF, Sutherland DER, Dunn DL, Najarian JS, Matas AJ. Preemptive transplantation - A cost effective approach to the patient with renal failure. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

295. Matas AJ, Lawson W, McHugh L, Payne WD, Najarian JS. Dynamics of post kidney transplant employment. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

296. Pandian K, Johnson E, Wermager J, Lawson W, McHugh L, Matas AJ. Quality of life after failed kidney transplant. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

297. Matas AJ, Lawson W, McHugh L, Felton K, Dunn DL. Pregnancy after kidney donation. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

298. Troppmann C, Gillingham KJ, Gruessner RWG, Dunn DL, Payne WD, Sutherland DER, Najarian JS, Matas AJ. Is there a late impact of delayed graft function on outcome after cadaver renal transplantation? Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

299. Matas AJ, Gillingham KJ, Schmidt W, Payne WD, Dunn DL, Gruessner RWG, Sutherland DER, Najarian JS. A third kidney transplant - Cost-effective for patients with ESRD? Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

300. T-lymphocyte precursor frequencies (cytotoxic, helper): Correlation with clinical status of kidney and lung recipients. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

301. Reinsmoen NL, Ninova D, Weisner R, Jackson AJ, McSherry C, Kondo M, Matas AJ, Krom RAS. Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

302. Chavers BM, Gillingham KJ, Matas AJ. Histology of acute rejection and renal allograft outcome in patients with a single rejection episode. Submitted to:American Society of Transplant Physicians 14th Annual Meeting, Chicago, IL May 1995.

303. Fryer J, Chen S, Johnson E, Simone P, Sun L, Goswitz J, Dalmasso A, Matas AJ. The influence of T-cells in the delayed rejection of discordant xenografts. Submitted to: American Society of Transplant Surgeons 14th Annual Meeting, Chicago, IL May 1995.

304. Johnson E, Leventhal J, Dalmasso A, Goswitz J, Simone P, Chen S, Moyle M, Matas AJ. The role of MAC-1 (CD11b/CD18)--C3bi receptor ligand interaction in effector cell recruitment during delayed xenograft rejection. Submitted to: American Society of Transplant Surgeons 14th Annual Meeting, Chicago, IL May 1995.

305. Ingulli E, Matas AJ, Nevins T, Kashtan C, Mauer SM, Gillingham K, Najarian JS, Chavers BM. The impact of first rejection on renal allograft survival in children: A single center experience. Submitted to: American Society of Transplant Surgeons 14th Annual Meeting, Chicago, IL May 1995.

306. Fryer J, Chen S, Simone P, Matas AJ. The role of macropages in delayed vascular xenograft rejection. Submitted to: American College of Surgeons, New Orleans LA, October 22-27, 1995.

307. Leichtman AB, Bennett WM, Curtis JJ, Halloran PF, Matas AJ, Monaco AP, Salomon DR. OG37-325 Demonstrates equivalent efficacy to cyclosporin A: Report of two,, phase III multicenter trials. Submitted to: American Society of Transplant Physicians 14th Annual Meeting,Chicago, IL May 1995.

308. Leichtman AB, Bennett WM, Curtis JJ, Halloran PF, Matas AJ, Monaco AP, Salomon DR. OG 37-325 is equally efficacious to, but more hepatotoxic than cyclosporin A. 1995 International Consensus Conference on Immunosuppressive Drugs. May 5-7, 1995.

309. Sorenson AL, Canafax DM, Matas AJ. Comparison of Iohexol and Inulin as determinants of glomerular filtration rates (GFR) in renal transplant recipients. Submitted to: American College of Clinical Pharmacy 1995 Annual Meeting, Washington DC, August 6-9, 1995.

310. Hakim N, Benedetti E, Pirenne J, Gillingham K, Payne W, Dunn D, Sutherland D, Gruessner R, Matas AJ, Najarian JS. Urologic anastomotic complications after kidney transplantation a single center experience with 3 anastomotic techniques. Submitted to: 36th World Congress of Surgery, Lisbon, Portugal, August 27 to September 2, 1995.

311. Jones JW, Chen S, Matas AJ. Intrasplenic injection of class I antigen causes suppression of in vitro response to allospecific stimulus. Academy of Surgical Research 11th Annual Scientific Session, Albuquerque, New Mexico, October 5-7, 1995.

312. Sorenson AL, Canafax DM, Matas AJ. A multicenter, double-bblinded, randomized comparison of cyclosporine (CSA) and OG 37-325 (OG) for the prevention of renal allograft rejection. 21st Annual Midwest Pharmacy Residents Conference, Rohcester, MN, April 27-29, 1995.

313. Benedetti E, Moon C, Gruessner AC, Hakim NS, Troppmann C, Matas AJ, Uckun F, Gruessner RWG. Effect of donor-dpecific bone marrow administration (DSBMA) on kidney allograft survival under FK506: A prospective randomized study in a porcine model. Submitted to: International Congress on New Immunosuppressive Drugs. August 27-30, 1995.

314. Papalois BE, Moon C, Nakhleh RE, Gruessner AC, Sehgal SN, Matas AJ, Gruessner RWG. Perioperative immunosuppression as critical determinant of early outcome after discordant xenoislet transplantation: A comparative study. Submitted to: International Congress on New Immunosuppressive Drugs. August 27-30, 1995.

315. Johnson EM, Canafax D, Gillingham KJ, Pandian K, Matas AJ. Do early cyclosporine (CSA) levels affect incidence of acute rejection in renal transplant recipients? Journal of the American Society of Nephrology 6: 1096, 1995.

316. Johnson EM, Zimmerman J, Duderstadt K, Chambers J, Sorenson AL, Granger DK, Almond PS, Fryer JP, Leventhal JR, Scarola J, Matas AJ, Canafax DM. A randomized, double blind, placebo controlled study of the safety, tolerance, and perliminary pharmacokinetics (pk) of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Journal of the American Society of Nephrology 6: 1096, 1995.

317. Ingulli E, Matas AJ, Gillingham KJ, Chavers BM. The outcome of renal transplantation in children with posterior urethral valves (PUV) in the cyclosporine (CSA) era. Journal of the American Society of Nephrology 6: 1094, 1995.

318. Chavers BsM, Mauer M, Gillingham KF, Matas AJ. Histologly of acute rejection (AR) impacts renal allograft survival (GS) in patients (pts) with a single rejection episode (SRE). Journal of the American Society of Nephrology 6: 1076, 1995.

319. Johnson EM, Pandian K, Chen S, Leventhal J, Matas AJ. The effect of defibrination on hyperacute rejection.. Presented to the Society of University Surgeons, 38th Annual Residents Conference, February 10, 1996, Washington, D.C.

320. Johnson EM, Pandian K, Gillingham K, Schmidt W, Hayes W, McHugh L, Matas A (Dunn D). The impact of failed kidney transplant. Central Surgical Association. March 8-10, 1996, Minneapolis, MN.

321. Jackson AM, McSherry C, Butters K, Diko M, Almond S, Matas AJ, Reinsmoen NL. Polerizing effects of pretransplant exposure to donor HLA-DR antigen in random transfusion units for kidney recipients. 12th Int Histocompatibility Conference. June 9-12, 1996, Paris.

322. Johnson EM, Remucal M, Pandian K, Gillingham K, Schmidt W, Dahms R, Najarian JS, Matas AJ. Review of complications and risks in renal transplant donors. Presented to the Minnesota Surgical Society, May 3, 1996, Rochester, Minnesota.

323. Johnson EM, Matas AJ, Gillingham K, Dunn DL, Gruessner RWG, Payne W, Sutherland DER, Najarian JS. Risk factors for early kidney allograft rejection--a multivariate analysis. Presented to the American Society of Transplant Physicians, May 29, 1996, Dallas, Texas.

324. Johnson EM, Dalmasso AP, Leventhal J, Chen S, Loung C, Apasova E, Simone P, Matas AJ. Depletion of C3 and C5 prolongs cardiac xenograft survival and decreases leukocyte infiltration in a model of delayed xenograft rejection. Presented to The American Society of Transplant Surgeons, May 31, 1996, Dallas, Texas.

325. Wrenshall LE, McHugh L, Felton PK, Dunn DL, Matas AJ. Pregnancy after donor nephrectomy. American Society of Transplant Physicians. May 26-29, 1996, Dallas, Texas.

326. Jackson A, Almond S, McSherry C, Butters K, Diko M, Grahs B, Matas AJ. Polerizing effect of pretransplant exposure to donor HLA-DR antigen in random transfusions for kidney recipients. American Society of Transplant Physicians. May 26-29, 1996, Dallas, TX.

327. Matas AJ, Gillingham KJ, Johnson E, Dunn DL, Gruessner RWG, Payne WD, Sutherland DER, Najarian JS. Risk factors for early kidney allograft rejection -- A multivariate analysis. American Society of Transplant Physicians. May 26-29, 1996, Dallas, TX.

328. Kerr SR, Matas AJ. Chronic renal allograft rejection: Outcomes following diagnosis. American Society of Transplant Physicians. May 26-29, 1996, Dallas, TX.

329. Reinsmoen NL, Troppmann C, Matas AJ. Combination of immune and clinical parameters -- Best predictors of long-term graft outcome after kidney transplantation. American Society of Transplant Physicians. May 26-29, 1996, Dallas, TX.

330. Metrakos P, Tortorelis DG, Gillingham KJ, Najarian JS, Matas AJ. 123 patients with kidney allografts functioning > 20 years. American Society of Transplant Physicians. May 26-29, 1996, Dallas, TX.

331. Birk PE, Matas AJ, Gillingham KJ, Schmidt WJ, Chavers BM. Predictors of late acute rejection in renal transplant recipients. American Society of Transplant Physicians. May 26-29, 1996, Dallas, TX.

332. West M, Chavers BM, Pirenne J, Matas AJ. Clostridium difficile colitis after renal transplantation. American Society of Transplant Physicians. May 26-29, 1996, Dallas, TX.

333. Nevins TE, Gillingham KJ, Schmidt W, Matas AJ. Natural history of medication compliance after transplant: preliminary results. American Society of Transplant Physicians. May 26-29, 1996, Dallas, TX.

334. Matas AJ, Gillingham KJ, Elick B, Dunn DL, Gruessner RWG, Payne WD, Sutherland DER, Najarian JS. Risk factors for a prolonged stay after kidney transplant. American Society of Transplant Surgeons. May 29-31, 1996, Dallas, TX.

335. Kahan BD, Pescovitz M, Julian B, Chan G, Vanrenterghem Y, Sirolimus Multi-Center Study Group. Multi-Center phase II trial of sirolimus (SRL) in renal transplantation: six month results. American Society of Transplant Surgeons. May 29-31, 1996, Dallas, TX.

336. Dalmasso AP, Johnson EM, Leventhal J, Chen S, Loung C, Apasova E, Simone P, Matas AJ. Depletion of C3 and C5 prolongs cardiac xenograft survival and decreases leukocyte infiltration in a C6 deficient rodent model of delayed xenograft rejection. American Society of Transplant Surgeons. May 29-31, 1996, Dallas, TX.

337. Leventhal J, Johnson E, Dalmasso A, Aposova E, Luong C, Chen S, Simone P, Moyle M, Matas AJ. Neutrophil inhibitory factor (NIF) a novel CD11b/CD18 inhibitory agent, to evaluate delayed xenograft rejection in a C6 deficient rat. American Society of Transplant Surgeons. May 29-31, 1996, Dallas, TX.

338. Johnson EM, Leventhal J, Chen S, Apasova E, Luong C, Remucal M, Dahms R, Matas AJ. Analysis of the impact of T-cell inhibition on rejection of guinea pig xenografts in C6 deficient rodents. American Society of Transplant Surgeons. May 29-31, 1996, Dallas, TX.

339. Farney A, Payne WD, Najarian JS, Matas AJ. Indicators of chronic rejection in primary kidney allograft recipients with a single acute rejection episode. American Society of Transplant Surgeons. May 29-31, 1996, Dallas, TX.

340. Johnson EM, Matas AJ. Delayed xenograft rejection.. Minnesota Surgical Residents Society, 19th Annual Meeting, June 10, 1996, Minneapolis, Minnesota.

341. Wrenshall L, McHugh L, Felton PK, Dunn DL, Matas AJ. Pregnancy after donor nephrectomy. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

342. Metrakos P, Tortorelis D, Gillingham KJ, Matas AJ, Najarian JS. 123 patients with kidney allografts functioning $ 20 years. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

343. Farney A, Payne WD, Najarian JS, Matas AJ. Indicators of chronic rejection in primary kidney allograft recipients with a single acute rejection episode. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

344. Kerr S, Matas AJ. Chronic renal allograft rejection: outcomes following diagnosis. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

345. West M, Sutherland DER, Matas AJ. Kidney transplant recipients who die with functioning grafts: serum creatinine level and cause of death. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

346. Najarian JS, Durand B, McHugh L, Matas AJ. No deaths directly caused by Minnesota ALG after kidney or kidney- pancreas transplantation. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

347. Matas AJ, Gillingham KJ, Payne WD, Sutherland DER, Dunn DL, Gruessner RWG, Najarian JS. Acute rejection, the predominant risk factor for chronic rejection: an updated analysis. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

348. Leventhal J, Johnson EM, Chen S, Apasova E, Luong C, Remucal M, Dahms R, Matas AJ. Analysis of the impact of T-cell inhibition on rejection of guinea pig xenografts in C6 deficient rodents. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

349. Jackson A, Almond S, McSherry C, Butters K, Diko M, Grahs B, Matas AJ, Reinsmoen NL. Polerizing effect of pretransplant exposure to donor HLA-DR antigen in random transfusions for dikney recipients. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

350. Reinsmoen NL, Troppmann C, Matas AJ. Combination of immune and clinical parameters -- best predictors of long-term graft outcome after kidney transplantation. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

351. Kerr S, Johnson E, Pandian K, Gillingham K, Schmidt W, Hayes W, McHugh L, Matas AJ. The psychological impact of a failed kidney transplant. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

352. Johnson E, Pandian K, Chen S, Apasova E, Leventhal J, Matas AJ. Defibrination alone prolongs xenograft survival suggesting an active role of fibrin in xenograft rejection. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

353. Johnson E, Remucal M, Pandian K, Gillingham K, Schmidt W, Dahms R, Najarian JS, Matas AJ. Review of 860 donor nephrectomies: complications and risks. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

354. Matas AJ, Gillingham K, Johnson E, Dunn DL, Gruessner RWG, Payne WD, Sutherland DER, Najarian JS. Risk factors for early kidney allograft rejection -- a multivariate analysis. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

355. Matas AJ, Gillingham K, Elick B, Dunn DL, Gruessner RWG, Payne WD, Sutherland DER, Najarian JS. Risk factors for a prolonged stay after kidney transplant. XVI International Congress of the Transplantation Society. August 25-30, 1996, Barcelona, Spain.

356. Johnson EM, Gillingham K, Humar A, Matas AJ. Effect of gender and weight on kidney allograft survival and acute rejection. Presented to the 29th Annual Meeting of the American Society of Nephrology, November 3-6, 1996, New Orleans, Louisiana.

357. Johnson EM, Dahms R, Rudy J, Humar A, Gillingham K, Remucual M, Kerr S, Matas AJ. Chronic rejection and donor-recipient size disparity. Presented to the 29th Annual Meeting of the American Society of Nephrology, November 3-6, 1996, New Orleans, Louisiana.

358. Humar A, Gillingham K, Johnson EM, Matas AJ. Effect of initial slow graft function on renal allograft rejection and survival. Presented to the 29th Annual Meeting of the American Society of Nephrology, November 3-6, 1996, New Orleans, Louisiana.

359. Johnson EM, Remucal M, Pandian K, Gillingham K, Schmidt W, Dahms R, Matas A. Complications and risks of renal donation. Presented to the 29th Annual Meeting of the American Society of Nephrology, November 3-6, 1996, New Orleans, Louisiana.

360. Johnson EM, Dahleen LM, Chmielewski B, Matas AJ. Further investigation into the role fibrin plays in hyperacute rejection. Presented at The Society of University Surgeons Residents' Program, February 15, 1997, Tampa, Florida.

361. Kerr SR, Johnson EM, Dalmasso AP, Matas AJ. Xenotransplantation -- a new small animal model of classical pathway hyperacute rejection. Poster presented at the 15th Annual Scientific Meeting of the American Society of Transplant Physicians, May 10-14, 1997, Chicago, Illinois.

362. Reinsmoen NL, Matas AJ,, Carter S, CCTT Study Group. Differences in immune parameters in two study populations--impact of pre- and peritransplant clinical events. 15th Annual Scientific Meeting of the American Society of Transplant Physicians, May 10-14, 1997, Chicago, Illinois.

363. Kerr SR, Johnson EM, Gillingham KJ, Matas AJ. Living donors (LDs) age > 55: to use or not to use? 15th Annual Scientific Meeting of the American Society of Transplant Physicians, May 10-14, 1997, Chicago, Illinois.

364. Matas AJ, Payne WD, Gruessner RWG, Wrenshall LE, Dunn DL,Sutherland DER, Najarian JS. Long-term quality of life (QOL) after kidney and kidney/pancreas transplantation. 23rd Annual Meeting of the American Society of Transplant Surgeons, May 14-16, 1997, Chicago, Illinois.

365. Suhr B, Johnson E, Reinartz J, Dahms R, Matas AJ. Comparative effects of topical microbicides on duodenal mucosa. Poster presented at 23rd Annual Meeting of the American Society of Transplant Surgeons, May 14-16, 1997, Chicago, Illinois.

366. Humar A, Johnson E, Gillingham K, Payne WD, Sutherland DER, Gruessner RWG, Matas AJ. Venous thromboembolic complications after kidney and kidney-pancreas transplant--a multivariate analysis. Poster presented at 15th Annual Scientific Meeting of the American Society of Transplant Physicians, May 10-14, 1997, Chicago, Illinois.

367. Humar A, Uknis M, Carlone-Jambor C, Gillingham K, Dunn DL, Matas AJ. Recurrent CMV disease after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Poster presented at 23rd Annual Meeting of the American Society of Transplant Surgeons, May 14-16, 1997, Chicago, Illinois.

368. Humar A, Johnson E, Gillingham K, Matas AJ. The disappearing face of acute rejection. Poster presented 15th Annual Scientific Meeting of the American Society of Transplant Physicians, May 10-14, 1997, Chicago, Illinois.

369. Humar A, Gillingham K, Johnson E, Payne WD, Dunn DL, Sutherland DER, Gruessner RWG, Wrenshall LE, Najarian JS, Matas AJ. Effect of initial slow graft function on renal allograft rejection and survival. Presented at 23rd Annual Meeting of the American Society of Transplant Surgeons, May 14-16, 1997, Chicago, Illinois.

370. Johnson EM, Dahleen L, Chmielewski B, Pandian K, Chen S, Dalmasso AP, Matas AJ. Pit viper venom and leech derived-hirudin used to determine the role of fibrin in hyperacute rejection. Poster presented at 23rd Annual Meeting of the American Society of Transplant Surgeons, May 14-16, 1997, Chicago, Illinois.

371. Johnson E, Anderson K, Jacobs C, Humar A, Suhr B, Kerr S, Matas AJ. Long-term follow-up of living organ donors. Presented at 15th Annual Scientific Meeting of the American Society of Transplant Physicians, May 10-14, 1997, Chicago, Illinois.

372. Reinsmoen NL, Matas AJ, Carter S, CCTT Study Group, Impact of pre- and peritransplant clinical events on posttransplant immune parameters in two study populations. Presented at 23rd Annual Meeting, American Society for Histocompatibility and Immunogenetics. October 14-19, 1997, Atlanta, Georgia.

373. Birk PE, Engeland WC, Kashtan CE, Levay-Young BK, Rogers L, Manivel C, Mauer M, Chavers BM, Chen S, Matas AJ. Increased expression of TGF-b1 and procollagen I mRNA during acute renal allograft rejection in the Fisher-Lewis rat model. Presented at the 30th Annual Meeting, American Society of Nephrology. November 2-5, 1997, San Antonio, Texas.

374. Matas AJ, Payne WD, Gruessner RWG, Wrenshall LE, Dunn DL, Sutherland DER, Najarian JS. Long-term quality of life (QOL) after kidney and kidney/pancreas transplantation. Presented at the 30th Annual Meeting, American Society of Nephrology. November 2-5, 1997, San Antonio, Texas.

375. Humar A, Johnson E, Payne WD, Gruessner RWG, Matas AJ. The acutely ischemic extremity after transplant: an approach to management. Presented at the 30th Annual Meeting, American Society of Nephrology. November 2-5, 1997, San Antonio, Texas.

376. Humar A, Uknis M, Carlone-Jambor C, Gillingham K, Dunn D, Matas AJ. Recurrent CMV disease after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Presented at the 30th Annual Meeting, American Society of Nephrology. November 2-5, 1997, San Antonio, Texas.

377. Johnson EM, Boerner TB, Remucal M, Gillingham K, Matas A. Posttransplant diabetes: risks and outcomes. Presented at the 30th Annual Meeting, American Society of Nephrology. November 2-5, 1997, San Antonio, Texas.

378. Noreen HJ, McKinely D, Gillingham K, Matas AJ, Segall M. Positive remote crossmatch is associated with reduced graft survival in cadaveric renal transplantation. Presented at the American Society of Transplant Physicians 17th Annual Scientific Meeting. May 9-13, 1998, Chicago, Illinois.

379. Noreen HJ, McKinley D, Gillingham K, Matas AJ, Segall M. Remote crossmatch and graft survival in cadaveric renal transplantation. Presented at the American Society of Transplant Physicians 17th Annual Scientific Meeting. May 9-13, 1998, Chicago, Illinois.

380. Doyle SE, Gillingham K, Matas AJ, Rosenberg ME. High mortality in the first year after graft loss in elderly kidney recipients. Presented at the American Society of Transplant Physicians 17th Annual Scientific Meeting. May 9-13, 1998, Chicago, Illinois.

381. Doyle SE, Gillingham K, Matas AJ, Rosenberg ME. Predicting outcome in the elderly renal transplant recipient. Presented at the American Society of Transplant Physicians 17th Annual Scientific Meeting. May 9-13, 1998, Chicago, Illinois.

382. Doyle SE, Gillingham K, Matas AJ, Rosenberg ME. Poor survival in repeat kidney transplant recipients over age 60. Presented at the American Society of Transplant Physicians 17th Annual Scientific Meeting. May 9-13, 1998, Chicago, Illinois.

383. West M, Chavers B, Pirenne J, Matas AJ. Clostridium difficile colitis after renal transplantation. Presented at the American Society of Transplant Physicians 17th Annual Scientific Meeting, May 9-13, 1998, Chicago, Illinois.

384. Kerr SR, Humar A, Granger DK, Suhr BJ, Gillingham K, Matas AJ. Perioperative cardiac morbidity in renal transplant recipients: Incidence and risk factors. Presented at the American Society of Transplant Physicians 17th Annual Scientific Meeting, May 9-13, 1998, Chicago, Illinois.

385. Jacobs CL, Johnson E, Gillingham K, Anderson , Matas AJ. Living unrelated kidney donation: Is quality of life affected? Presented at the American Society of Transplant Physicians 17th Annual Scientific Meeting, May 9-13, 1998, Chicago, Illinois.

386. Humar A, Kerr S, Hassoun A, Granger D, Suhr B, Gillingham K, Matas A. Features of acute rejection that predict increased risk for chronic rejection. Presented at the American Society of Transplant Surgeons 24th Annual Scientific Meeting. May 13-15, 1998, Chicago, Illinois.

387. Matas AJ, Sutherland DER. Kidney transplantation without a final crossmatch. Presented at the American Society of Transplant Surgeons 24th Annual Scientific Meeting. May 13-15, 1998, Chicago, Illinois.

388. Kerr SR, Dalmasso AP, Kirschfink M, Matas AJ. Validation of the mouse-to-rabbit combination as a model for pig-to-primate xenotransplantation. Presented at the American Society of Transplant Surgeons 24th Annual Scientific Meeting. May 13-15, 1998, Chicago, Illinois.

389. Granger DK, Lehmann SL, Humar A, Hunter DW, Matas AJ. What is the ideal intervention for ureteral obstruction/stricture? Presented at the American Society of Transplant Surgeons 24th Annual Scientific Meeting. May 13-15, 1998, Chicago, Illinois.

390. Doyle SE, Gillingham K, Matas AJ, Rosenberg ME,. Predicting outcome in the elderly renal transplant recipient. ASTP 17th Annual Scientific Meeting May 9-13, 1998, Chicago, IL.

391. Doyle SE, Gillingham K, Matas AJ, Rosenberg ME. Poor survival in repeat kidney transplant recipients over age 60.
ASTP 17th Annual Scientific Meeting, May 9-13, 1998, Chicago, IL.

392. Doyle SE, Gillingham K, Matas AJ, Rosenberg ME. High mortality in the first year after graft loss in elderly kidney.
ASTP 17th Annual Scientific Meeting, May 9-13, 1998, Chicago, IL.

393. Granger DK, Gillingham K, Zheng Y, Matas AJ. Allograft and patient outcome affected by pretransplant disease. Presented at the Transplantation Society XVII World Congress. July 12-17, 1998, Montreal, Quebec, Canada.

394. Kronson J, Gillingham K, Sutherland D, Matas AJ. Renal transplantation in type II diabetic patients. Presented at the Transplantation Society XVII World Congress. July 12-17, 1998, Montreal, Quebec, Canada.

395. Birk P, Hills K, Grimm P, Nickerson P, Rush D, Chen S, Apasova E, Chavers B, Kashtan C, Matas A. Acute renal allograft rejection (AR) is associated with vascular expression of fibrogenic genes. ASN 31st Annual Meeting & Scientific Exposition, October 25-28, 1998, Philadelphia, PA.

396. Humar A, Hassoun A, Kandaswamy R, Matas A. The questionable importance of nonimmunologic risk factors in long-term graft survival. ASN 31st Annual Meeting & Scientific Exposition, October 25-28, 1998, Philadelphia, PA.

397. Matas A, Granger D, Humar A, Kandaswamy R, Hassoun A, Dunn D, Najarian J, Payne W, Sutherland W. When should I use the new immunosuppressive agents? ASN 31st Annual Meeting & Scientific Exposition, October 25-28, 1998, Philadelphia, PA.

398. Kandaswamy R, Hassoun A, Payne W, Matas A. Retransplants-markedly improved outcome using CSA-based immunosuppression. ASN 31st Annual Meeting & Scientific Exposition, October 25-28, 1998, Philadelphia, PA.

399. Matas A, Gillingham K, Humar A, Dunn DL, Sutherland DER, Najarian JS. Both immunologic and nonimmunologic factors are risks for decreased long-term graft survival-a single-center multivariate analysis. ASN 31st Annual Meeting & Scientific Exposition, October 25-28, 1998, Philadelphia, PA.

400. Nevins T, Thomas W, Skeans M, Matas A. Medication compliance affects the outcome of renal transplantation (RTx). ASN 31st Annual Meeting & Scientific Exposition, October 25-28, 1998, Philadelphia, PA.

401. Vats A, Gillingham K, Matas, Chavers B. Variables associated with improved graft survival and half lives in children (<18 years) after the first year of transplantation-a single center experience. ASN 31st Annual Meeting & Scientific Exposition, October 25-28, 1998, Philadelphia, PA.

402. Matas AJ. Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Presented at 119th Annual Meeting of the American Surgical Association, April 15-17, 1999, San Diego, CA.

403. Humar A, Hassoun A, Kandaswamy R, Matas A. The questionable importance of nonimmunologic risk factors in long-term graft survival. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

404. Matas AJ, Gillingham K, Payne W, Sutherland DER, Dunn DL, Najarian JS. Should I accept this kidney? Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

405. Reinsmoen NL, deOliveira A, Peplinski S, Matas AJ. Th2 intracellular cytokine patterns in kidney recipients hyporesponsive to donor antigen. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

406. Matas AJ, Gillingham K, Humar A, Dunn DL, Payne W, Sutherland DER, Najarian JS. Decreased acute kidney transplant rejection is associated with decrease chronic rejection. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

407. Humar A, Moss A, Suhr B, Gillingham K, Matas A. Determinants of recurrent acute rejection in kidney transplant recipients. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

408. Humar A, Arrazola L, Kerr S, Gillingham K, Matas A. Cadaver donors greater than age 55: which kidneys to use? Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

409. Nevins T, Thomas W, Skeans M, Matas A. Medication compliance following renal transplantation: The natural history. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

410. Humar A, Prieto M, Kerr S, Gillingham K, Dunn D, Matas A. The association between CMV infection and Chronic rejection in kidney transplant recipients. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

411. Norman DJ, Curtis JJ, Kaplan B, Brayman KL, Matas AJ, Levitt D, Light SE. A phase I/II multiple dose study of HuM291, a humanized anti-CD3 monoclonal antibody, in patients experiencing renal allograft rejection. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

412. Reinsmoen NL, Kaestner S, Harland R, Matas AJ, Ward FE. Increased risk of acute and chronic rejection in sensitized kidney recipients with HLA class II-directed donor antigen-specific antibodies. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

413. Hassoun A, Humar A, Kandaswamy R, Long A, Manivel C, Drangstveit M, Matas A, Gruessner R, Sutherland DER. The low incidence of PTLD after pancreas and simultaneous kidney-pancreas transplant. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

414. Arrazola L, Prieto M, Moss A, Humar A, Matas A. Death with function (DWF)-the next major hurdle. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

415. MacDonald AS for the Rapamune Global Study Group Transplant Service. A randomized trial of sirolimus, cyclosporine and prednisone vs. cyclosporine-prednisone alone in recipients of mismatched first kidney grafts: results at one year. Presented at the 18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999, Chicago, IL.

416. Matas A, Ewell M for the Cooperative Clinical Trials in Adult Transplantation Group. Prednisone withdrawal in kidney transplant recipients on CSA/MMF-A prospective randomized study. Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

417. Humar A, Arrazola L, Gillingham K, Matas A. An increased incidence of cardiac complications in kidney tranpslant recipients with cytomegalovirus (CMV) disease. Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

418. Kerr S, Apasova E, Suhr B, Dalmasso A, Matas A. Reduced cell infiltration in hearts from TNF-aR or IL-1R knockout mice transplanted into rats. Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

419. Suhr B, Guzman M, Apasova E, Matas A, Dalmasso A. Inhibition of complement-mediated xenogeneic injury by the membrane attack complex is sufficient to allow induction of accommodation in the hamster-to-rat model. Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

420. Arrazola L, Humar A, Sozen H, Moss A, Prieto M, Matas A. Kidney transplant using pediatric donors-effect on long term graft and patient survival rates. Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

421. Humar A, Moss A, Gillingham K, Matas A. Preemptive transplants in renal failure: an argument for not waiting until dialysis. Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

422. Humar A, Key N, Prieto M, Matas A. Kidney retransplantation after initial graft loss to vascular thrombosis. Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

423. Arrazola L, Humar A, Sozen H, Moss A, Prieto M, Matas A. Increasing incidence of steroid resistant rejection in kidney transplantation. Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

424. Matas A, Humar A, Gillingham K. Both immunologic and nonimmunologic factors are risks for long-term graft survival-a multivariate analysis. Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

425. Humar A, Moss A, Gillingham K, Matas A. Living unrelated donors in kidney transplants: better long-term results than non-HLA identical living related donors? Presented at the 25th Annual Meeting of the American Society of Transplant Surgeons, May 19-21, 1999, Chicago, IL.

426. Sutherland DER, Gruessner RWG, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS. >1,000 pancreas (Px) transplants (Txs) at a single institution. Presented at the 120th Annual Meeting of the American Surgical Association, April 6-8, 2000, Philadelphia, PA.

427. Erturk S, Hertz M, Matas A, Savik K, Ishani A, Rosenberg M. Renal transplantation for end-stage renal disease following lung or heart/lung transplantation. Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

428. Kaplan B, Norman D, Curtis J, Matas A, Levitt D, Light S. A Phase I/II dose escalation study of the humanized anti CD3 antibody HUM291. Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

429. Durand BJ, Matas A, Ingulli E. Thymoglobulin is less expensive and as effective as Atgam for induction therapy in pediatric renal transplant recipient. Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

430. Humar A, Arrazola L, Durand B, Gillingham K, Mauer M, Kashtan C, Nevins T, Chavers B, Matas A. Increased incidence of late acute rejection (AR) episodes in young pediatric kidney transplant recipients. Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

431. Humar A, Uknis M, Papalois V, Gillingham K, Matas A. Is there an association between cytomegalovirus (CMV) and renal artery stenosis (RAS) in kidney transplant recipients? Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

432. Nyberg SL, Matas AJ, Sterioff S, Prieto M, Stegall MD. Donor parameters predict early graft outcome after cadaveric renal transplantation. Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

433. Matas AJ, Gillingham K, Humar A, Payne W, Kandaswamy R, Dunn DL, Sutherland DER, Najarian JS. The impact (?) of HLA-ABDR match on chronic rejection (CR). Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

434. Kamps MA, Ajas NM, Gillingham KJ, Matas AJ. Intraoperative thymoglobulin administration reduces infusion-related adverse events. Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

435. Radosevich DM, Chen KC, Matas AJ, Doyle AJ, Rosenberg ME. Health-related quality of life in the elderly renal transplant recipient. Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

436. Humar A, Kandaswamy R, Papalois VE, Arrazole L, Gillingham K, Matas AJ. Superficial and deep wound infections developing after kidney transplant (KTx) Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

437. Matas AJ, Jacobs C, Garvey C, Kahn J. Nondirected living kidney donation-an opportunity to expand the donor pool. Presented at Transplant 2000, the 1st Joint Meeting of the ASTS and AST, May 13-17, 2000.

438. Reinsmoen NL, Fallang LE, Burnette A, Mohler K, Matas A, DeOliveira A. Quantifying posttransplant changes in the activated responder frequency of donor antigen-specific alloreactive CD4+ or T cells in renal recipients. Submitted to the American Society for Histocompatibility and Immunogenetics, 2000.

439. Paraskevas S, Denny R, Matas AJ. No pathologic diagnosis after kidney biopsy: what next? Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

440. Humar A, Ramcharan T, Paraskevas S, Denny R, Meirelles R, Gillingham K, Matas A. A multivariate analysis of risk factors for slow graft function (SGF) after kidney transplant. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

441. Matas AJ, Gruessner A, Sutherland DER. Transplantation without a preoperative final crossmatch-it can be done in selected circumstances. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

442. Matas AJ, Irish WD, the DGF Study Group. Poor renal allograft function after transplant (TX) predicts poor outcome at 1 year. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

443. Humar A, Kandaswamy R, Denny R, Paraskevas S, Gillingham K, Matas A. Outcome after treatment of biopsy proven vs. presumptive actue rejection (AR) in kidney transplant recipients. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

444. Gran C, Hulbert J, Roberts K, Jain S, Matas A, Humar A. Urologic cancers in kidney transplant recipients. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

445. Grubbs B, Zapzalka D, Hunter D, Matas A, Humar A. Lymphoceles after kidney transplantation-what's the best approach for treatment? Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

446. Paraskevas S, Denny R, Ramcharan T, Gillingham K, Kandaswamy R, Humar A, Matas A. Long-term cyclosporine immunosuppression: Is there nephrotoxicity in kidney transplant recipients? Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

447. Manske CL, Oo T, Matas AJ. Perioperative MI in renal transplant recipients. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

448. Jacobs C, Roman D, Garvey C, Humar A, Matas A. Who becomes a non-directed kidney donor? Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

449. Gran C, Hulbert J, Roberts K, Jain S, Matas A, Humar A. Kidney cancers in renal transplant recipients. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

450. Matas AJ, Ramcharan T, Paraskevas S, Kandaswamy R, Humar A, Gillingham K. Steroid avoidance (minimization) after kidney tranplantation. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

451. Jacobs C, Garvey C, Roman D, Humar A, Matas A. Non-directed donation: who volunteers? Who is rejected? Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

452. Ramcharan T, McHugh L, Kandaswamy R, Gruessner RW, Payne W, Sutherland DER, Humar A, Dunn D, Najarian J, Matas A. Living kidney donation: Long-term (20-37 yrs) consequences. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

453. Humar A, Denny R, Mierelles R, Gillingham K, Matas A. Quality of life in elderly recipients of a kidney transplant. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

454. Khan Khalid, Schwarzenberg SJ, Sharp H, Matas AJ, Chavers BM. Morbidity from congenital hepatic fibrosis after kidney transplantation for autosomal recessive polycystic disease. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

455. Kandaswamy R, Humar A, Gruessner A, Gruessner RW, Hering B, Matas AJ, Sutherland DER. Cytokine gene polymorphisms (CGP) in "pancreas transplant along" (PTA) recipients-can they predict outcome? Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

456. Ramcharan T, Matas A, Gruessner RW, Sutherland DER, Kandaswamy R. Kidney (KD) and kidney-pancreas (KP) transplants in Jehovah's Witnesses (JW)-a single-center experience with 50 transplants. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

457. Humar A, Payne W, Rmacharan T, Denny R, Gillingham K, Matas A. The impact of increasing donor age on long-term kidney graft survival-each year counts. Presented at Transplant 2001, 2nd Joint Meeting of the ASTS and AST, May 12-16, 2001.

458. Reinsmoen NL, Fallang LE, Burnette A, Mohler K, Matas A, DeOliveira A. Quantifying posttransplant changes in the activated responder frequency of donor antigen-specific alloreactive CD4+ or CS8+ T cells in renal recipients. Presented as poster at the 27th Annual Meeting of the American Society for Histocompatibility and Immunogenetics, October 13-17, 2001 in San Francisco.

Top of page

INVITED PRESENTATIONS/SESSION CHAIRS - NATIONAL AND INTERNATIONAL:

2007

ASTS State-of-the-Art Winter Symposium. "Rewarded Gifting – a Regulated System of Kidney Sales."  Marco Island,  FL, January 12-14

"Controversies in Transplantation" Conference.  "Compensation for Donation."  Breckenridge, CO, March 9-11.

Maimonides Society.  "The Cutting Eduge of Organ Donation:  A Maimonides Society Event." Minneapolis, MN, March  21.

Transplant Seminar, Beth Israel Deaconess Medical Center.  "6 Years Using a Rapid Discontinuation of Prednisone  Protocol –The University of Minnesota Experience."  Boston, MA, March 27.

Dutch Transplant Foundation and the Erasmus Medical Center.  International symposium on "Ethical, Legal and  Psychological Aspects of Organ Transplantation."  Rotterdam, the Netherlands, April 1-4.

Fourth Annual World Summit on Organ Donation.  "A Regulated System of Living Donor Sales." Dearborn, MI, April  18-19.

American Transplant Congress.  "A Regulated System of Living Kidney Sales – How It Could Work."  San Francisco,  CA, May 5-9.

UNOS/OPTN Leadership Roundtable Discussion.  Collaboration of Presidents of AST, ASTS, AOPO, NATCO,  ISHLTS, and ASHI, June 1.

2006

ASTS Winter Symposium.  Debate: “The Match Game.”  Scottsdale, AZ, January 20-22.

NATCO Transplant Institute.  “Calcineurin Inhibitor & Steroid Minimization Protocols after Kidney Transplantation.”  Scottsdale, AZ, January 21.

Grand Rounds, UW Hospital, Madison, WI.  “Paying Kidney Donors.”  February 27.

ASTS Retransplantation Conference, Adult Kidney Workgroup.  “Immunosuppression in retransplantation.”  March 7-8.

Genzyme Leipzig Symposium.  Presentation on Immunosuppression.  March 3.

Urology Core Curriculum Conference.  “Renal Transplantation,”  May 3

Interactive Case Based Workshop “Optimizing Long-Term Outcomes in Kidney Transplantation. “  Philadelphia, May 11; New York, May 23.

Richard L. Burleson Lecture, “Some Ethical Considerations in Kidney Transplantation—Increasing the Organ Supply by conventional or Unconventional Market Approaches.”  Syracuse, NY, April 25-26.

Global Leadership Conference on Transplantation.  Talks:  “Key Components of Low-Toxicity Regimens” and Dialog and Debate:  “Should Organ Donors be Paid—the Pro Side.”  Montreal, May 17-20.

Research and Issues Conference, Shands Healthcare, University of Florida.  “Safety of Living Donors and Increasing the Organ Supply by Use of Paid Donors (Vendors)”  Gainesville, FL, May 22-23.

Advisory Committee on Organ Transplantation.  US Department of Health and Human Services.  “Regulated Payment for Organs.”  Rockville, Maryland, May 5.

Living Donor Abdominal Organ Transplantation:  State of the Art, Conference in Sardegna, Italy, July 23-25 

Astellas Virtual Symposium.  “Consequences of Nonadherence.” London, September 24.

Genzyme National Congress of Transplants, "Immunosuppressive low toxicity, outcomes, and future trends."  Monterrey, Mexico, September 12-16.

Living Donor Solid Organ Transplant:  State of the Art Summit.  "Paid donation—should we rethink policy—US perspective."  Cleveland, OH, September 29-20.

Current Issues Forum of San Diego.  Matching donors to organs: the politics, ethics and economics.  San Diego, October 18.

Renal Week, ASN Clnical Nephrology Conference.  "Should we change our organ allocation policies for kidney transplantation" conference, talk "Expanded donor criteria."  San Diego, CA, November 15-19.

Wyeth International Expert Consultants Assembly on Rapamune, "Workshop, What factors in your experience have led to successful outcomes for renal transplant patients treated with sirolimus?"  Collegeville, PA, December 10-12.

2005

American Society of Transplant Surgeons Winter Symposium.  Ethics Workshop:  Talk, “Case for Payments for Organs,” Panel Discussion; Talk, “Should Maintenance Immunosuppression be Changed after a Diagnosis of Acute or Chronic Rejection.” Miami Beach, FL, January 21-23.

University of Alabama conference.  “Steroid Sparing Immunosuppression” and “Organ Shortage.  Birmingham, AL, February 10.

5th Wyeth International Transplantation Symposium.  “Steroid-Free Immunosuppression for Improved Long-Term Outcomes.” Athens, Greece, March 4-12.

Mayo Clinic.  Transplant Center Grand Rounds, “Unconventional Approaches to Expanding Living Donation:  Should we use Financial Incentives?”  Rochester, MN, March 14.

6th Annual Cutting Edge Conference.  “Arguments for and against a Regulated System of Organ Sales” Keynote Address with Dr. Jeffrey Kahn, Radisson Metrodome, Minneapolis,  March 16.

British Transplantation Society.  “Living Donation in the USA.”  Belfast, Ireland, April 5-8.

Surgery Grand Rounds.  U.T. Southwestern Medical Center.  “Steroid Sparing and Steroid-Free Immunosuppression.”  Dallas, TX, April 13.

Johns Hopkins Comprehensive Transplant Center Research Lecture Series.  “Rapid Discontinuation of Prednisone After Kidney Transplantation”, June 3.

American Transplant Conference.   Talks:  May 23, Clinical Science Symposium, “Immunosuppressive Minimization—Steroid Withdrawal in Kidney Transplant Recipients” May 24, Clinical Science Symposium, “The Case for a Regulated System of Living Kidney Sales”  Seattle, WA, May 20-25.

Edmonton and Calgary, Transplant Research Rounds.  June 8, Edmonton, Kidney Vendors: The Case for a Regulated System of Sales”  June 9, Calgary “Rapid Discontinuation of Steroids After Kidney Transplantation”

Institute of Medicine Committee on Increasing Rates of Organ Donation.  Panel Discussion.  Washington DC, June 19-21.

Surgery Grand Rounds, University of Iowa.  “Steroid Sparing and Steroid Free Immunosuppression.”  Iowa City, IA, June 24.

Living Donor Conference – A Discussion of Issues Surrounding Compensation of Living Kidney Donors.  Organized by Dr. Robert Gaston, University of Alabama, July 29, Chicago, IL.

NATCO 30th Anniversary Meeting, Two talks, July 30 – “Steroid Sparing Protocols”, August 1 – “When to Say No to Transplant – The Marginal Transplant Recipient.  July 31-August 3, Atlanta, GE.

Trends in Transplant Immunosuppression Conference, Fujisawa Healthcare, Inc. (Astellas), during NATCO, “Steroid Sparing Protocols.”  Atlanta, GE, July 30.

Scripps Transplant Conference—New Advances in Solid Organ Transplantation & Controversies in Living Donor Transplantation.   “Case for Living Donor Sales,”  San Diego, CA, August 13-14.

MeritCare Kidney Services Conference.  Patient Selection:  Risk Stratification and Immunosuppression Choices.  “Rapid Discontinuation of Prednisone after Kidney Transplantation,”  Fargo, ND, September 15.

Transplantation Society International Forum.  International forum to address the medical care of the live lung, liver, intestinal and pancreas donor.  Participated in forum.  September 14-16, Vancouver, BC

AST Diversity and Disparity in Transplantation Workshop.  Diversity and Disparity in Solid Organ Transplantation:  Bench to Bedside, Facts and Solutions.  “Obesity and Diabetes Before and After Transplantation.”  Washington DC, September 21-22.

Transplant Immunosuppression 2005:  Improving Recipient Outcome.  Organized 3-day course, presented at Radisson Metrodome, Minneapolis, September 28-October 1.

2004

Loyola University (Roche sponsored). Talk on steroid minimization., Chicago, January 20.

Fourth Annual State of the Art Winter Symposium.  Surgical Challenges in Transplantation.   Two talks, “Living Donor Uninephrectomy, and “An Argument in Favor of Living Donor Kidney Sales.”  January 23-25, Scottsdale, AR

Fifth International Bioethics Conference.  Setting Limits to Healthcare:  The Time is Now.  Talks, “A surgeon’s view on healthcare rationing,”  “The case for paying organ donors”and panel discussion, “The Heartless Criminal.”  Honolulu, HI, February 12-13.

Research Medical Center (Genzyme-sponsored), Kansas City, MO, talk, “Rapid Discontinuation of Prednisone After Kidney Transplant.”  February 18.

University of Pennsylvania conference, The Changing Basis of Immunosuppressive Therapy in Renal Transplantation:  Redefining Goals, Broadening Expectations.  Talk, “Emergent Treatment Options:  Steroid-sparing/Minimization Immunosuppression Protocols in Renal Transplantation.”  Philadelphia, PA, March 31. 

American Surgical Association.  Presented abstract, “4-year outcome of prednisone-free maintenance immunosuppression after kidney transplantation.”  San Francisco, CA,  April 15-17.

Novartis talks in Toronto and London.  “Steroid-sparing/minimization immunosuppression protocols in renal transplantation.”  April 13-15.

American Transplant Conference.  Symposium #1 Complications of transplant and infections.  Talk, “Lessons learned from steroid sparing studies.”  Early morning workshop moderator:  Early steroid withdrawal in kidney transplantation.  Chair, Scientific Session, Kidney Transplantation:  Living Donors.  Boston, MA, May 14-19.

Montefiore Medical Center.  Patient Selection:   Risk Stratification and Immunosuppression Choices, funded by Wyeth Pharmaceuticals.  Bronx, NY, June 14.

Porter Hospital.  Nephrology Conference.  “Steroid sparing and steroid free immunosuppression.”  Denver, CO, June 18.

2nd International Conference on Abdominal Organ Transplant from Living Donors.  “”Living Donor Morbidity and Mortality” and “The Good Samaritan Donor.”  Taormina, Sicily, Italy, June 25-27.

Late Renal Allograft Loss Workshop. “Endpoints and Study Designs to Evaluate Renal Allograft Loss,” Bethesda, MD, July 15.

Transplant Coordinators Advisory Board/Symposium (Fujisawa). “Marginal Donors,”  San Francisco, CA, August 5-8.

United Resource Network, “Keynote Debate:  Ethical Issues Surrounding Live Organ Donation,” Minneapolis, September 12-14.

40th Annual Meeting of the  Japan Society for Transplantation.  “Update on Renal Transplantation”, Okayama, Japan, September 16-18.

5th Annual Canadian Transplant Forum:  Deceased Donor Kidney Transplantation—Recipient and Donor Issues.  “Marginal Donors,” Vancouver, BC, Canada, November 12-14

2003

AST Women’s Health Committee Consensus Conference – Reproductive Issues in Transplant Recipients.  March 1-3, Bethesda, MD

Transplant Conference, Good Samaritan Hospital, Phoenix, AR, March 5

NATCO 2003 Transplant Institute “Steroid Avoidance in Renal Transplantation” San Diego, CA, March 15

Conference to Analyze Humoral Rejection in Solid Organ Transplantation, April 23-24, Bechesda, MD

National Kidney Foundation, Diabetes and Transplantation Conference, Workgroup 2 – Therapeutic alternatives for the diabetic patient with CKD, May 7-8, Chicago, IL

XVII Transplant Congress of Latin American/Caribbean, May 20-23, Cuzco, Peru

American Transplant Congress, May 30-June 4, Washington, DC

World Congress of Nephrology,  “Kidney Transplantation in the Elderly” Satellite Symposium, June 12-14, Weimar, Germany

University of Massachusetts Medical School, Seminar, “Organ and Tissue Transplantation:  What is Hot and What is Not?”  June 14, Boston, MA

Albany Medical Center, Talk on “Steroid Minimization and Avoidance in Kidney Transplantation.”  July 31, Albany, NY

Advances in Transplantation – Contemporary Forums.   Maximizing Organ Transplant Outcomes:  Preventing and Managing Complications.  “Debate on Donor Advocacy”, September 7-10, Chicago, IL

Mexican Society of Transplantation, 7th Annual Meeting.  October 21-25, Cancun, Mexico

2002

Urology Core Curriculum Conference, “Renal Transplantation,” VA Medical Center, Minneapolis, January 3

Grand Rounds, University of Virginia, “Discontinuation of prednisone after kidney transplantation.” Charlottesville, VA, February 15

Cutting Edge: New Frontiers in Transplantation.  Fairview-University Medical Center and University of Minnesota, Minneapolis Radisson Hotel Metrodome, March 20

University of Southern California Conference, “Immunosuppression – Meeting the Needs of the Individual.” Los Angeles, CA, March 23

Jewish Hospital, “Rapid discontinuation of prednisone after kidney transplant,” Louisville, KY, March 27

American Transplant Congress.  Review course, April 27; Chair, scientific session, “Clinical Science I” April 29

University of Nebraska, Transplant Research Conference, Omaha, NB, May 15

First Quebec Live Donor Kidney Symposium, “Long-term outcomes of the donor.”  June 1 (conference May 31-June 2), Manoir Hovey, North Hatley, Quebec

Seminar, FibroGen, San Francisco, June 11-12

Abdominal Organ Transplantation from Living Donors:  State of the Art.  “Good Samaritan Donation.” Conference in Gubbio, Italy, June 21-23

Lifelink, Tampa, July 17;  Transplant and Organ Procurement Conference, Florida Hospital Cancenter Institute, Orlando, July 18

Living Donor Kidney Transplantation 2002:  Exploring the challenges.  “Non-directed donation programmes:  Is there a need for concern?” August 25.  During XIX International Congress of Transplantation Society, Miami, August 25-30. 

United Resources Networks 11th Annual National Clinical Conference.  “Rapid discontinuation of steroids after kidney transplantation,” September 22-24, Minneapolis, MN

Audio Conference, “Antibody therapy in organ transplantation.  Rabbit anti-thymocyte globulin (Thymoglobulin) vs. basiliximab (Simulect) in cadaveric renal tranpslant:  Results from a multi-center, randomized trial.”  September 30, October 1; October 28, 29.  (supported by Sangstat)

Fujisawa Transplant Update Conference.  Current Issues in Kidney Transplantation.  “Steroid Avoidance” October 10-12, Rancho Mirage, CA

Transplant Journal Club, Honolulu, HI, October 21-27

2001

South-Eastern Organ Procurement Foundation, “Long-term Outcomes: Living donor kidney transplantation: recipients and donors,”  “Non-directed kidney donation: the Minnesota experience,” and panel discussion, “Living donor transplantation: is there an optimal immunosuppressive protocol,” Tampa, FL, January 18

Grand Rounds, Yale University, Hartford, CT, January 29

ASTS Winter Symposium, “Living Donor Adult-to-Adult Transplantation of the Kidney and Liver.”  Senior Panel Discussion, February 23-25

University of California Grand Rounds, “Posttransplant steroid avoidance,” Davis, CA, March 7

Natco Transplant Institute Course, “Steroid Avoidance,” “Why Transplants Fail,” “Update on nondirected donation.”  New Orleans, March 8-11

UNOS Forum, “Nondirected donation,” “Long-term risk for donors.”  Las Vegas, NV, March 22

Mt. Sinai Medical Center, New York, and St. Barnabus Medical Center, Livingston, NJ, “Steroid avoidance,” April 2 and 3

Cutting Edge—New Frontiers in Transplantation Conference, sponsored by Fairview-University Medical Center.  “Steroid avoidance in kidney transplantation,” Minneapolis, April 18

Grand Rounds, “Steroid sparing after kidney transplant,” Gainesville, FL, April 30

Transplant 2001, Concurrent symposia, clinical science symposium: clinical trials update (presented talk on steroid sparing),” co-moderated workshop “Selected Posters on Kidney Transplantation.”  Presented abstracts, “Living kidney donation: long-term (20-37 yrs) consequences,” “Steroid avoidance (minimization) after kidney transplantation,” Transplantation without a preoperative final crossmatch—it can be done in selected circumstances,” Chicago, IL, May 11-16

Audioconference, “Steroid avoidance in solid organ transplantation: Can it be done?  June 4 and 6, Minneapolis

Grand Rounds, University of Chicago, Chicago, IL, June 6

SangStat sponsored talk, Lexington, KY, “Steroid avoidance after kidney transplant,” June 7

Association of Organ Procurement Organizations Annual Meeting, “Voluntary living unrelated donation: is there a role—or not—for OPOs?”  Minneapolis, June 20-22

Fujisawa sponored talks, “Steroid free immunosuppression,” Vancouver, BC, and Alberta, ED, June 25 and 26

SangStat sponsored Grand Rounds, Seattle, August 28

Midwest Regional Advisory Board, “Cardiovascular risk factors in the transplant patient: overview,” Lake Geneva, WI, September 21

10th Congress of Europeon Society for Organ Trasplantation, Living Donor Kidney Transplantation: Current Controversies/Innovative Ideas, “Can nondirected donation be ethically justified?” Lisbon, Portugal, October 6-11

UCLA Transplant Symposium, “Rapid Discontinuation of Steroids after Kidney Transplantation,” Los Angeles, CA, October 20

Corticosteroids in Transplantation Workshop, Steroid Free Immunosuppressive Regimens: Exploring New Options in Kidney and Pancreas Transplantation. “New approaches to rapid corticosteroid elimination in kidney transplantation,” Dallas, TX, November 1-2

SangStat sponsored Grand Rounds, “Steroid-free renal transplantation,” Portland, OR, November 15

National Kidney Foundation Conference, “Altruistic Donation.”  Chicago, IL, December 6

2000

Talk to Transplant team, University of Michigan, Ann Arbor, "Long-term kidney graft survival-where shall we go from here", Detroit, Michigan, January 26

Medical Grand Rounds, Thomas Jefferson University Hospital, "Renal transplant outcome-where shall we go from here?" Philadelphia, PA, March 2

Fairview-University Medical Center and University of Minnesota course, "The Cutting Edge-New Frontiers in Transplantation," talk "New Immunosuppressive Agents," May 3

Talk to Transplant Clinical Research area, Novartis Pharmaceuticals, East Hanover, NJ. Presented data on long-term database for Sandimmune and Neoral, May 22

Transplant 2000, combined meeting of American Society of Transplantation and American Society of Transplant Surgeons, Chicago, May 13-17, Session chair; lunch workshop

Grand Rounds, Vanderbilt University, Nashville, TN, June 9

Transplant Conference, Emory University, Atlanta, GA, September 7

Transplant Conference, Queen Elizabeth II Medical Center, Halifax, Nova Scotia, Canada, September 14-15

United Resources Networks, 9th Annual National Clinical Conference. "Steroid Avoidance After Kidney Transplantation," Minneapolis, September 10

Session Chair, American Society of Nephrology, October 11-16

Organized Symposium, "Long-term risk factors after transplantation," Phoenix, November 1-3

"SGF" and "Polyclonal Antibodies, presented at symposium on Delayed Graft Function, November 9-11

"Chronic Rejection," presented at Fujisawa Fellows Symposium, November 8-11

"Steroid Free Immunosuppression" presented at University of Colorado Transplant Conference, December 1

1999

ASTP Winter Symposium, Kapalua, Maui, Hawaii, January 14-18
"Role and impact of acute rejection on chronic rejection: the adult experience"

"Transplantation for Diabetes" symposium, Yale University, New Haven, Connecticut,
January 28, "Transplantation in diabetic recipients"

Symposium on Noncompliance, Salzburg, Austria, February 4-6
"The potential role of immunosuppressive noncompliance in chronic rejection"

Grand Rounds, University of Nebraska, Omaha, Nebraska (sponsored by SangStat),
February 23-24, Presented information from research

Washington Hospital Center, March 30, Surgery Grand Rounds

Academy of Managed Care Pharmacy, Minneapolis Convention Center, April 30
Noncompliance in transplantation: clinical impact and system costs

Solid Organ Transplantation Rounds, Winnipeg, Manitoba, Canada, September 15

Organized course, Posttransplant Immunosuppression: New Paradigms, October 20-23, Minneapolis Radisson Hotel Metrodome

Transplant Conference, Des Moines, Iowa, November 19, "Improving kidney transplant outcome"

Transplant Conference, Iowa City, December 17, 1999, "Improving long-term outcome"

1998

ASTP Winter Symposium, San Juan, Puerto Rico, January 15-18
"Chronic allograft dysfunction: clinical definitions and risk factors"

New Dimensions in Transplantation, Florence, Italy, February 13-February 22
"Acute rejection is prognostic of chronic rejection

Fournier Advisory Panel, Paris, France, April 27, Presentation on clinical experience in the use of Deoxyspergualin in kidney transplantation

American Society of Transplant Physicians, Chicago, Illinois, May 9-15,
"The impact of acute rejection" (Satellite symposium), panel-Management of chronic graft dysfunction"

Mexican Society of Transplantation, Merida, Mexico, June 24-27,
"Prognostic factors in chronic rejection"; Kidney transplantation-long-term follow-up (workshop)

XVII World Congress of the Transplantation Society, Montreal, Quebec, Canada, July 12-17,

Unresolved Problems in Transplantation Symposium, Northwestern University Medical School, Chicago, Illinois, October 9,
"Clinical risks of chronic rejection"

John S. Najarian Transplant Fellows Symposium, Scottsdale, Arizona, October 21-24, .
"Predicators of outcome in renal transplantation"

1996

16th Sigrid Juselius International Symposium on Pediatric Transplantation, Helsinki, Finland, June 5-8, "Kidney transplantation-is retransplantation in adulthood inevitable?

XVI International Congress of the Transplantation Society, Barcelona, Spain, August 25-30,
"Acute rejection, the predominant risk factor for chronic rejection: an updated analysis;" "Risk factors for early kidney allograft rejection -- a multivariate analysis;" Risk factors for a prolonged stay after kidney transplant"

Conference on Optimal immunosuppression in the high-risk renal transplant patient. Tucson, Arizona, November 14-15,
"Optimal immunosuppression in the elderly kidney transplant recipient"

Jewish Hospital, University of Louisville, Louisville Kentucky, December 11
"Chronic rejection in renal transplantation"

1995

NIAID Panel on Immunologic Intervention, February 8-9, Bethesda, Maryland
"Immunologic interventions for promoting transplant tolerance: state of the art and future directions"

North American Pediatric Renal Transplant Cooperative Study Meeting, March 22-25, San Francisco, California
"Transplant protocol-what do you use and why?"

Transplantation and the Community Nephrologist Symposium, Albert Einstein College of Medicine, Montefiore Medical Center, April 27-28, New York, NY, "Diagnosis and management of rejection"

Scientific Committee of the International Transplantation Consensus Conference-The Efficacy Endpoints Conference, May 13-14, Chicago, Illinois

American Society of Transplant Physicians, May 14-17, Chicago, Illinois
Sunrise Symposium, "Cyclosporine induction therapy: new strategies in adult and pediatric renal transplant recipients: adult"

American Society for Histocompatibility and Immunogenetics, Dallas, Texas, October 8-11,
"Chronic rejection in solid organ transplantation"

International Symposium: Swine in Biomedical Research, College Park, Maryland, October 22-25, "Porcine model of allotransplantation"

National Kidney Foundation Annual Scientific Meeting, San Diego, California, November 3-5,
"Chronic renal allograft rejection/dysfunction; chronic rejection-clinical and laboratory correlates"

5TH Annual Postgraduate Course: New York (November 29-December 1); Transplant Fellows Training Course (December 2), New York University Medical Center, New York, NY
"Risk factors in allograft rejection"; presentation on specific organ transplantation, "Kidney"; (Postgraduate Course), "Immunobiology of transplant rejection and its recognition" (training course for fellows)

1994

University of Toronto, March 15-16, Toronto, Ontario, Canada, Visiting Professor
"Risk factors for rejection in the cyclosporine era"

The Third International Congress on Cyclosporine, Chronic Rejection Workshop, March 25-April 1, Seville, Spain, Invited speaker

American Society for Histocompatibility and Immunogenetics, Northeast Regional Education Workshop, May 5, invited speaker

American Society of Transplant Physicians, May 16-20, Chicago, Illinois
Presented abstracts

University of Pittsburgh, June 23, Pittsburgh, Pennsylvania (invited speaker, Sandoz)
"Experience with new cyclosporine analogue compounds" (Transplant Lecture Series)

XVth World Congress of the Transplantation Society, August 26-September 3, Kyoto, Japan
"Should patients with renal allograft loss to noncompliance be retransplanted?" (abstract)

Top of page